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ABSTRACT 
 
MOLECULAR RECOGNITION OF SUBSTRATES BY PROTEIN 
FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE-I  
 
by 
 
Corissa L. Lamphear 
 
 
 
Chair: Carol A. Fierke 
 
 
Prenylation is an important post-translational modification that targets proteins to 
the cellular membrane. Farnesyltransferase (FTase) catalyzes the attachment of the 15-
carbon farnesyl moiety from farnesyldiphosphate to a cysteine near the C-terminus of a 
protein, while geranylgeranyltransferase-I (GGTase-I) catalyzes the analogous 
attachment of the 20-carbon geranylgeranyl group from geranylgeranyldiphosphate. 
Substrates of the prenyltransferases are involved in a myriad of signaling pathways and 
processes within the cell, therefore inhibitors targeting FTase and GGTase-I are being 
developed as therapeutics for treatment of diseases such as cancer, parasitic infection, and 
progeria. FTase and GGTase-I were proposed to recognize a Ca1a2X motif, where C is 
the cysteine where the prenyl group is attached, a1 and a2 are aliphatic amino acids, and X 
confers specificity between FTase and GGTase-I with X being methionine, serine, 
glutamine, and alanine for FTase and leucine or phenylalanine for GGTase-I. Recent 
work indicates that the Ca1a2X paradigm should be expanded; therefore, further studies 
are needed to define the prenylated proteome, to understand normal cellular processes,
xv 
and to determine the targets of prenyltransferase inhibitors. In this study, we probed the 
molecular recognition of GGTase-I by testing a 400 peptide library for activity with 
GGTase-I. The enzyme modifies two classes of substrates: multiple turnover substrates 
(MTO) and single turnover-only (STO) which undergo chemistry but not product release. 
Statistical analysis was used to determine that MTO substrates typically follow the 
Ca1a2X definition, but the STO sequences are more diverse, further indicating GGTase-I 
recognizes a broader range of substrates. Additionally, with collaborators at the Hebrew 
University of Jerusalem, a computational program that predicts FTase substrates was 
developed, FlexPepBind. This novel method successfully predicted new peptide 
substrates with FTase and identified a new class of substrates containing a positively 
charged X residue. Lastly, to examine prenylation in vivo, we created a library of GFP-
Ca1a2X fusion proteins and measured protein localization using fluorescence microscopy. 
The identity of the C-terminal sequence caused the proteins to localize to different 
cellular compartments presumably due to modification status. Together, these studies 
provide insight into the in vivo specificity of prenyltransferases and the involvement of 
prenylation in various cellular processes. 
 1
CHAPTER I 
 
INTRODUCTION1 
 
Prenylation Background 
General information: lipidation 
 In the eukaryotic cell, an assortment of proteins resides in or at the membrane in 
order to perform necessary biological functions. Typical membrane proteins include 
those with transmembrane domains that span the lipid bilayer one or multiple times. 
However, another mode of targeting proteins to the cellular membranes is by the 
attachment of a lipid group post-translationally or co-translationally in a process called 
lipidation which increases the affinity of the protein to the membrane. Lipidation can be 
broadly classified into two groups: modifications that target the protein to the outer 
membrane or those that target a protein to inner membrane leaflet.  
 Two examples of lipid modifications that attach proteins to the outer membrane 
are the GPI anchor and the cholesterol modification. The glycosylphosphatidylinositol 
(GPI) moiety is a complex structure containing a phospholipid, sugars and ethanolamine 
and is attached to the C-terminal amino acid of a protein (1, 2) which targets the protein 
to the outer leaflet (3-5). This modification is thought to play a part in a variety of signal  
                                                 
1 A portion of Chapter 1 is taken from Lamphear, C. L., Zverina, E. A., Hougland, J. L., and Fierke, C. A. 
(2011) Global Identification of Protein Prenyltransferase Substrates: Defining the Prenylated Proteome, in 
The Enzymes (Tamanoi, F., Hrycyna, C. A., and Bergo, M. O., Eds.) pp 207-234, Academic Press. 
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transduction pathways, partitioning to lipid rafts, cell communication, and prion disease 
pathogenesis (1, 2, 6). Cholesterylation also occurs at the C-terminus, forming 
acholesteryl ester. One example of a cholesterylated protein is the Sonic hedgehog (Shh) 
protein which is involved in organ development (7). The Shh protein has both cholesterol 
and palmitoyl modifications (8, 9) that are required for proper secretion and signaling 
(10).  
 Modifications that target proteins to the inner membrane leaflet include 
myristoylation, palmitoylation, and prenylation (Figure 1.1). Myristoylation is catalyzed 
by myristoyl-CoA:protein N-myristoyltransferase (NMT) (11) and typically involves the 
attachment of 14-carbon saturated fatty acid to an N-terminal glycine on a protein via an 
amide bond (12, 13). Although this modification was originally thought to solely occur 
co-translationally, recent studies have indicated that this modification can also occur 
post-translationally in apoptotic cells (14, 15). Myristoylated proteins are involved in a 
variety of signaling pathways; modified families include G proteins, the non-receptor 
protein kinases, and calcium binding proteins (16). Palmitoylation is the second type of 
acylation, which in most cases is the attachment of the 16-carbon palmitate at a cysteine 
forming a thioester bond (17, 18). Palmitoylation is unique from the other types of 
lipidation since it is readily reversible (19, 20). The attachment of palmitate is catalyzed 
by protein acyl transferases (PATs) (21-23) and removal is catalyzed by protein 
acylthioesterases (APTs) (24) but both processes can occur non-enzymatically as well. 
Palmitoylation does not occur at a specific consensus sequence, but the modification is 
found in four patterns including alone, proximal to protein transmembrane domains, at 
the C-terminus with a prenylation modification, and finally, near a myristoyl 
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modification (22). Examples of palmitoylated proteins include N- and H-Ras (25) (further 
discussed in a later section) and the Huntington protein, which is involved in 
Huntington’s disease (26). Lastly, prenylation comes in two forms: the 15-carbon 
prenylation and the 20-carbon geranylgeranylation. Protein farnesyltransferase (FTase) 
catalyzes the transfer of the 15-carbon farnesyl moiety from farnesyldiphosphate (FPP) to 
a cysteine residue near the C-terminus of the target protein; protein 
geranylgeranyltransferase-I (GGTase-I) and geranylgeranyltransferase-II (GGTase-II or 
RabGGTase) catalyze the analogous attachment of a 20-carbon geranylgeranyl group 
from geranylgeranyldiphosphate (GGPP) to cysteine(s) near the C-terminus of the 
substrate protein (Figure 1.2) (27, 28). These hydrophobic modifications help to localize 
proteins to cellular membranes to carry out their function as well as to facilitate protein-
protein interactions (29-31). GGTase-II (also called RabGGTase) modifies the Rab 
family of proteins at cysteines near the C-terminus in diverse motifs such as CC or CXC 
(32-34), and requires the Rab escort protein (REP) as an accessory protein to bind to 
substrates for activity (35). FTase and GGTase-I are termed the “CaaX” 
prenyltransferases, have similar modes of recognition, and are the focus of this work. 
 
FTase and GGTase-I properties 
 FTase and GGTase-I are proposed to recognize the “Ca1a2X” motif on substrate 
proteins (28, 31, 36). This Ca1a2X motif is canonically defined as: “C” is a cysteine four 
amino acids from the C-terminus where the prenyl group is attached forming a thioether 
bond; a1 and a2 are small aliphatic amino acids; and X is proposed to confer specificity of 
substrates for modification by FTase or GGTase-I, with X being methionine, serine, 
 4
glutamine, and alanine for FTase and leucine or phenylalanine for GGTase-I (37-40). 
Although many substrates are described by this paradigm, recent studies have indicated 
that the Ca1a2X model should be revised, as many substrates fall outside the traditional 
Ca1a2X definition (41). Additionally, there is evidence for a large pool of dual substrates 
for FTase and GGTase-I, with these proteins potentially modified by both enzymes (42). 
Currently, although many prenyltransferase substrates have been identified, the full 
extent of prenylation within the cell is still unclear (41, 43-46). Understanding how FTase 
and GGTase-I recognize substrates would aid in defining the prenylated proteome and in 
understanding the biological signaling pathways involving prenylated proteins. 
 
Figure 1.1. Types of lipidation. The myristoyl, palmitoyl, and prenyl groups can target 
proteins to the inner leaflet of the membrane.  
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Figure 1.2. Enzymes in the prenylation pathway. FTase and GGTase-I catalyze the 
attachment of a farnesyl or geranylgeranyl group to the sulfur atom of a cysteine in the 
proposed C-terminal Ca1a2X sequence of a substrate protein using farnesyldiphosphate 
(FPP) or geranylgeranyldiphosphate (GGPP) as the lipid donor (27, 28). Next the last 
three amino acids of the protein can be proteolyzed by RCE1 or ZMPSTE24, and the 
carboxy terminus can be methylated by ICMT.  
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 FTase and GGTase-I are heterodimeric zinc-metalloenzymes, containing identical 
α subunits and distinct but homologous β subunits (47), with active sites in both enzymes 
composed predominantly of β subunit residues near the α/β interface (Figure 1.8 A and B 
(48)). The kinetic mechanism of FTase (and by similarity GGTase-I) is thought to be 
functionally ordered, with FPP binding first before the protein or peptide substrate 
followed by a conformational change in the prenyl diphosphate substrate that positions 
the C1 of FPP or GGPP closer to the sulfur of the peptide (49-52). An active site Zn2+ 
coordinates the sulfur of the cysteine, lowering the pKa and creating a reactive thiolate 
which performs a nucleophilic attack on the alpha carbon of FPP to form a thioether 
linkage between cysteine and the lipid (53, 54). Finally, diphosphate is rapidly released. 
In FTase, a bound Mg2+ coordinates and stabilizes the developing negative charges on the 
pyrophosphate leaving group (55, 56), while Lys311β accomplishes this task in GGTase-
I (57). There has been much debate in the literature about the nature of the transition state 
in the chemical step as various studies have suggested both SN1-like (associative) and 
SN2-like (dissociative) behavior (58-60). The latest work using 3H α-secondary kinetic 
isotope effect measurements suggested an associative mechanism with dissociative 
character for the FTase reaction (61). New work using quantum mechanical molecular 
mechanical studies (QM/MM) with FTase has suggested that the transition state structure 
is actually peptide dependent. For instance, one peptide may exhibit an SN1-like 
transition state, while the transition state for a different peptide shows SN2-like behavior 
(Yue Yang, Bing Wang, Melek N. Ucisik, Guanglei Cui, Carol A. Fierke, and Kenneth 
M. Merz, Jr, unpublished data).  
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History: the discovery of prenylation 
 C-terminal prenylation was first discovered on the Rhodotorucine	A	mating	factor	
in	yeast	 in	1979 (62)	 and	discovered in mammalian cells in 1984 during studies of the 
cholesterol biosynthesis pathway. Researchers were studying the effect of inhibitors of 
the enzyme 3-hydroxy-3-methylglutaryl-CoA-reductase (HMG-CoA reductase), which 
blocks the synthesis of mevalonate, and thus, isoprenoids (Figure 1.3). When cells were 
treated with radiolabeled mevalonate after treatment with lovastatin, the radiolabel was 
found to be incorporated onto cellular proteins (later found to be due to prenylation) and 
soon it was demonstrated that all mammalian cells displayed this behavior (63, 64). Then, 
in Saccharomyces cerevisiae, a gene that affected the labeling on the RAS proteins and 
the RAM a-mating factor was identified, and the only similarity between the two 
substrates was in the C-terminal CaaX sequence (65). Therefore, a connection was forged 
between the CaaX sequence and the modification, which is prenylation. These studies 
opened doors as more and more classes of modified proteins were found, and it was 
ascertained that the molecules responsible for the labeling were the isoprenoids. 
 
In vivo prenylation pathway: further modifications 
 Additionally, in vivo, substrates can undergo further modification after 
prenylation (Figure 1.2). The last three amino acids of prenylated substrates can be 
proteolyzed by zinc metalloprotease Ste24 (ZMPSTE24) or Ras-converting enzyme 1 
(RCE1) at the endoplasmic reticulum, followed by methylation of the carboxy terminus, 
catalyzed by isoprenylcysteine methyl transferase (ICMT) (66-68). These additional 
modifications can aid in membrane localization, but it is not yet known whether these 
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modifications occur on every prenylated substrate. Specificity studies of RCE1 and 
ZMPSTE24 are also limited, but it is known these enzymes require a prenylcysteine for 
recognition and that some substrates may overlap between the two proteases (68-75). 
Besides these modifications, some proteins (like the Ras proteins) are palmitoylated or 
contain an upstream polybasic region of the CaaX sequence that aid in membrane 
association (Figure 1.4) (76-80). Therefore, it will be useful to understand which 
modifications or combination of modifications occurs on various prenylation pathway 
substrates.  
 
Prenylation and disease implications 
 Many proteins are modified by the prenyltransferases, including the small Ras and 
Rho GTPase superfamilies (31, 81) and the nuclear lamins (82), and often the prenyl 
modification is essential for the biological function (31, 83). Prenyltransferases are being 
investigated as targets for inhibitors to treat a variety of diseases, including cancer (84), 
Hutchinson-Gilford progeria syndrome (85), and parasitic diseases such as malaria (86). 
Prenyltransferase inhibitors were initially developed to target Ras protein signaling 
pathways implicated in cancer, but it was later determined that inhibitor efficacy is the 
result of modulating prenylation of non-Ras proteins (87). Studies of the pleitropic effects 
of statin treatment, which blocks the biosynthesis of FPP and GGPP and therefore affects 
prenylation, suggest the involvement of prenylated proteins in diseases such as leukemia 
(88), asthma (89), and cardiovascular disease (90). Therefore, understanding how 
prenyltransferases recognize their substrates, which substrates are prenylated in vivo, and, 
finally, what substrates are responsible for inhibitor efficacy are important outstanding 
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questions. More details about the modifications and biology of Ras family and the lamins 
are discussed in the next section. 
 
 
 
 
Figure 1.3: The cholesterol biosynthesis pathway. Cholesterol is synthesized starting 
from acetyl-CoA. Farnesyldiphosphate and geranylgeranyldiphosphate substrates 
originate from this pathway.   
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Figure 1.4. The in vivo prenylation pathway. Proteins can be prenylated in the cytosol, 
proteolyzed by the CaaX proteases zinc metalloprotease Ste24 (ZMPSTE24) or Ras-
converting enzyme 1 (RCE1) at the endoplasmic reticulum, and carboxy methylated by 
isoprenylcysteine methyl transferase (ICMT). Besides these modifications, some proteins 
(like the Ras proteins) are palmitoylated or contain an upstream polybasic region of the 
CaaX sequence that aid in membrane association. 
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Lamin A and Hutchinson-Gilford progeria syndrome 
 The nuclear lamina provides scaffolding for the nucleus and is involved in a 
multitude of processes ranging from gene transcription to protein trafficking (91-95). 
Some major players in the nuclear lamina are the lamins, which include lamin A, lamins 
B1 and B1, and lamin C, and all but lamin C are modified by FTase at some stage in the 
protein processing (91). Lamin A is unique in that it exists in two forms: prelamin A and 
lamin A. The prelamin A is farnesylated, proteolyzed by RCE1, and methylated by ICMT 
like many other FTase substrates. It is then presumably trafficked to the nucleus where it 
is cleaved between residues Y646 and L647 by ZMPSTE24 to clip off the C-terminal tail, 
which includes the farnesyl group, to generate the mature lamin A (Figure 1.5 A (85, 
96)). Hutchinson-Gilford progeria syndrome (HGPS) is caused by a mutation in the 
prelamin A that removes the cleavage site for the final proteolysis step (96). This 
devastating premature aging disease is marked by alopecia, slow growth, short stature, 
osteoporosis, osteolysis, loss of subcutaneous fat, thin skin, and limited joint mobility, 
resulting in premature death around 7-20 years typically by heart disease or stroke (97). 
HGPS is thought to be caused by the build-up of the farnesylated mutant pre-lamin A 
which is called “progerin” (Figure 1.5 B). On the cellular level, the progerin likely 
disrupts the structure of the nucleus, and visually, causes misshapen nuclei with blebbing 
of the membranes. Treatment with FTIs (farnesyltransferase inhibitors) seems to 
ameliorate this effect (98), improves symptoms in mouse models of the disease (99), and 
may be a method of treating the disease in the future for patients. In fact, a clinical study 
with the FTI lonafarnib is currently underway with twenty-seven children (100, 101).  
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Ras GTPases, prenylation, and palmitoylation: interplay of lipid modifications 
 As mentioned above, the Ras family of proteins is a substrate of the prenylation 
pathway (Figure 1.6), is involved in cellular proliferation, and mutations in this family 
that cause GTPase activation are found in cancer (102, 103). The Ras superfamily is a 
well-studied system that exemplifies the interplay between prenylation and 
palmitoylation. H-Ras, N-Ras, and K-Ras isoforms 4A and 4B are all farnesylated, but 
under treatment with an FTI, N-Ras and K-Ras4B can become geranylgeranylated (104-
106). Prenylation is sufficient for association with the ER and Golgi membranes; 
however an additional “secondary signal” is necessary for targeting to the plasma 
membrane. Palmitoylation is required for N-Ras and H-Ras to be located to the 
membrane, but K-Ras has a polybasic region which directly aids in membrane 
association (107-109). Prenyl modifications are stable, but palmitoylation is a method of 
regulating the localization back and forth to the plasma membrane as this modification is 
readily reversible (110-112). The PATs (protein acyl transferases) catalyze the 
attachment of the palmitoyl group, while the APTs (protein acylthioesterases) catalyze 
removal of this group (Figure 1.6, left (21-24)). The dually prenylated and palmitoylated 
Ras is localized to the plasma membrane where the activity is regulated by bound 
nucleotides. When GDP is bound to Ras, the protein is in the “off” state; however, a 
guanine nucleotide exchange factor (GEF) can aid in exchanging the GDP for GTP, 
leading to active Ras•GTP. Conversely, a GTPase activating protein (GAP) can enhance 
the GTPase activity of Ras, causing the protein to form the inactive, Ras•GDP state. The 
active Ras•GTP state binds effectors and activates a kinase cascade, eventually leading to 
gene expression in the nucleus and cell proliferation (as shown in the simplified diagram  
 13
 
Figure 1.5. Trafficking of Lamin A in normal and Hutchinson-Gilford Progeria 
Syndrome cells. A) Normal Lamin A trafficking. Prelamin A is farnesylated in the 
cystosol by FTase, trafficked to the ER membrane where the three C-terminal amino 
acids are removed and methylated at the C-terminus. Then, the modified prelamin A is 
localized to the nucleus where it is proteolyzed between internal sites, removing the 
farnesyl group and becoming the mature lamin A protein. Lamin A is then thought to 
locate to the nucleoplasm. B) Trafficking of Lamin A in Hutchinson-Gilford Progeria 
Syndrome cells. All of the trafficking is the same, until the final proteolysis step. There is 
a mutation in the prelamin-A which does not allow the ZMPSTE24 to cleave the protein; 
therefore, the prelamin A retains the lipid modification. The membrane localized 
prelamin A is proposed to cause nuclear blebs and contribute to development of the 
disease. 
  
Figure 1.6. Ras family prenylation and palmitoylation. Members of the Ras family must be prenylated and palmitoylated to 
localize to the cellular membrane. The presence or absence of the palmitoyl group allows the protein to cycle back and forth between 
the ER, Golgi, and outer membrane. At the cellular membrane, the Ras proteins are regulated, with active Ras binding to effectors to 
stimulate a kinase cascade for gene expression. 
14 
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 in Figure 1.6 (25, 48, 103)). The Ras family shows the importance and effect of 
localization on the type and combination of lipidation. 
 
Parasitic prenyltransferases 
 An emerging field is the study of prenyltransferases from pathogenic and parasitic 
organisms as potential therapeutic targets (113-116). For instance, the pathogenic yeast 
strain Candida albicans, known to affect immunocompromised patients, utilizes both 
protein farnesyltransferase and geranylgeranyltransferase-I enzymes to catalyze 
prenylation of substrate proteins (117, 118). The specificity of these two enzymes is 
currently being studied to define the complement of prenylation of proteins in this 
organism, since it is possible that inhibitors of the prenyltransferases could be used as 
antifungal therapeutics (117, 119). Additionally, inhibitors are being developed as 
therapeutics for the treatment of parasitic diseases such as malaria, caused by 
Plasmodium falciparum (120). These FTase inhibitors, based upon ethylenediamine 
(115) and tetrahydroquinoline (114) scaffolds, are thought to block P. falciparum FTase 
activity, which is essential for the organism. Based upon modeling and resistance 
mutation studies (121), these inhibitors may chelate the catalytic Zn2+ and bind to the 
enzyme in the lipid substrate grove. Recently, it has also been discovered that the gram 
negative bacterium, Legionella pneumophila, hijacks the host prenyltransferase 
machinery to catalyze prenylation of bacterial proteins, raising the possibility that current 
mammalian prenyltransferase inhibitors could also be used as antibiotics (122, 123).  
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Prenyltransferase Substrate Specificity and the Prenylated Proteome 
 Defining the extent of prenylation within the proteome of an organism can be 
approached using two complementary tactics: 1) direct in vivo determination of proteins 
that are prenylated; or 2) definition of the recognition elements used by FTase and 
GGTase-I to select peptide and protein substrates. This next section summarizes both 
approaches. The summary of the direct in vivo identification modes includes a brief 
discussion of methods for detecting prenylation on a small or large scale. Additionally, 
methods used to definite molecular recognition in prenyltransferases are described, 
including structure/function studies, peptide library studies, and computational predictive 
methods.  
 
Methods for discovering and predicting prenyltransferase substrates: identification of 
substrates one-by-one 
 In the past, the methodology to determine prenyltransferase substrates has been 
difficult, and typically, was carried out by studying one protein at a time. The prenyl 
modification status of a particular protein in many cases can be assessed through 
incubation of cells or lysate with radioactive (3H or 14C) molecules, including:  FPP or 
GGPP (124-126); a metabolic precursor of FPP or GGPP such as mevalonate (124, 125, 
127); or an alcohol precursor of GGPP and FPP, such as geranylgeraniol (GGOH) or 
farnesol (FOH) (126, 128), that is phosphorylated in vivo (129). Treatment of cells with 
these compounds allows the protein of interest to be radiolabeled upon prenylation. A 
significant limitation of this method is the low signal from the prenylated proteins arising 
at least partly from the low specific activity of the radioactive molecules typically used 
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(27, 126, 130). Control experiments to eliminate false positive results from radiolabeling 
studies include mutation of the cysteine of the Ca1a2X in the target protein to serine to 
block prenylation and/or incubation with prenyltransferase inhibitors (130, 131). These 
studies are difficult to perform on a large pool of protein targets since there is not a facile 
method to pull-down proteins containing prenyl groups. Antibodies have been raised to 
the prenyl modifications for detection using immunoblotting (132, 133); however, these 
antibodies can exhibit problematic cross-reactivity with other lipid modifications (134) 
and are not able to distinguish between farnesyl and geranylgeranyl modifications (89, 
133, 134). 
 
FPP and GGPP analogs: aiding in prenyl group detection 
 Using synthetic organic chemistry, multiple research groups have developed FPP 
and GGPP donor analogs with properties that enhance prenylated protein isolation and 
identification (43, 135-137). FTase and GGTase recognize various prenyl donor analogs 
as substrates for incorporating recognition tags onto prenylated proteins, both in vitro and 
in vivo, allowing for parallel identification of multiple substrates within the available pool 
of proteins as well as the monitoring of prenylation status changes upon inhibitor 
treatment.  We will briefly focus on three recently reported classes of analogs: 
immunogenic analogs, analogs with functional groups allowing for chemoselective 
bioorthogonal labeling following prenylation, and analogs that contain an affinity tag 
such as biotin (Figure 1.7).  
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Figure 1.7. Lipid structures. Structures of:  A) farnesyldiphosphate (FPP); B) 
geranylgeranyldiphosphate (GGPP); C) 8-anilinogeranyl diphosphate (AGPP); D) azido-
FPP; E) biotin-geranyl pyrophosphate (BGPP) (43, 136, 138). 
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 Immunogenic analogs incorporate a chemical moiety that can serve as the epitope 
for an analog-specific antibody. An example of such an analog is anilinogeraniol, 
developed by the Spielmann lab (135).  Anilinogeraniol (AGOH), which is converted to 
the 8-anilinogeranyl diphosphate (AGPP) substrate in vivo (Figure 1.7 C) (138), replaces 
the terminal isoprene unit of FPP with an aniline moiety that serves as an epitope.  In 
studies employing AGOH as an immunogenic tag, cells are treated with the analog, lysed, 
and proteins fractionated by 1- or 2-D gel electrophoresis.  The farnesylated proteins are 
detected using Western blotting with an antibody raised to recognize the AG-KLH 
moiety (135, 139). This method detected several known FTase substrates using 1-D gel 
electrophoresis, but failed to identify many small GTPases known to be FTase substrates; 
however, coupling the Western blot analysis with 2-D gel electrophoresis increases the 
efficiency of prenylated protein identification (139).  
An emerging class of FPP and GGPP analogs employs bioorthogonal ligation 
methods, wherein analogs containing an azido or alkyne group on the terminal isoprenoid 
of FPP or GGPP are attached to substrate proteins. These functional groups are amenable 
to Staudinger ligation or Huisgen 1,3-dipolar cycloaddition (“click” chemistry) (140, 
141), which allows for chemoselective attachment of reporter molecules such as a 
fluorophore or biotin following protein prenylation. The first use of an azido analog for 
identification of prenylated proteins was reported by Kho and coworkers (43). They 
treated COS-1 cells with azido-FPP (Figure 1.7 D) or azido-farnesol, and demonstrated in 
vivo incorporation of this analog onto substrates catalyzed by FTase. Following cell lysis, 
the azido-farnesylated proteins were labeled with a biotin-containing phosphine capture 
reagent using the Staudinger ligation, purified using streptavidin beads and identified 
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using mass spectrometry (43). This method was used to detect eighteen FTase substrates, 
including known farnesylated proteins such as H-Ras and Rheb. More recently, azido-GG 
alcohol has been used to identify geranylgeranylated substrates using click chemistry 
with TAMRA-alkyne, 2-D gels, and mass spectrometry (142) and to label substrates in 
prenylation deficient mouse tissue (143). Additionally, alkyne derivatives of FPP and 
GGPP are gaining popularity for identification of prenylated proteins in vitro and in vivo 
(144-146). 
An alternative method, the “affinity tag” approach, uses a biotin-geranyl 
diphosphate analog (BGPP, Figure 1.7 E) (136).  This analog serves as an efficient 
substrate for GGTase-II, but not FTase or GGTase-I. To expand the utility of this analog, 
Alexandrov and coworkers “engineered” FTase and GGTase-I enzymes with altered 
substrate selectivity by mutating residues in the active site (W102T/Y154T or 
W102T/Y154T/Y205T for FTase, and F53Y/Y126 or F52Y/F53Y/Y126 for GGTase-I), 
allowing the engineered enzymes to catalyze modification of substrate proteins using the 
BGPP analog. Compactin was used to block native FPP and GGPP synthesis, increasing 
the pool of unmodified FTase and GGTase-I substrates. The compactin-treated cell 
lysates were incubated in vitro with BGPP and mutant or wild-type prenyltransferases, 
pulled down using streptavidin beads, and modified proteins were identified using mass 
spectrometry. Many Rab proteins were detected and quantified as GGTase-II substrates, 
while various molecular weight substrates were identified from the engineered FTase- 
and GGTase-I-treated lysates.  
Although there has been much success using analogs to identify prenylated 
substrates, there are caveats to these approaches. First of all, the FPP and GGPP analogs 
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may alter the protein specificity of the enzyme (147-149) since the prenyl group forms a 
portion of the protein substrate binding site (46). In particular, for use of the biotin 
analogs the FTase and GGTase-I enzymes were engineered at positions in the active site 
that can alter the enzyme specificity (150). Another concern is the “hit rate” for these 
analogs, as treatment with several of these analogs did not identify known substrates as 
prenylated proteins; these issues with false negatives may indicate that these analogs may 
not be incorporated into substrates at a high enough level to allow identification. One 
method to obtain higher incorporation of the analogs is to treat the cells with an inhibitor 
of FPP or GGPP synthesis, such as compactin (136, 151); however this treatment may 
disrupt the homeostasis of the cell, not allowing for true identification of substrates under 
normal conditions. Additionally, the BGPP analog was incubated with cell lysates in an 
in vitro context, identifying potential substrates, but perhaps not identifying substrates 
that are prenylated under native in vivo conditions. 
 
Identifying prenyltransferase substrates through structural and structure-function 
biochemical studies 
 This section reviews the findings from crystallographic data and structure-activity 
studies that combine to provide a functional and structural picture of the interactions 
important for prenyltransferase selectivity. Such studies have yielded valuable insights 
suggesting that the prenylated proteome may be much richer in size and diversity than 
has been previously proposed.  Future studies, focusing on identifying additional 
interactions and quantifying the energetic contribution of each enzyme-substrate 
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interaction, have the potential to provide the basis of a quantitative model for predicting 
the full complement of prenylated proteins within the cell. 
 
Structural studies 
 Over the past 15 years, a series of crystallographic structures of mammalian 
FTase and GGTase-I have provided insight into the active site interactions and structural 
context of the peptide substrate binding site within prenyltransferases (46, 51, 152). 
Using these structures as a reference, the selectivity for each amino acid within the 
Ca1a2X motif can be interpreted in light of potential contacts with active site residues.  
The binding site for the a1 residue of the peptide substrate is exposed to solvent at the 
interface of the FTase  and  subunits (46), consistent with the relaxed specificity at the 
a1 position observed in biochemical studies (39-41, 45). In contrast, the a2 and X residue 
binding sites lie within the solvent-excluded active site, suggesting that these two 
positions may be primarily responsible for prenyltransferase selectivity. The a2 site in 
FTase is mainly composed of the side chains of W102, W106, and Y361 (Figure 1.8 
D), with analogous residues T49, F53, and L321 in GGTase-I.  In addition, the prenyl 
donor co-substrate also contacts the a2 residue in both enzymes (46). Structures of FTase 
complexed with peptides containing different X groups suggest the possibility of two 
different X-residue binding pockets: S, Q and M interact with Y131, A98, S99, 
W102 and H149(Figure 1.8 E), while F (and likely L, N and H) interacts with L96, 
S99, W102, W106 and A151These X-group binding sites in FTase (the 
former list) generally confer a preference for prenylation of peptides with moderately 
polar amino acids such as Ser, Met, and Glu at the X position. In GGTase-I, amino acids 
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T45, T49, and M124replace the A98, W102, and P152 side chains in the X-
group binding pocket in FTase.  Unexpectedly, this less hydrophobic X residue binding 
site in GGTase-I leads to a preference for catalyzing prenylation of peptides with more 
hydrophobic X residues, such as Leu and Phe. These contacts, acting in concert, suggest a 
set of preferences for FTase and GGTase-I substrates that can serve to guide studies for 
identifying novel prenyltransferase substrates. 
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Figure 1.8. Prenyltransferase structures and FTase active site. A) The overall structure of 
FTase (PDB ID 1D8D). B) The overall structure of GGTase-I (PDB ID 1N4Q). The α subunits 
are shown in red, the β subunit for FTase is shown in blue and the β subunit of GGTase-I is 
shown in purple. Additionally, the peptide substrates are shown in green, the lipid substrates are 
shown in orange, and the catalytic zinc ions are shown as spheres. In C), D), and E), the FTase 
active site is shown (PDB ID 1D8D) with FTase residues in purple or green, peptide substrate 
KKKSKTKCVIM in pink, FPP analog (FPT Inhibitor II) in orange, and the catalytic Zn2+ in light 
blue. For clarity, only a portion of the peptide substrate is shown: TKCVIM in C) and CVIM in 
D) and E). C) The structure of the rat FTase active site showing the position of the bound FPP 
analog and peptide; D) Structure of the contacts between the substrate a2 residue (isoleucine) and 
FTase residues W102β, W106β, and Y361β (green) and the 3rd isoprene of FPP (orange); E) 
Structure of the contacts between the substrate X residue (methionine) and the X residue binding 
pocket in FTase, including residues Y131, A98β, S99β, W102β, H149β, A151β, and P152β 
(green) (46, 153).  
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Structure-function studies of peptide reactivity 
 While structural studies provide insight into the interactions that engender FTase 
and GGTase-I peptide substrate specificity, the energetic benefit (or cost) of each 
interaction must be identified to ascertain the functional substrate preference at each 
position within the Ca1a2X sequence.  Structure-function studies of peptide reactivity, 
wherein changes in peptide reactivity are correlated with changes in amino acid 
properties such as hydrophobicity or steric size, provide one method for identifying the 
properties that are used by FTase or GGTase-I to recognize substrates. At the X position, 
Hartman and coworkers assayed the reactivity of a series of peptide substrates derived 
from the C-terminal sequence of K-Ras-4B (-TKCVIM) wherein the terminal amino acid 
was substituted with 14 amino acids, including the natural Met (154). This study 
illustrated that peptide selectivity for FTase versus GGTase-I arises from relative peptide 
reactivity, rather than relative binding affinity. Furthermore, peptide reactivity correlates 
strongly with hydrophobicity, with FTase and GGTase-I displaying inverse reactivity; 
FTase reactivity decreases and GGTase-I reactivity increases with increasing 
hydrophobicity at the X position.  This “reciprocal” reactivity pattern yielded three 
groups of peptides: 1) peptides terminating in moderately polar X residues (i.e. S and Q) 
that exhibit exclusive reactivity with FTase; 2) peptides terminating in nonpolar X 
residues (i.e. L and I) that exhibit exclusive GGTase-I reactivity; and 3) peptides 
terminating in a subset of X residues, such as Met or Phe, that react efficiently with both 
FTase and GGTase-I.  Furthermore, these studies identified a number of peptides that 
were rapidly prenylated under single turnover conditions but not under multiple turnover 
conditions, presumably due to slow product dissociation.  Further studies of peptide 
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reactivity demonstrate that FTase is capable of catalyzing farnesylation of peptides with a 
variety of X-group residues, including leucine (155). Additionally, the functional 
importance of positively-charged residues upstream of Ca1a2X motif, often referred to as 
the polybasic region, has been explored by comparing the reactivity of FTase and 
GGTase-I with the C-terminal sequence of K-Ras4B (KKKSKTKCVIM versus 
TKCVIM) (42). This work demonstrated that the upstream sequence enhances dual 
prenylation of substrates by decreasing the efficiency of FTase-catalyzed farnesylation to 
a level comparable to that of geranylgeranylation catalyzed by GGTase-I. These 
structure-function studies of X residue recognition indicate that both FTase and GGTase-
I can recognize a much wider range of side chains at this position than had been 
previously proposed. In addition, the possibility for a class of substrates that can be 
prenylated by either enzyme underscores the potential role of “leaky prenylation” in 
affecting the makeup and biological role of the prenylated proteome.  Taken together, 
these findings indicate that more than half of the 20 amino acids can serve as the X 
residue of a prenyltransferase-competent Ca1a2X substrate sequence.  
 A similar structure-activity profile at the a2 position both underscored predictions 
from structural work regarding a2 sequence preferences and uncovered a previously 
unknown example of context-dependent substrate recognition at the a2 position of the 
Ca1a2X sequence (156).  Analysis of the relative reactivity of a series of peptide 
substrates varying at the a2 position (-GCVa2S and –GCVa2A) indicated that FTase 
recognizes both the polarity and steric volume of the a2 side chain simultaneously, 
discriminating against polar amino acids and both large and small amino acids at this 
position; maximal activity is observed for amino acids containing a steric volume near 
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that of valine.  These preferences match those predicted by structural studies (46), 
providing a functional picture of the energetic contribution of the structurally predicted 
interactions to substrate selectivity. Surprisingly, when the reactivity of FTase with 
analogous peptides with different X residues (-GCVa2M and –GCVa2Q) was analyzed, 
substrate recognition at the a2 position was predominantly due to polarity.  In these 
peptides, the steric volume of the amino acid at the a2 position did not significantly affect 
reactivity as long as that amino acid was either weakly polar or nonpolar. This context-
dependent a2 selectivity, wherein a larger range of a2 residues can be present in FTase 
substrates when the X residue is Met or Gln compared to when X is Ser or Ala, suggests 
that FTase can catalyze farnesylation of proteins with a wide range of a2 residues as 
efficient substrates provided that an appropriate X residue is present. 
 Structural studies of FTase and GGTase-I have provided an intricate picture of the 
interactions and active site microenvironment responsible for recognizing 
prenyltransferase substrates from among the milieu of all cellular proteins.  Structure-
function analysis of peptide reactivity indicates that both FTase and GGTase-I recognize 
a much wider range of protein sequences as substrates than was originally proposed.  
Furthermore, the specific chemical properties recognized by prenyltransferases at 
positions within the Ca1a2X sequence have been characterized by correlation of peptide 
reactivity with amino acid properties such as size and polarity.  These structural and 
functional insights will serve as essential foundations for development of models for 
comprehensive prediction of prenyltransferase substrates based on protein C-terminal 
sequence data. 
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Peptide library studies: a high-throughput method of identifying potential 
prenyltransferase substrates and defining substrate specificity  
 An additional method of determining prenyltransferase substrates is to define the 
molecular recognition elements of FTase and GGTase-I using peptide library studies. 
Short peptides, as small as tetra-peptides, are efficient substrates for FTase and GGTase-I 
with comparable affinity and reactivity to full-length proteins (39, 40, 53, 157, 158). 
Adding a dansyl group to the N-terminus of the peptide allows for continuous monitoring 
of the reaction using a fluorescence assay, as the dansyl group increases in fluorescence 
upon prenylation (158, 159). Conveniently, this assay can be carried out in a high-
throughput manner using 96-well plates in a plate reader, and with large libraries, 
statistical analysis of peptide reactivity can be used to determine patterns of substrate 
recognition (41). The use of these peptide libraries to study prenyltransferase specificity 
is advantageous, since potential substrates can be screened quickly and efficiently, using 
wild-type enzymes and the natural lipid substrates FPP and GGPP.  One limitation with 
this method is that in some cases the structure of protein substrates may alter recognition. 
Many research groups have tested small or non-homogenous libraries of peptides as a 
means to identify prenyltransferase substrates (148, 160, 161).  For instance, groups have 
tested the Ca1a2X paradigm using GCxxS and GCxxL libraries (155, 161), finding that 
their results generally correlate well with structural studies (46) and computational 
algorithms (44, 45).   
To more completely define the scope of the prenylated proteome, a large-scale 
peptide library study of the substrate selectivity of FTase was carried out, using statistical 
analysis to analyze FTase preference patterns (41). The library peptides were screened for 
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reactivity with FTase under both multiple turnover (MTO), subsaturating peptide 
(kcat/KMpeptide) conditions and single turnover (STO) conditions, using the dansyl 
fluorescence assay or an in vitro radioactive assay with 3H-FPP (41, 158, 159). In 
experimental practice, the MTO reaction is performed under conditions with excess 
substrate such that [E] << [S] while the STO reaction includes excess enzyme and 
peptide substrate with limiting concentrations of FPP ([FPP] < [E]). 
Two kinetic parameters, kcat/KMpeptide and kfarnesylation, can be measured to describe 
peptide reactivity with FTase. The value of kcat/KMpeptide, measured under MTO 
conditions, is also termed the “specificity constant” (162) and is most representative of 
the reactivity of a particular substrate in a biological context where all of the protein 
substrates compete for prenylation catalyzed by FTase and GGTase-I (162). In vivo the 
relative rate of prenylation of a given substrate (and hence the selectivity) depends on 
both the concentration of the protein substrate and the value of kcat/KMpeptide. For the 
prenyltransferase reactions, kcat/KMpeptide represents all of the reaction steps up to the first 
irreversible step in a reaction (162). Previous kinetic studies of FTase suggest the basic 
kinetic pathway shown in Figure 1.9 (158, 163-167). Substrate binding is functionally 
ordered, with FPP binding before peptide, followed by a conformational rearrangement 
of the first two isoprene units of FPP required to position the C1 of FPP near the sulfur of 
the peptide substrate for facile reaction (49-52). After the chemical step, diphosphate 
dissociation is rapid (165).  For FTase, the kcat/KM parameter includes the rate constants 
for peptide binding to E•FPP (forming the ternary complex) through the formation of the 
prenylated peptide and pyrophosphate products, including the conformation change prior 
to chemistry and the chemical step (kfarnesylation, Figure 1.9) (51, 52, 61, 165, 166). Under 
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these conditions, dissociation of the diphosphate product is the first irreversible step (165, 
166); therefore dissociation of the prenylated peptide product does not contribute to the 
observed value of kcat/KMpeptide.  The MTO kinetic parameter measured at saturating 
concentrations of peptide and FPP, kcat, includes all of the rate constants describing the 
formation of dissociated products (prenylated peptide and diphosphate) from the ternary 
complex (E•FPP•peptide).  Under these conditions, dissociation of the farnesylated 
peptide is frequently the rate-limiting step (165, 167).  Furthermore, dissociation of the 
prenylated product is enhanced by binding FPP, and possibly peptides, to the 
FTase•farnesylated-peptide complex (Figure 1.9 B) (154, 167, 168). 
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Figure 1.9. FTase kinetic pathway. The proposed catalytic cycle for FTase under A) 
single turnover conditions (STO, [E] > S); and B) multiple turnover conditions (MTO, 
[E] << [S]). The STO-only substrates are proposed to undergo farnesylation, but not 
product release. FTase catalyzes turnover of MTO substrates where binding of either an 
additional peptide or FPP molecule to the E•farnesylated-peptide complex may facilitate 
product release. The rate constant kfarnesylation includes both the conformational change and 
chemistry steps (41, 50, 163-167, 169). 
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In addition, it is possible to directly measure the rate constant (kfarnesylation) for the 
formation of the farnesylated product by detecting the formation of diphosphate using a 
coupled assay under single-turnover (STO) conditions ([E] > [S]) (Figure 1.9 A) (165). 
The kfarnesylation parameter for FTase includes rate constants for binding the peptide 
substrate to FTase•FPP, the conformation change before the chemistry step, the 
farnesylation step and the rapid dissociation of diphosphate, thereby including all of the 
reaction steps up to but not including release of the prenylated protein (51, 52, 61, 165). 
At saturating concentrations of FTase under STO conditions, kfarnesylation reflects solely the 
conformational change and farnesylation steps.  Previous studies have demonstrated that, 
in some cases, peptide substrates are rapidly farnesylated by FTase, as measured under 
STO conditions, but that product dissociation is so slow that MTO activity is not 
observable by the current assays (154, 170).  Measurement of both MTO and STO 
activity provides additional information to probe the molecular recognition modes of 
FTase.  
 The reactivity of FTase with two peptide libraries was measured: an “initial 
library” of 213 peptides was designed based on the Cxxx sequences taken from the 
human proteome with a mild bias toward sequences predicted by the Ca1a2X model, and 
a second library, the “targeted library” of 88 peptides, was similarly designed using 
human sequences but with a stronger bias towards sequences predicted to be FTase 
substrates based on the results from the initial library. The peptides in these libraries were 
of the form dansyl-TKCxxx, where x is any amino acid, and the upstream lysine was 
included to increase peptide solubility (50).  Overall, FTase catalyzed the farnesylation of 
a surprisingly large number of peptides (41). FTase catalyzed prenylation of 77 peptides, 
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or 36%, of the initial library under MTO conditions, and an additional 85 peptides (40%) 
under STO conditions. Together, this means that 76% of the initial 213 peptides were 
FTase substrates. Additionally, in the targeted library 29 (33%) and 45 (51%) of the 
peptides were farnesylated by FTase under MTO and STO conditions, respectively.  In 
both libraries, FTase catalyzed farnesylation of 78% of the peptides, including both MTO 
and STO conditions. 
 The values of kcat/KMpeptide and kfarnesylation were measured for a subset of FTase 
substrates (41). The kcat/KMpeptide parameters for the MTO substrate subset demonstrate a 
variation of approximately 100-fold.  Furthermore, the values for kfarnesylation roughly 
correlate with kcat/KMpeptide, that is, more reactive substrates generally had higher 
kfarnesylation values. For the STO substrates, the values for kfarnesylation are comparable to 
those measured for the MTO substrates. Therefore, dissociation of the prenylated peptide 
must be sufficiently slow for the STO substrates such that MTO activity is not detectable.  
In this special case, product dissociation rates can alter substrate selectivity even in the 
presence of multiple competing substrates.  
To further probe substrate recognition by FTase, the amino acid preferences at the 
a1, a2, and X positions of the MTO, STO, and non-substrate peptides from the initial 
library were compared using statistical analysis. For this analysis, the percentages of 
“canonical” and “non-canonical” Ca1a2X sequences at the a2 and X positions, for the 
overall library, MTO, STO, and NON pools of peptides (Figure 1.10, top panel) were 
evaluated (41). With “canonical” defined as V, I, L, M, and T for a2, and A, S, M, Q, and 
F for X, the MTO peptide substrates were generally well-described by the Ca1a2X 
paradigm; however, the STO substrates contain more varied sequences. A 
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hypergeometric distribution model (41) was used to determine statistically significant 
enrichment (overrepresentation) or depletion (underrepresentation) of a specific amino 
acid as compared to the overall library. Using p ≤ 0.02, sequence preferences for FTase 
could be divided into three classes of peptides (MTO, STO, and NON). MTO substrates 
are relatively well described by the original Ca1a2X paradigm: little sequence selectivity 
is observed at a1; a nonpolar amino acid, like isoleucine and leucine, is preferred at a2; 
and the X residue is preferentially phenylalanine, methionine, or glutamine.  
Additionally, cysteine and lysine were depleted at the a2 position in the reactive MTO 
substrates. Conversely, STO substrates are not well described by the Ca1a2X paradigm or 
other more recently published substrate prediction models (44-46, 50, 154, 156).  For the 
STO peptide substrates: cysteine is enriched while leucine is depleted at the a1 position; 
at the a2 position, serine is enriched while isoleucine and lysine are depleted; and at the X 
position, no amino acid is enriched, while methionine is depleted. The anticorrelation of 
methionine for the MTO and STO substrates at the X position suggests that this amino 
acid enhances product release (41). For unreactive peptides: at the a1 position no 
sequence preferences were observed; at the a2 position D, K, and R were enriched while 
V, I, L, and T were depleted; and at the X site, P and R were enriched.  In this case, 
enrichment reflects amino acids that decrease reactivity.  These statistically-significant 
sequence preferences for FTase substrates derived from the human genome, along with 
other data (41, 44, 45, 156), further broadens and defines the Ca1a2X paradigm describing 
FTase selectivity. Figure 1.10 (bottom panel) shows a summary of FTase sequence 
preferences for substrates at the a1, a2, and X positions derived from these peptide library 
studies.  
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 The observation of a large number of peptide substrates farnesylated under single 
turnover but not multiple turnover conditions leads to the important question as to 
whether the STO substrates will likely be prenylated in vivo.  Since slow dissociation of 
the farnesylated-peptide product is predicted to lead to STO behavior, it is possible that 
STO substrates could form long-lived product complexes with FTase in the cell, raising 
the possibility that these sequences function as inhibitors rather than biologically relevant 
substrates. However, at least two STO substrates, with C-terminal sequences 
corresponding to the peptides -CAVL and -CKAA (43, 131), have been demonstrated to 
be farnesylated in vivo, suggesting that these proteins can turnover. One model consistent 
with these data is that a MTO substrate (or another “release factor”) could facilitate the 
dissociation of the farnesylated-STO protein, similar to the FPP-catalyzed dissociation of 
product (see kinetic scheme in Figure 1.9 B) (51, 167) and this may have a regulatory 
function within the cell.  This model enjoys some support from studies of small peptide 
reactivity (154, 167, 168). Overall, these studies indicate that FTase may farnesylate a 
larger pool of proteins in vivo than would be predicted from the previously-described 
Ca1a2X model.  
 
Computational work  
 In addition to the biochemical and structural methods used to identify FTase and 
GGTase-I substrates, which rely on various in vitro and in vivo approaches, in silico 
approaches have also been developed to help address this challenge of substrate 
identification.  Various computational approaches have been introduced over the last 
several years to aid in large-scale prediction of prenylated proteins (44, 45), with features 
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that enable the user to rank the likelihood of a particular sequence being a substrate for 
FTase, GGTase-I, both, or neither.  The methods are iteratively improved by 
continuously incorporating new biochemical data as it becomes available to further refine 
the predictive power of the computational analyses. 
Several computer algorithms have been developed to help predict protein 
substrates for mammalian prenyltransferases.  Among prediction software, one of the first 
tools built was Prosite protocol PS00294 which used the consensus pattern C-{DENQ}-
[LIVM]-x> (http://www.expasy.org/prosite/, (171)). However, this tool is unable to 
distinguish between FTase and GGTase-I substrates, nor does it predict prenylation by 
GGTase-II enzyme. Crystallographic analysis of FTase and GGTase-I complexed with 
eight cross-reactive substrates used interactions with the binding-pocket in the structures 
of the enzyme-substrate complexes to draw inferences about FTase and GGTase-I 
substrate recognition elements (46). The most significant drawback of this approach is 
that it only identifies a subset of verified substrates, missing key substrate-protein 
interactions that are not covered by the peptide diversity in the available crystal 
structures. 
PrePS is the most recent algorithm developed to predict prenyltransferase 
substrates (44).  To define this algorithm, the authors built a training set of known and 
homologous substrates (defined by specific rules) which resulted in a set of 692 FTase 
and 486 GGTase-I substrates.  One of the difficulties in predicting prenylation substrates 
is the inherent complexity of substrate recognition motifs, which may extend beyond the 
Ca1a2X box to include the upstream region of the protein.  To address this additional 
complexity, the authors of PrePS included an eleven amino acid upstream region of the 
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Ca1a2X motif to refine their algorithm, as well as expanding the list of acceptable amino 
acids for the Ca1a2X motif. The upstream region typically consists of a flexible linker 
region that often has a compositional bias towards small or hydrophilic amino acids.  
Using this learning set, the PrePS algorithm defines a set of rules that is used to predict 
the likelihood of a fifteen amino acid sequence being a FTase, GGTase-I, and/or 
GGTase-II substrate. In cross-validation experiments, they were able to establish 92.6% 
and 98.6% true positive rate for FTase and GGTase-I substrates, respectively, with false 
positive rates of 0.11% and 0.02% for FTase and GGTase-I, respectively. Consistent with 
this, analysis of the substrates identified in the peptide library screen described above 
using the PrePS algorithm yielded a very low number of false positive results (41).  
However, the PrePS analysis led to a large number of false negative predictions, around 
40%, indicating that the PrePS algorithm potentially misses a large number of 
prenyltransferase substrates. 
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Figure 1.10. Reactivity of FTase with a library of peptide substrates.  Top panel: The 
percentages of “canonical,” “non-canonical,” and “reactive” pools of peptides in either 
the total library, or the MTO, STO, or NON peptide pools catalyzed by FTase and sorted 
by the amino acid at either the a2 and X position. For a2, canonical = V, I, L, M, T, non-
canonical = all remaining amino acids; for X, canonical = A, S, M, Q, F, reactive = C, N, 
T and non-canonical = I, L, R, Y, D, V, E, G, H, K, P, W. An asterisk (*) represents 
percentages which are statistically different (p<0.02) as compared to the library. Bottom 
panel: FTase sequence preferences for MTO and STO substrates at the a1, a2, and X 
positions. Upstream region selectivity can include residues that form a flexible linker 
region. The a2 and X position amino acids are recognized by FTase in a context 
dependent manner (41, 44, 45, 156).  
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Conclusions  
 Multiple approaches have been employed to identify proteins that are prenylated 
in vivo, catalyzed by FTase and GGTase-I. Although prenyltransferase substrates can be 
identified and studied one at time, FPP and GGPP analogs are being developed to allow 
detection of farnesylated and geranylgeranylated proteins in a “high-throughput” fashion. 
Furthermore, structural and structure/function studies have provided insight into the 
interactions between substrates and the FTase and GGTase enzymes that are important 
for molecular recognition. Peptide library studies have supplied data regarding the amino 
acid composition of substrates and non-substrate pools, allowing the use of statistical 
analysis to determine patterns of FTase recognition and indicating that the Ca1a2X 
paradigm does not sufficiently describe the recognition of substrates by FTase.  
Furthermore, these studies have uncovered the puzzle of the reactivity of single-turnover 
substrates.  Computational studies have allowed prediction of substrates in vivo, based 
upon both the C-terminus of the protein as well as the upstream region. All of these 
studies in concert have helped to define the current pool of proteins known to be 
prenyltransferase substrates. Definition of the prenylated proteome will be essential to 
better understand the roles of prenylation in cellular signaling, disease processes, and the 
complex array of post-translational modifications within the cell.  
 
Objectives of this work 
 Detailed substrate specificity studies for FTase have been carried out using 
peptide library studies, but less information about GGTase-I specificity is available. To 
begin, the expression conditions for recombinantly expressed GGTase-I were improved 
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using auto-induction media, in turn increasing the purification yield of GGTase-I 2.7-
fold. The reactivity of a 402 dansyl-TKCxxx and dansyl-GCxxx peptide library with 
GGTase-I was tested. It was found that 111 of these peptides were substrates with 
GGTase-I (28% of the library) under MTO conditions and 178 (44%) peptides were 
active with GGTase-I under STO conditions. Statistical analysis revealed amino acid 
preferences for GGTase-I substrates in each pool (MTO, STO, and NON) of the peptides. 
For instance, for peptides with MTO activity, GGTase-I prefers I and L at the a2 position, 
F, L, M, and V at the X position. Little sequence selectivity occurs at the a1 position 
under MTO conditions. Further, peptides with STO activity with GGTase-I tend to have 
P and S at the X position and little sequence overrepresentation at the a1 and a2 positions. 
Although this analysis suggests that GGTase-I tends to recognize substrates with typical 
canonical CaaX residues, this work also indicates that a large percentage of peptides with 
non-canonical sequences can still react with GGTase-I.  
 In collaboration with Dr. Ora Schueler-Furman and Nir London at the Hebrew 
University of Jerusalem, a computational method called FlexPepBind was developed and 
tested to enhance the prediction of FTase substrates. This algorithm uses modeling based 
on structural data and the Rosetta suite, and calculates binding energy scores for CaaX 
sequences of potential FTase substrates. Twenty-nine good scoring peptides predicted 
from FlexPepBind were chosen to be tested in vitro and FTase catalyzed farnesylation of 
26 peptides under MTO or STO conditions. FlexPepBind also enhanced prediction of 
non-canonical X residues of FTase substrates with a negatively charged X group, such as 
E or D, and also correctly identified a larger pool of the STO FTase substrates than 
previous algorithms. It is unclear at this time what physically measureable parameter 
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correlates with and explains the predictive power of the FlexPepBind algorithm, but 
nevertheless, the program is very successful at predicting FTase substrates.  
 Finally, it is unknown what substrates are modified in the prenylation pathway so 
more techniques are needed to identify farnesylated, geranylgeranylated, palmitoylated, 
proteolyzed, and methylated proteins in vivo. The lipid donor analogs azido-farnesol and 
azido-geranylgeraniol were used to tag and pull-down potential FTase and GGTase-I 
substrates. Overall, prenylated proteins were detected by this method, but the analogs 
were incorporated at a low level and there was high background. A different approach 
using a library of His6-EGFP-TEV-X11-CaaX genes in mammalian expression vectors, 
transfections, and fluorescence microscopy was used to evaluate FTase and GGTase-I 
specificity in vivo. The EGFP-fusion proteins that matched C-terminal sequences reactive 
with the prenyltransferases in vitro typically displayed membrane localization when 
overexpressed in cells, suggesting that the proteins undergo modification. Likely, mass 
spectrometry will be the most useful tool in the future to analyze the modifications on 
these fusion proteins. Together, this work furthers the understanding the substrate 
recognition of FTase and GGTase-I, helps to predict substrates in vivo, and will help to 
understand which signaling and metabolic pathways may be affected by treatment with 
FTase and GGTase-I inhibitors.  
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CHAPTER II 
 
INVESTIGATION OF PROTEIN GERANYLGERANYLTRANSFERASE-I 
SUBSTRATE SPECIFICITY USING PEPTIDE LIBRARY STUDIES1 
 
Introduction 
 Protein geranylgeranyltransferase-I (GGTase-I) and protein farnesyltransferase 
(FTase) catalyze the attachment of a 20-carbon or 15-carbon geranylgeranyl or farnesyl 
group, respectively, to the C-terminus of a substrate protein (1, 2). These hydrophobic 
modifications help to target substrates to the cellular membranes and promote 
protein/protein interactions (3, 4) and are involved in a myriad of cellular processes and 
pathways. Therefore, inhibitors towards GGTase-I and FTase are of interest for the 
treatment of diseases such as cancer (5), Hutchinson-Gilford Progeria syndrome (6), and 
parasitic diseases like malaria (7). Some examples of prenylated proteins include the Ras 
and Rho GTPase superfamilies (8, 9) and the nuclear lamins (10) although the full 
complement of in vivo substrates of GGTase-I and FTase are unknown. Because of the 
impact of prenylation on a host of diseases, it is necessary to define the set of in vivo 
substrates of the prenyltransferase enzymes to allow for development of targeted 
                                                 
1 A portion of the screening and kinetic analysis of peptide reactivity with GGTase-I that is discussed in 
this work was carried out by Hartman, H.A., Janik, L.S., Kelley, R.A., and Hendershot, J. The statistical 
analysis was carried out in collaboration with Watt, T.J. Dansyl-GCxxx peptides were provided by Aditya, 
A..V. and Gibbs, R.A. at Purdue University. 
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therapeutics against these prenylation-dependent pathways. Both FTase and GGTase-I 
were proposed to recognize a canonical “Ca1a2X” sequence at the C-terminus 
of protein substrates (2, 8, 11), where “C” is cysteine, “a1” and “a2” are aliphatic amino 
acids, and “X” is typically methionine, alanine, glutamate or 
serine for FTase and leucine or phenylalanine for GGTase-I (12-15). Although the 
Ca1a2X sequence can act as model for some substrates, it is becoming increasingly 
evident that substrate recognition by FTase and GGTase-I is more complex than 
previously proposed and that the CaaX paradigm should be expanded (16). In vitro, short 
peptides can be utilized as prenyltransferase substrates with similar activity and affinity 
to full-length proteins (14, 15, 17-19), allowing for the investigation and expansion of the 
CaaX paradigm. Previous studies have shown that FTase and GGTase-I selectivity arises 
from relative peptide reactivity rather than binding affinity (20). Furthermore, FTase and 
GGTase show inverse correlation with substrate X group hydrophobicity (20); FTase 
tends to be less reactive as the hydrophobicity of X increases (preferring residues such as 
S and Q), whereas GGTase-I is more reactive with increasingly nonpolar X residues like 
I and L (20). A group of X residues with optimum hydrophobicity can act as dual 
substrates for both FTase and GGTase-I (i.e., M and F) (20). Additionally, in vivo many 
proteins contain a polybasic region upstream of the CaaX sequence, and peptide studies 
have shown that in FTase, a polybasic region increases peptide binding affinity but 
decreases reactivity, while in GGTase-I there appears to be no effect (21). Therefore, dual 
substrates of FTase or GGTase-I could also arise because of similar reactivity (21). 
Further studies have also characterized the relationship of the X residue to the a2 residue 
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in substrates for FTase, finding that the FTase recognizes substrates in a context- 
dependent manner (22).   
  
 
Figure 2.1. Preferred kinetic mechanism of GGTase-I. This is a simplified diagram of 
the kinetic pathway. The GGTase-I enzyme binds the lipid donor GGPP and the peptide 
or protein substrate. In order for the reaction to occur, the prenyl chain of the GGPP must 
rotate to move the C1 of GGPP closer to the thiolate of the peptide. Another substrate 
binds to help facilitate product release. MTO peptides are able to proceed through steps 
1-5 whereas STO substrates only go through chemistry, steps 1-3. The E•GGPP and 
E•GG-Spep complexes can also slowly dissociate; however, for clarity these pathways 
are not shown. See Chapter 1 Figure 1.9 for a more detailed scheme.  
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 Both of the CaaX prenyltransferases have been proposed to proceed through the 
kinetic scheme shown in Figure 2.1. The mechanism is thought to be kinetically ordered 
with FPP and GGPP binding to FTase or GGTase-I before the peptide or protein (23-25), 
consistent with the binding affinities of FPP and GGPP being in the low nanomolar range 
(26, 27). Additionally, for FTase, formation of the E•FPP complex enhances the affinity 
for the peptide (19). Once the ternary complex is formed, the C1 of FPP and GGPP are 
about 7Å away from the catalytic Zn2+, so the first and second isoprene units rotate such 
that the C1 is near the sulfur of the peptide or protein substrate (28-31). Then, the 
reaction occurs,  forming the prenylated product and diphosphate, and the diphosphate 
substrate is rapidly released (32). For the prenyltransferase reactions under subsaturating 
substrate and initial rate conditions, the dissociation of the diphosphate product is the first 
irreversible step (24, 32), so kcat/KMpeptide includes the rate constants from peptide binding 
to E•GGPP (or E•FPP) through the conformational change and the chemistry step, but 
does not include the rate constants for the release of the farnesylated peptide product (24, 
28, 31-33). Conversely, kcat conditions (saturating substrates) include the rate constants 
after the formation of E•GGPP•peptide through product release and product release is 
frequently the rate limiting step (32, 34). Lastly, the rate of dissociation of the prenylated 
peptide is enhanced by the binding of GGPP (or FPP) to the product•enzyme complex 
(20, 34, 35).  
 Recently, large peptides libraries have been used to determine elements of 
molecular recognition for FTase, using statistical analysis to determine FTase sequence 
preferences. Two libraries were tested: a library based on sequences derived from the 
human proteome and a targeted library that was designed based on results from the 
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original library. FTase was found to catalyze prenylation of two pools of substrates: 1) 
multiple turnover substrates (MTO) and 2) single turnover-only substrates (STO), 
peptides that are farnesylated but for which multiple turnovers do not occur (16, 20). In 
short, MTO substrates are able to proceed through the whole kinetic cycle (steps 1-5 in 
Figure 2.1), but modified STO substrates are not released from the enzyme, only 
progressing through the chemical step (steps 1-3 in Figure 2.1). The MTO pool of 
substrates followed the Ca1a2X paradigm more closely, while STO substrates had a wider 
range in sequences. Additionally, GCxxS and GCxxL libraries (where x is any amino 
acid) were tested with FTase by the Gibbs lab at Purdue University, finding that FTase 
can modify many proteins in both libraries (36, 37), contrary to the prediction that a 
leucine at the terminal amino acid confers specificity for GGTase-I.  
 Less information is available to describe how GGTase-I recognizes its substrates. 
Peptide libraries studies are a useful approach, since a large number of sequences can be 
screened quickly and efficiently using a 96-well plate assay, using the wild-type enzyme 
and the natural lipid donor, GGPP. Statistical analysis can then be applied to indentify 
elements important for substrate recognition for GGTase-I. In this chapter, I design a 
diverse library of peptides and measure the reactivity of GGTase-I with these peptides to 
evaluate the determinants of substrate recognition. These studies provide useful 
information for predicting potential in vivo GGTase-I substrates, and analyzing the 
potential for dual prenylation of substrates. This work will also aid in identifying the 
effects of GGTase-I and FTase inhibitors on prenylation of in vivo proteins and metabolic 
pathways.  
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Experimental Procedures 
GGTase-I expression and purification 
 The E. coli expression vector for rat GGTase-I in the pET23a-GGPT vector was 
constructed by previous Fierke lab members as described in (38). The pET23a-GGPT 
plasmid was transformed into BL21(DE3) E. coli cells and grown overnight at 37ºC on 
LB/agar plates with 100 μg/mL ampicillin. To improve and test GGTase-I expression 
conditions, sterile 24-well plates were prepared with 0.9 mL per well of LB containing 
10% glycerol, 100 μg/mL ampicillin, isopropyl β-D-1-thiogalactopyranoside (IPTG, 0, 
50, 100, or 400 μM) or zinc (0, 100 μM ZnSO4 or 100 μM ZnSO4/67 μM NH4Cl). 
Additionally, protein production was measured using autoinduction media (Overnight 
Express Autoinduction System, Novagen) with varying zinc. An inoculating loop was 
used to pick one colony from the LB/agar plate with ampicillin, and then was dipped into 
three media conditions to inoculate the cultures. The cultures were grown for 24 hours at 
28°C shaking at 350 rpm. A sample of 0.75 mL was removed from each culture and 
transferred to a microcentrifuge tube. The cells were harvested by centrifugation at 
10,000xg for 5 minutes and lysed by adding 113 μL of B-per Reagent (Thermo) spiked 
with 0.2 μL benzonase (Sigma). The soluble and insoluble fractions were separated by 
centrifugation at 15,000xg for 5 minutes, and the insoluble fraction was dissolved in 113 
μL 6M urea. Undissolved material was removed from the insoluble fraction by 
centrifugation at 15,000xg for 5 minutes. To visualize protein expression, both soluble 
and insoluble fractions were fractionated on an SDS-PAGE gel and protein bands were 
visualized using Coomassie dye. As the autoinduction media plus ZnCl2 showed the best 
expression, for large scale protein purification, the pET23a-GGPT plasmid was 
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transformed into BL21(DE3) E. coli cells like before, and one colony was inoculated into 
5 mL of 2xYT media with 100 μg/mL ampicillin. This culture was grown for 4 hours at 
37ºC shaking at 225 rpm until it was cloudy. Then the 5 mL starter culture was added to 
1L of autoinduction media and 100 μg/mL ampicillin and incubated at 28ºC for 24 hours, 
shaking at 185 rpm. Cells were harvested by centrifugation (15 minutes, 4°C, 6,000 rpm) 
and resuspended in 20 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) pH 7.8, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM tris(2-
carboxyethyl)phosphine hydrochloride (TCEP),  10 ng/mL phenylmethanesulfonyl 
fluoride (PMSF), and 1 ng/mL Nα-p-Tosyl-L-arginine methyl ester hydrochloride 
(TAME) and frozen at -80ºC. For purification, the cells were thawed on ice, lysed using a 
microfluidizer (Microfluidics, Newton, MA), and the nucleic acids were precipitated by 
addition of 1/10 volume of 10% w/v streptomycin sulfate followed by centrifugation at 
12,000 rpm for 45 min at 4°C. The GGTase-I protein was purified from the supernatant 
of this cleared lysate (generated from a 1L original culture) on approximately 100-150 
mL DEAE-cellulose column (Whatman) using a 500 mL gradient of 0.1 to 0.5 M NaCl in 
50 mM HEPES pH 7.8, 10 μM ZnCl2, and 2 mM TCEP (HTZ buffer). After analyzing 
the fractions from the column for GGTase-I using SDS-PAGE, the fractions containing 
GGTase-I were pooled and concentrated to 10 mL using Amicon Ultra centrifugal filter 
devices with a 10,000-MW cutoff filter (Millipore) and dialyzed against 2x4L of HTZ 
buffer. Next, the protein was further fractionated by loading the entire 10 mL of 
concentrated partially purified GGTase-I on a 20 mL HQ POROS column (Applied 
Biosystems) using a gradient 0 to 0.5 M NaCl in 750 mL HTZ buffer. Fractions 
containing GGTase-I were pooled and concentrated to using Amicon Ultra centrifugal 
64 
filter devices with a 10,000-MW cutoff filter and dialyzed against 50 mM HEPES pH 7.8 
and 2 mM TCEP. Aliquots of 250-500 μM GGTase-I (5-20 μL) were flash frozen and 
stored at -80ºC. An active site titration was performed to determine the protein 
concentration by monitoring fluorescence resonance energy transfer (FRET, 280 nm 
excitation/496 nm emission) of the dansyl-GCVLL peptide and GGTase-I when the 
peptide is titrated into a stock of GGTase-I alone or GGTase-I/3-aza-GGPP (an inactive 
GGPP analog) complex.  
 
Peptide libraries 
 To increase the diversity of amino acids at the a1, a2, and X positions of the lab’s 
peptide libraries, a “diversity set” of peptides was added to the overall peptide library. In 
collaboration with Dr. Terry Watt, human protein sequences from the Swiss-Prot 
database were downloaded that contained a cysteine four amino acids from the C-
terminus and all redundant and viral sequences were removed. Eighty-three additional 
CaaX sequences were chosen from this unique human sequence list such that each of the 
20 amino acids would be represented in a minimum of 10 peptides at each of the a1, a2, 
and X positions in the final combined library. Peptides of the form dns-TKCxxx (where x 
is any amino acid, and dns is the dansyl fluorophore) were purchased from Sigma 
Genosys (The Woodland, TX) in the PEPscreen™ format , to form the “diversity” library 
and are >70% pure. The peptides were dissolved in 10% DMSO in EtOH and stored at -
80ºC and peptide concentration was calculated by measuring free thiols from the 
absorbance change after reaction with 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) (39) 
using an extinction coefficient of 14,150 M-1cm-1 at 412 nm. Additionally, peptides of the  
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1. Original 
Library 
2. Targeted 
Library 
3. Diversity 
Library 
4. “G” 
Library
CKAA CTVF CIVK CGIM CGCR CVTT CPLA CRLR CWLA CMMK CAWV CIHF 
CGCA CSKG CHDL CNIM CTCR CNVT CSLA CTLR CTQA CWNK CLYV CSHF 
CEDA CFLG CSDL CSIM CVIR CVVT CVPA CDTR CEVA CVYK CARY CCIF 
CQDA CPLG CTDL CVIM CTKR CACV CAAF CFTR CYYA CFFL  CFIF 
CQEA CSLG CSFL CKKM CAVR CCFV CFAF CLTR CRGC CDGL  CKIF 
CSEA CFMG CGGL CSKM CPAS CTHV CFIF CGVR CRKC CWGL  CVIF 
CGIA CSSG CIHL CLLM CGCS CVIV CDLF CTFS CDRC CWKL  CSKF 
CVIA CATG CLHL CNLM CKCS CTKV CFTF CFPS CGSC CRLL  CDLF 
CKKA CCTG CAIL CSLM CTDS CWQV CFVF CRPS CPSC CVPL  CGLF 
CTKA CCAH CCIL CTLM CAES CPFW CLAG CEVS CMTC CLSL  CQPF 
CCLA CVAH CGIL CVQM CGHS CIGW CNFG CVLT CTVC CAYL  CGQF 
CTLA CGCH CIIL CLVM CVHS CRLW CHLG CKIV CQED CGEM  CTVF 
CVLA CLEH CLIL CYVM CKIS CGTW CPVG CTIV CLFD CWEM  CGCI 
CVLA CCHH CNIL CNFN CRIS CEVW CHTH CGLV CEGD CKWM  CHCI 
CCNA CGKH CPIL CGGN CSIS CQVW CFII CKLW CALD CIGN  CPSI 
CCTA CCLH CSIL CVIN CVIS CRVW CVII CAAY CPRD CYQN  CNTI 
CQTA CVLH CVIL CRKN CAKS CSVW CHLK CRLY CSSD CQWN  CHVI 
CIVA CQRH CEKL CKLN CQKS CWDY CSLK CYTY CRGE CWRP  CCWI 
CNWA CACI CFKL CLLN CFLS CDIY CDTK CAVY CCIE CAGQ  CGCL 
CSAC CGCI CALL CCSN CQLS CVIY CETK CYVY CFLE CWLQ  CTIL 
CTGC CKFI CCLL CYSN CVLS CTKY CDVK  CLME CAMQ  CQLL 
CVIC CIHI CILL CVVN CTMS CGLY CKGL  CENE CNNQ  CRLL 
CSLC CGII CSLL CSIP CFPS CVLY CMIL  CKSE CFDR  CVLL 
CGRC CIII CTLL CKKP CFSS CNSY CPLL  CYSE CMKR  CMPL 
CPED CSII CVLL CLKP CSSS CSVY CPVL  CGTE CMVR  CVPL 
CNHD CTII CLML CLMP CVSS CTVY CCLM  CAVE CRLS  CHSL 
CVID CVII CLNL CAQP CLTS CIYY CHVM  CKYE CDMS  CVSL 
CYPD CNKI CQNL CCRP CNTS  CYPN  CHDF CKNS  CCVL 
CSVD CQKI CGQL CSGQ CSVS  CFVN  CMGF CLPS  CLVL 
CIHF CTKI CSQL CVIQ CEYS  CRVN  CADG CMPS  CVIM 
CSHF CQNI CISL CVKQ CLIT  CLIP  CPMG CQPS  CKWM
CCIF CSPI CVSL CNLQ CVIT  CHLP  CCNG CNRS  CCFV 
CKIF CGQI CTTL CTLQ CCKT  CGVP  CWVG CMSS  CLLV 
CVIF CNTI CAVL CVLQ CLKT  CHVP  CGYG CLWS  CPPV 
CSKF CHVI CCVL CKQQ CALT  CEIQ  CRYG CQWS  CTSV 
CTKF CSVI CNVL CITQ CHLT  CHIQ  CMKI CLET   
CGLF CTAK CSVL CQTQ CLLT  CDLR  CCWI CGNT   
CLLF CEEK CSFM CVTQ CSPT  CFLR  CHWI CRRT   
CNLF CWHK CVFM CAVQ CSRT  CMLR  CKWI CTMV   
CGQF CVKK CLHM CACR CKTT  CPLR  CRWI CGNV   
  
Table 2.1. List of total peptide libraries. Libraries 1, 2, and 3 are dns-TKCxxx peptides 
and library 4 is dns-GCxxx peptides, where x is any amino acid. 402 peptides are in the 
total library. Some of the Cxxx sequences in library 4 are identical those in libraries 1-3.  
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 form dns-GCxxx (G library) were synthesized by Animesh Aditya at Purdue University 
as described in (37). A full list of the peptides tested is shown in Table 2.1. The 
“Original” library (Library 1) and the  “Targeted” library (Library 2) were previously 
tested with FTase (16), and the “Diversity” library (Library 3) and the “G” library 
(Library 4) are new.  
 
Multiple turnover assay screen  
 Peptides were screened for multiple turnover (MTO) activity with GGTase. The 
“Original” and “Targeted” libraries of dns-TKCxxx peptides were already screened for 
MTO activity catalyzed by GGTase-I by previous lab members Dr. Heather Hartman and 
Dr. Rebekah Kelley, but the remainder of the library was screened as follows: 3 μM dns-
peptide, 20 nM GGTase-I, and 10 μM geranylgeranyl diphosphate (GGPP) were 
incubated together in 50 mM N-(2-Hydroxyethyl)piperazine-N'-(2-
hydroxypropanesulfonic acid) sodium salt (HEPPSO) pH 7.8 and 5 mM TCEP at 25ºC. 
Peptides were incubated in buffer for at least 20 minutes to reduce any disulfide bonds to 
free thiols before the reaction was initiated. Prenylation of a dansyl peptide leads to an 
enhancement in fluorescence that was monitored continuously (λex=340 nm, λem=520 nm, 
(40)) in a 96-well plate (Costar, non-binding surface, Corning, Corning, NY) using a 
POLARstar Galaxy plate reader (BMG Labtechnologies, Durham, NC) (Figure 2.2). Any 
peptide that showed an increase in fluorescence compared to a no enzyme control 
background after 12 hours at 25ºC was considered a MTO substrate. Using the 
assumptions that [peptide] < KM, [GGPP] is saturating, and 10% product is formed the 
lower limit of this assay is approximately 400 M-1s-1, similar to other work (16). 
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(Reaction conditions in Drs. Hartman and Kelley’s work included 50 mM Tris-HCl pH 
7.5, 5 mM DTT, 5 mM MgCl2, 10 μM ZnCl2, 10 μM GGPP, and 10 μM dns-TKCxxx 
peptide. Reactions were initiated by addition of 200 nM GGTase-I and monitored using 
the fluorescence assay described above. Peptides that showed a ≥15% change in 
fluorescence after 1 hour were designated a MTO substrate. Using the same assumptions 
as above, the lower limit of this assay is 200 M-1s-1). Therefore, under both conditions the 
lower limit of the assay is 200-400 M-1s-1.  
 
Single turnover assay screen 
 Peptides that were not prenylated under MTO conditions were screened for STO 
reactivity using either a radioactive or fluorescent assay. For the radioactive assay, 1 μM 
GGTase-I, 0.8 μM 3[H]-GGPP, and 3 μM dns-TKCxxx or dns-GCxxx peptide were 
incubated for 30 minutes in 50 mM HEPPSO pH 7.8 and 5 mM TCEP at 25ºC before the 
reaction was quenched by the addition of an equal volume of 80:20 isopropanol:acetic 
acid. The reactions were spotted on a silica TLC plate, fractionated using 8:1:1 
isopropanol:ammonium hydroxide: water solvent, and the radioactive products on the 
plates were visualized by autoradiography. Peptides were considered a STO substrate if 
at least 10% of the 3[H]-GGPP reacts with the peptide after 30 minutes (by comparing to 
a sample of 1/10 3[H]-GGPP reacted with GGTase-I and dns-TKCVLL). The lower limit 
of the peptide reactivity in this assay is estimated to be ≥ 0.0009 s-1 and is a similar cutoff 
as in other work with FTase (16). 
 For the STO fluorescent assay, 384-well plates were used to screen for STO 
activity with GGTase-I using the POLARStar plate reader. Reactions contained 0, 1 or 2 
68 
μM GGTase-I, 0.8 μM GGPP, and 3 μM dns-TKCxxx or dns-GCxxx peptide in 50 mM 
HEPPSO and 5 mM TCEP at 25ºC. Peptides were incubating in buffer for at least 20 
minutes before the reaction was initiated in order to reduce any disulfide bonds. If a 
significant increase in fluorescence over the no enzyme control was observed for both 
reactions containing GGTase-I (1 or 2 μM) after 30 minutes - 1 hour, the peptide was 
designated a STO substrate. The lower limit of this assay is also ≥ 0.0009 s-1. 
 
 
Figure 2.2. Continuous fluorescence assay to monitor the prenyltransferase reaction. 
Short dansylated peptides can be used as prenyltransferase substrates, and the dansyl 
group increases in fluorescence upon modification due to the enhanced hydrophobic 
environment of the dansyl group in the prenylated product (18, 40). The 
farnesyltransferase reaction is used here as an example.  
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Statistical analysis of amino acid sequence in GGTase-I peptide substrates 
 In collaboration with Dr. Terry Watt (Xavier University of Louisiana), GGTase-I 
substrate preferences were analyzed using statistical analysis. A Chi-square test was used 
to determine the significance of canonical vs. non-canonical sequences in the MTO and 
STO pools of GGTase-I substrates at the a1, a2 and X positions. Next, hypergeometric 
square model analysis (Equation 1) was used to determine if any amino acid sequences 
were over-represented or under-represented compared to the overall library at the a1, a2, 
and X positions of the peptide substrates. p is the probability that a particular amino acid 
occurring at a certain frequency at a position in the substrate pool due to random chance, 
N is the size of the total library, P is the number of peptides in the total library with a 
given amino acid at the position (a1, a2, X), S is the total number of peptide substrates, 
and R is the number of substrate peptides in the pool that have a particular amino acid at 
the position of interest (16).  
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Steady state kinetics 
 The steady state parameter kcat/KMpeptide was measured for a subset of active 
GGTase-I MTO substrates using the fluorescent assay described above, and rotation 
student Jenna Hendershot aided in measuring the reactivity of several of these peptides. 
Reactions contained 0.2 – 40 μM dns-peptide, 20 -100 nM GGTase-I, and 10 μM GGPP 
in 50 mM HEPPSO pH 7.8 and 5 mM TCEP at 25ºC. The concentration of dns-peptide 
was maintained at a concentration ≥ 5 times the concentration of GGTase-I. All curve 
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fitting was performed using Graphpad Prism (Graphpad Software, San Diego, CA). 
Reactions were monitored such that both an initial slope correlating to the initial velocity 
and the reaction endpoint could be observed. To convert fluorescence units (“fl”) to 
product concentration, the change in fluorescence to reach the reaction endpoint was 
divided by peptide concentration. Several peptide concentrations were used to calculate 
an average amplitude conversion factor (Ampconv). The initial slope, in fl/s, was converted 
to velocity (μM product/s) as in equation 2, where V is velocity (μM/s), R is the initial 
slope (fl/s), and Ampconv is the conversion factor (fl/μM).  
convAmp
RV                        (2) 
 To obtain values for kcat/KMpeptide, the Michaelis-Menton equation (Equation 
3).was fit to the dependence of the initial velocity (V/[E]) on the substrate concentration. 
In some cases the values for kcat and KM were also obtained from these fits. 
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Results 
Improvement of GGTase-I expression conditions 
 The rat GGTase-I (and FTase) genes are encoded in the pET23a vector, where the 
gene is behind a strong T7 promoter (41). Traditionally, the two subunits of the 
prenyltransferase proteins were expressed recombinantly by growth of BL21(DE3) E. 
coli cells containing the expression plasmid to mid-log phase, and then inducing by 
addition of IPTG, a lactose analog. The IPTG works to relieve the lac repressor on the lac 
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operon, allowing the chromosomal T7 polymerase under the lac operon to be synthesized 
and the prenyltransferase genes to be transcribed and translated (41, 42). Using this 
method yielded 15 mg of GGTase-I per 1 L of culture, as reported in (38). Overall yield 
from this new purification protocol was 40 mg of GGTase-I/L of culture, which is a 2.7-
fold improvement. Recently, autoinduction media has become a convenient method for 
protein expression, and in some cases even enhances expression. This method works by 
providing the cells with media containing optimal levels of glucose, glycerol, and lactose, 
such that the cells metabolize glucose and glycerol initially for optimal growth with 
lactose metabolized last. When the cells utilize the lactose, the expression is induced 
automatically (“autoinduction”) because the lac repressor is relieved (43, 44). Similarly, 
rather than inducing protein expression by addition of a high concentration of IPTG to a 
culture of cells in late log phase, growing the cells in media that contain a low level of 
IPTG throughout the growth helps to slowly express proteins. Both of these types of 
expression media are convenient, as they do not require monitoring of cellular density for 
induction. 
 Different media conditions were tested to improve GGTase-I expression. Five 
types of base media were used: either 0, 50, 100 or 400 μM ITPG in LB with 10% 
glycerol and 100 μg/mL ampicillin or autoinduction media with 100 μg/mL ampicillin. 
These media were tested alone, supplemented with 100 μM ZnSO4, or supplemented with 
100 μM ZnSO4/67 μM NH4Cl. The soluble fraction of the lysates of cell grown in each of 
these expression conditions was separated using SDS-PAGE as shown in Figure 2.3. On 
this gel, the 48 kDa  and 43 kDa β subunits of GGTase-I (45) run between 40 and 50 
kDa bands of the ladder (Lanes A, B, and C). ITPG concentrations of 50 or 100 μM in 
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LB/glycerol (lanes 2, 3, 7, 8, 12, and 13) and autoinduction media (lanes 5, 10, and 15) 
appeared to show improved expression of GGTase-I with ZnSO4 supplemented cultures 
having the best expression overall (lanes 7, 8, and 10). Overall, the cleanest expression 
appears to be lane 10, where autoinduction media was supplemented with ZnSO4. After 
this, a large scale growth in autoinduction media was used for GGTase-I purification, 
using the procedure described in the Experimental Procedures. Overall, this new method 
for expressing GGTase-I helped improved the total yield of GGTase-I protein 2.7-fold.  
 
 
Figure 2.3. Optimization of growth conditions for GGTase-I expression.  
Cultures were grown in 24-well plates in 0.9 mL of either LB media with 10% glycerol 
and 100 μg/mL ampicillin supplemented with IPTG or autoinduction media with 100 
μg/mL ampicillin. Additionally, cultures were supplemented with 100 μM ZnSO4 or 100 
μM ZnSO4/67 μM NH4Cl. Cells were grown for 24 hours at 28ºC shaking at 350 rpm and 
harvested, lysed with B-per Reagent, clarified by centrifugation, and the soluble fractions 
were fractionated on an SDS-PAGE gel. Lanes A, B and C are molecular mass markers, 
and the two subunits of GGTase-I run between 40 and 50 kDa and are indicated by the 
arrows. Cells grown in media containing 50 or 100 μM IPTG in LB/glycerol (lanes 2, 3, 
7, 8, 12, and 13) and autoinduction media (lanes 5, 10, and 15) appeared to have 
improved expression, with ZnSO4 supplemented cultures having the best expression 
overall (lanes 7, 8, and 10). The culture in Lane 14 did not grow properly. The 
darkness/contrast has been adjusted in this figure for clearer visualization of the bands 
over the gel.  
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Peptide substrates of GGTase-I  
 Overall, the reactivity of purified GGTase-I for catalyzing geranylgeranylation of 
402 peptides was tested under both multiple turnover (MTO) and single turnover (STO) 
conditions (Table 2.2). In this analysis, GGTase-I catalyzes prenylation of 111 or 28% of 
the peptides under MTO substrates conditions ([S] > [E]). Additionally, under STO 
conditions ([E] > [GGPP]), GGTase-I catalyzes geranylgeranylation of an additional 178 
peptides, or 44% of the library. STO activity indicates that the peptides bind to GGTase-I 
and are prenylated, but GGTase-I does not react with a second peptide, presumably due 
to slow product dissociation. Therefore, GGTase-I can recognize and catalyze 
geranylgeranylation to varying extents of 72% of the peptides in the library. Table 2.3 
lists the peptides in the MTO and STO substrate pools.  
 
Pool Number of Peptides 
Library 402 
Multiple Turnover (MTO) 111 (28%) 
Single Turnover (STO) 178 (44%) 
 
 
Table 2.2. Substrates of GGTase-I. 402 peptides were screened for activity with 
GGTase-I (a mix of dns-TKCxxx and dns-GCxxx peptides, where x is any amino acid). 
GGTase-I catalyzes prenylation of 72% of the peptides in this library.  
 
Sequence analysis of MTO and STO GGTase-I substrates 
 With the help of Dr. Terry Watt, we analyzed overall patterns in the peptide 
sequences for the MTO, STO, and non-substrate (NON) pools of GGTase-I substrates 
using a Chi-squared test. The peptides were separated into canonical or non-canonical 
Ca1a2X sequences and the sequence preferences were analyzed at the a2 and X positions. 
A canonical a2 residue for GGTase-I was defined as I or L (with the other 18 amino acids 
being non-canonical) and canonical GGTase-I residues at the X position were defined as 
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Multiple Turnover Single Turnover Non-substrates 
CWLA CMIL CWLQ CKAA CPMG CSFM CSIS CGCA CIVK CRIS 
CVIC CNIL CLIT CGIA CSSG CLHM CVIS CEDA CHDL CAKS 
CTVC CPIL CVLT CVIA CATG CKKM CQKS CQDA CTDL CFLS 
CFAF CSIL CCFV CPLA CCTG CSKM CQLS CQEA CDGL CDMS 
CCIF CTIL CCFV CTLA CWVG CLVM CRLS CSEA CGGL CFPS 
CCIF CVIL CKIV CVLA CGYG CYVM CVLS CKKA CIHL CFSS 
CFIF CWKL CTIV CVPA CRYG CKWM CTMS CTKA CEKL CSSS 
CFIF CALL CVIV CTQA CCAH CKWM CKNS CCLA CFKL CEYS 
CKIF CCLL CGLV CCTA CVAH CIGN CFPS CSLA CQNL CCKT 
CKIF CILL CLLV CEVA CGCH CVIN CLPS CVLA CGQL CLKT 
CVIF CPLL CTMV CIVA CCHH CKLN CMPS CCNA CISL CSPT 
CVIF CQLL CAWV CYYA CGKH CLLN CQPS CQTA CVSL CSRT 
CTKF CRLL CLYV CSAC CCLH CYPN CRPS CNWA CGEM CKTT 
CDLF CRLL CKLW CTGC CVLH CYQN CNRS CRGC CVQM CACV 
CDLF CSLL CRLW CRKC CHTH CRVN CMSS CDRC CNFN CTHV 
CGLF CTLL CVIY CSLC CACI CLIP CVSS CGRC CGGN CTKV 
CGLF CVLL CGLY CPSC CGCI CSIP CLTS CGSC CRKN CGNV 
CNLF CVLL CRLY CPED CHCI CLKP CNTS CMTC CCSN CWQV
CQPF CLML CVLY CQED CKFI CHLP CEVS CVID CYSN CIGW 
CFTF CMPL CAVY CLFD CMKI CAQP CSVS CALD CVVN CGTW
CFVF CVPL CYVY CEGD CNKI CCRP CLWS CSVD CQWN CEVW 
CTVF CVPL  CNHD CQNI CWRP CQWS CCIE CKKP CQVW
CTVF CVSL  CYPD CGQI CGVP CLET CENE CLMP CRVW
CFII CAVL  CPRD CPSI CHVP CVIT CAVE CAGQ CSVW 
CGII CCVL  CSSD CNTI CVIQ CALT CAAF CSGQ CTKY 
CIII CCVL  CRGE CCWI CVKQ CHLT CSKF CEIQ CARY 
CSII CLVL  CFLE CRWI CNLQ CLLT CLAG CAMQ  
CTII CNVL  CLME CTAK CTLQ CGNT CADG CNNQ  
CVII CPVL  CKSE CSLK CVLQ CRRT CNFG CKQQ  
CVII CSVL  CYSE CMMK CITQ CVTT CSKG CVTQ  
CNTI CAYL  CGTE CWNK CQTQ CNVT CPLG CAVQ  
CHVI CVFM  CKYE CDTK CTCR CVVT CFMG CACR  
CHVI CGIM  CHDF CETK CVIR CPPV CCNG CGCR  
CSVI CNIM  CMGF CDVK CMKR CTSV CPVG CFDR  
CCWI CSIM  CIHF CVYK CTKR CPFW CLEH CDLR  
CHWI CVIM  CIHF CGCL CPLR CAAY CQRH CFLR  
CKWI CVIM  CSHF CSDL CRLR CWDY CGCI CMLR  
CFFL CCLM  CSHF CKGL CAVR CDIY CIHI CTLR  
CSFL CLLM  CSKF CLHL CGVR CNSY CQKI CDTR  
CWGL CNLM  CLLF CLNL CMVR CYTY CTKI CFTR  
CAIL CSLM  CGQF CSQL CTDS CSVY CSPI CLTR  
CCIL CTLM  CGQF CHSL CAES CTVY CEEK CPAS  
CGIL CHVM  CFLG CLSL CTFS CIYY CWHK CGCS  
CIIL CFVN  CHLG CTTL CGHS  CVKK CKCS  
CLIL CHIQ  CSLG CWEM CVHS  CHLK CKIS  
 
Table 2.3. MTO and STO substrates of GGTase-I. Substrates are a mix of dns-
TKCxxx (regular) and dns-GCxxx peptides (bold). They are ordered by X group. 
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Figure 2.4. The percentages of canonical and non-canonical residues for peptides in 
the overall library, and in the pools of peptides that are substrates for GGTase-I 
under multiple turnover (MTO) and single turnover (STO) conditions. At the a2 
position, canonical is defined as I and L whereas at the X position, canonical residues are 
defined as F, L, and M  (12-15, 20). The sequences of the peptides in the MTO and STO 
pools are significantly different from the library (p≤0.01, Chi-squared test). The 
sequences of the MTO substrates generally follow typical CaaX predictions; however, the 
sequences of the STO peptides are not well described by the canonical CaaX paradigm. 
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Figure 2.5. Distribution of amino acids in peptides at the a1, a2, and X positions that 
are substrates for GGTase-I under MTO and STO conditions or are not reactive. 
Each amino acid was tallied at the a1 (A), a2 (B), and X (C) position for each pool of 
substrates and graphed by amino acid count vs. amino acid identity. Peptides with MTO 
activity with GGTase-I are in black, peptides with STO activity are in gray, and non-
substrates are in white. Additionally, the amino acids are organized on the X-axis by 
increasing hydrophobicity based on ∆Gtransfer values (kcal/mol) from reference (46). 
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F, L, or M (defining the other 17 amino acids as non-canonical) (12-15, 20). Figure 2.4 
shows the percentages of canonical and non-canonical amino acids contained in the 
library, the MTO pool, and the STO pool at the a2 and X positions.  
 The MTO and STO pools of GGTase-I substrates reveal unique sequence 
patterns. For the MTO substrates, there is a significant increase in the percentage of 
canonical sequences at both the a2 and the X positions as compared to the library. For 
instance, at the X position in the MTO pool vs. the library, the percentage of peptides 
with a canonical residue (F, L, or M) increases from 28% to 65%. This shows that in 
general, peptides that are active with GGTase-I under multiple turnover conditions are 
likely to have a canonical residue at the a2 or X position. Although many substrates 
contain canonical sequences at a2 and X, it is worth noting that many substrates do not. 
Figure 2.5 shows the frequency of each amino acid in each type of GGTase-I substrate at 
the a1, a2, and X positions of the peptides (Figure 2.5 A, B, and C, respectively). In 
general, at the a2 position, substrates that have MTO activity with GGTase-I (Figure 2.5 
B, black bars) can be hydrophobic, contain large residues such as W and Y, or even 
hydrophilic residues like K and S. The same trend is observed for the X position for 
GGTase-I substrates with MTO activity. Generally, GGTase-I recognizes more substrates 
containing hydrophobic amino acids (Figure 2.5 C, black bars), but also catalyzes 
geranylgeranylation of peptides with a variety of amino acids at the X position including 
hydrophilic ones like N and Q. Additionally, GGTase-I appears to recognize all amino 
acids at the a1 position for substrates with MTO activity.  
 Conversely, in the STO pool, the substrates for GGTase-I are more varied. 
Comparing the library peptides to the single turnover pool, there is actually a significant 
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increase in the non-canonical sequences at the a2 and X positions in the substrates of 
GGTase-I with single turnover activity (Figure 2.4). This trend is also illustrated in 
Figure 2.5. Each of the 20 amino acids is present at the a1, a2, and X positions in the 
substrates with STO activity with GGTase-I (gray bars Figure 2.5 B and C). Overall, this 
study suggests that GGTase-I is able to prenylate a wider range of substrates than 
originally proposed.  
 To more carefully examine these trends, a hypergeometric distribution model was 
used to analyze GGTase-I substrates for single amino acid preferences at the a1, a2 and X 
positions (with the help of Dr. Terry Watt). This analysis determines whether a single 
amino acid appears in a substrate more or less often compared to its appearance in the 
overall library; therefore, it shows whether a certain amino acid is overrepresented or 
underrepresented in the MTO, STO, and NON pools than the overall library. Table 2.4 
shows the final results of this analysis. For amino acids in bold, p ≤ 0.02, and for amino 
acids in italics, 0.02 ≤ p ≤ 0.05.  
 Overall, the results of this analysis reveal that, in general, GGTase-I shows a 
preference for reactivity with peptides containing canonical CaaX sequences at the a2 and 
X positions and shows little selectivity at the a1 position. However, the CaaX model 
should be expanded. At the a1 position, GGTase-I appears to slightly prefer V in 
substrates with MTO activity (p≤0.05) and Y for substrates with STO activity (p≤0.05), 
and selects against E (p≤0.05) and F (p≤0.02) for MTO and STO substrates, respectively. 
Furthermore, peptides that are not active with GGTase-I often contain an A (p≤0.05) or 
an E (p≤0.02) at the a1 position. The historical CaaX paradigm states that a1 should be 
small and aliphatic amino acids (and the overrepresentation of V in the MTO substrates 
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fits that definition); however, the structural data indicate the a1 residue is exposed to 
solvent in the FTase•FPP analog•peptide complex consistent with biochemical data 
suggesting broader selectivity. (14-16, 47, 48). In focusing on the a2 position, GGTase-I 
recognizes peptides that contain the residues I and L (p≤0.02) and to a lesser extent, V 
(p≤0.05) under MTO conditions. Furthermore, 10 amino acids that are hydrophilic or 
charged are underrepresented at the a2 position in peptides with MTO activity with 
GGTase-I. For substrates with STO activity with GGTase-I, the residue H (p≤0.05) 
appears more often and I (p≤0.02) appears less often at the a2 position. For peptides with 
no activity with GGTase-I, the amino acids C and D (p≤0.05) as well as K (p≤0.02) are 
overrepresented at the a2 position. Therefore, GGTase-I prefers substrates containing an I, 
L, and V (small and aliphatic) at the a2 position as the CaaX paradigm predicts and 
selects against amino acids with charged and hydrophilic side chains (like H, C, D, and 
K) at the a2 position as demonstrated in the STO and NON substrate pools. Finally, 
GGTase-I prefers substrates with residues like F, I, L, M and V at the X position under 
MTO conditions, while selecting against peptides with X residues like A, D, E, G, H, K, 
P, R and S, indicating that GGTase-I selects for hydrophobic residues and generally 
discriminates against smaller and charged residues at the X position. The analysis of 
substrates with STO activity with GGTase-I shows more non-canonical sequence 
preferences at the X position since H, P, and S are overrepresented and L and V are 
underrepresented. Additionally, small, large, and charged amino acids like A, R, and W 
are overrepresented in the peptides that are inactive with GGTase-I. Together, these data 
suggest that the canonical X-group residues for GGTase-I should be expanded to include 
V and I, and H, P, and S for substrates with STO activity. Although these data indicate 
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substrates preferences at each of the a1, a2, and X side chains; however, there is little 
strict discrimination against any one amino acid since almost all amino acids were 
observed at each position in at least one substrate with at least single turnover activity.  
 An interesting trend in this analysis is that many amino acids that are 
overrepresented in a particular substrate pool for GGTase-I are underrepresented in 
another substrate pool. For instance, F, L, M, and V are overrepresented in the MTO 
substrates at the X position but L and V are underrepresented in the STO substrates while 
F, L, and M are underrepresented in the NON substrates. Another example is I and L at 
the a2 position. These two residues are preferred in MTO substrates at a2 while I and I/L 
are depleted in the STO and NON substrates, respectively. These anticorrelation trends 
validate the preferences as they are depleted for the STO and/or NON pools.  
 
Steady state parameters for GGTase-I: importance of upstream regions 
 Steady state parameters were measured for a subset of MTO substrates. The 
kinetics for GGTase-I catalyzed geranylgeranylation of the dns-TKCxxx peptides were 
measured by previous Fierke lab members Dr. Hartman and undergraduate student L.S. 
Janik; however, dns-GCxxx peptides were measured in this work. Table 2.5 shows values 
for kcat/KMpeptide for peptides with identical CaaX sequences but varying upstream regions. 
In general, the values for kcat/KMpeptide for the reaction of GGTase-I with dns-GCxxx 
peptides are one to three times higher than the dns-TKCxxx peptides, correlating with 
similar observations with FTase (16, 22). 
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position 
 a1  a2  X 
 over-represented 
under-
represented  
over-
represented
under-
represented  
over-
represented
under-
represented
GGTase-I 
MTO  V E  I, L, V 
C, D, E, H, 
K, N, Q, R, 
S, T 
 F, I, L,  M, V 
A, D, E, G, 
H, K, P, R, 
S 
GGTase-I 
STO  Y F  H I  H, P, S  L, V, W 
GGTase-I 
NON  A, E V  C, D, K I, L  A, R, W F, L, M 
FTase 
MTO  L C  I, L, V C, D, K  F, M, Q None 
FTase 
STO  A, C L  A, S I, K  None M, P, Q 
FTase 
NON  K I  D, E, K, R V, I, L, T  P, R F, Q 
 
 
Table 2.4. Amino acids that are overrepresented or underrepresented in substrate 
and non-substrate pools as compared to the overall library. For amino acids in bold, p 
≤ 0.02 and for amino acids in italics, 0.02 ≤ p ≤ 0.05. FTase data is from reference (16).  
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Sequence kcat/KM (mM-1s-1) Sequence kcat/KM (mM-1s-1)  Fold Difference
GCRLL 54±4  TKCRLL 21±3  2.6 
GCTIL 53±8      
GCVLL 50±7  TKCVLL 38.6±0.4  1.3 
GCVIM 48±5      
GCVIF 42±6      
GCCIF 40±5      
GCCIF 24±3  TKCCIF 15±1  1.6 
GCCVL 20±1  TKCCVL 11.0±0.5  1.8 
GCFIF 19±1      
GCKIF 17±2  TKCKIF 5.0±0.7  3.3 
GCLVL 13.5±0.9      
GCLLV 10±2      
GCMPL 4.6±0.3      
GCTVF 3.3±0.7  TKCTVF 2.9±0.1  1.1 
 
 
Table 2.5. Steady state parameters of peptides with GGTase-I. kcat/KM (mM-1s-1) was 
measured for active MTO dns-GCxxx peptides and compared to dns-TKCxxx peptides 
(measured by previous Fierke lab members). Dns-GCxxx peptides are generally 1-3 fold 
more active than dns-TKCxxx peptides.  
 
Limits of this analysis 
 The lower limits of the reactivity of peptides with GGTase-I under MTO and STO 
conditions in this work are estimated to be ≥200-400 M-1s-1 and ≥ 0.0009 s-1, 
respectively. It is possible that some peptides classified as STO may in fact have MTO 
activity with GGTase-I, but that the MTO activity is below the detection limit under the 
conditions chosen in this work. Further, non-substrate peptides could perhaps have low 
activity with GGTase-I under STO conditions after longer incubation time. However, the 
cutoffs chosen in this work are similar to the peptide library studies done with FTase (16) 
to allow for comparison of the two studies. Overall, cutoffs must be chosen to classify the 
400 peptides into different pools of reactivity; however, any one particular peptide might 
display a different type of reactivity with GGTase-I under a different set of assay 
conditions or time course.  
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Discussion 
MTO and STO substrate specificity  
 Different steps of the prenyltransferase reactions likely contribute to specificity 
for the MTO and STO substrates. For MTO peptides, selectivity arises from everything 
up to the first irreversible step under kcat/KMpeptide conditions; this means selectivity is 
before or at the chemistry step of the reaction since dissociation of the diphosphate 
product is irreversible (22, 49). For peptides that are reactive with GGTase-I under MTO 
conditions, it is likely that the rate limiting step of the reaction is the chemical step, which 
can include the conformational change or the actual chemistry. Recently, mean force 
QM/MM studies with FTase suggest that the activity of FTase arises more from the 
chemistry than the conformational change (Yue Yang, Bing Wang, Melek N. Ucisik, 
Guanglei Cui, Carol A. Fierke, and Kenneth M. Merz, Jr, unpublished data). Similar 
trends may occur with GGTase-I, but have not been elucidated. Additionally, under kcat 
conditions, the release of the prenylated product can be rate limiting for some peptides, at 
least with FTase (32, 34). For substrates with activity with GGTase-I under STO 
conditions, a step after chemistry such as the dissociation of the product, is slow and rate-
limiting. Therefore, under both MTO and STO conditions, GGTase-I binds to the 
peptides and catalyzes geranylgeranylation. For MTO substrates, product dissociation 
occurs sufficiently rapidly to observe turnover. However, for STO substrates, product 
dissociation is slow. This could reflect additional interactions leading to a high affinity 
product or could be due to the inability of the geranylgeranylated peptide to move from 
the binding pocket to the exit groove (28, 50).  
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Comparison of FTase and GGTase-I substrates 
 This work and peptide library studies with FTase have revealed similarities and 
differences in selectivity of FTase and GGTase-I for substrates. Table 2.5 shows the 
results from the statistical analysis of previous work done with FTase in reference (16) 
and the work described above with GGTase-I.  
 At the a2 position for substrates, it is striking that FTase and GGTase-I both select 
for residues I, L, and (to a lesser extent) V in the MTO pool. However, there are not 
overlapping residues for STO substrates; H is overrepresented for GGTase-I substrates 
while A and S are overrepresented for FTase. For both prenyltransferases, C, D, and K 
are underrepresented at a2 in MTO substrates, I in STO substrates, and I and L for non-
substrates. Crystallographic studies have shown that the a2 position of the substrate is 
contacted by residues W102β, W106β, Y361β, and the 3rd isoprene of FPP for FTase and 
T49β, F53β, and L320β, and the 3rd and 4th isoprene of GGPP and the X residue for 
GGTase-I (48). These mainly hydrophobic pockets were predicted to recognize a range 
of small and hydrophobic residues, preferring I and L, but also accepting V, F, Y, T, and 
M (48). The current analysis is consistent with the crystallographic work and provides 
further definition of this selectivity. Although these predictions can define many FTase 
and GGTase-I substrates, these rules are not absolute. A large group of substrates poorly 
defined by this paradigm are reactive with FTase and GGTase-I (16). For instance, when 
defining the canonical a2 residues as I, L, and V for GGTase-I substrates, this paradigm 
describes 78 % of the pool of MTO substrates but only describes 31 % of the pool of 
STO substrates.  
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 For the X position, the library studies in reference (16) with FTase and the studies 
here with GGTase-I indicate that F and M are preferred substrates for both FTase and 
GGTase-I under MTO conditions, demonstrating overlapping specificity. However, the 
selectivity is not identical as FTase prefers Q while GGTase-I also prefers L, V, and to a 
lesser extent, I. These substrate preferences are consistent with previous biochemical 
studies (20) as well as structural work (at least for the phenylalanine) (48). 
Crystallographic studies have shown that the X binding pocket for FTase is more 
hydrophilic in nature, whereas the X pocket for GGTase-I is more hydrophobic leading to 
FTase preferring more polar residues in general and GGTase-I preferring more 
hydrophobic residues (48). The differences in amino acid preferences in the peptide 
library studies reinforce the differences in the specificity of FTase and GGTase-I. Though 
this work and other studies define distinct sequence preferences at the X position for 
GGTase-I and FTase substrates, there are still many substrates for these 
prenyltransferases that do not contain a canonical X side chain and even canonical FTase 
X residues can be recognized by GGTase-I and vice versa. Biochemical work with FTase 
has indicated that selectivity can be context-dependent, meaning that the a2 and X residue 
can be recognized together, suggesting that the identity of one amino acid in the CaaX 
sequence can impact the recognition of another (22). It is possible that similar patterns 
may occur with GGTase-I. Figure 2.5 is a summary of how the CaaX paradigm can be 
updated for general GGTase-I substrate preferences. Overall, if canonical X residues for 
GGTase-I substrates are defined as F, I, L, M, and V, this updated paradigm describes 
85% of the MTO pool of substrates and 24% of the STO pool of substrates.  
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Figure 2.6. Updated Ca1a2X paradigm for GGTase-I. Based upon peptide library 
studies and statistical analysis where p≤0.05, there is selectivity at the a2 and X position 
for MTO substrates and selectivity in X for STO substrates. The upstream region may or 
may not be important for reactivity. 
 
 
Implications of the residues upstream of the CaaX sequence 
 In the cell, the regions of the C-terminus of prenyltransferase substrates are 
variable and often contain a polybasic region (47, 51). In this work we compare the 
reactivity of dns-TKCxxx vs. dns-GCxxx peptides, a charged upstream region vs. an 
uncharged upstream region. Past biochemical work has shown that for GGTase-I, 
multiple lysines have little effect on the reactivity or binding affinity of peptides, but for 
FTase, a polybasic region decreases reactivity but increases affinity (21). As seen in the 
Results section and Table 2.5, G peptides generally have slightly higher values for 
kcat/KMpeptide than the TK peptides. As the proposed rate limiting step is chemistry for the 
peptides reacting with GGTase-I under these conditions, the upstream lysine could form 
long range electrostatic interactions with the GGTase-I enzyme which may alter the 
position of the peptide affecting the reactivity. This upstream polybasic sequence could 
have further implications in vivo, as the region could contain amino acids that are post-
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translationally modified and polybasic regions have been shown to enhance the 
interactions with the plasma membrane for some prenylated proteins (52-54).  
 
In vivo implications 
 A wider range of peptide sequences are accepted as GGTase-I substrates, 
including many non-canonical sequences, especially in the STO pool. Are STO substrates 
truly prenylated in vivo? Since the STO products are not rapidly released from the 
enzyme under in vitro conditions, the product may form a complex with the modified 
protein and inhibit the enzyme; however, there are at least two known examples of in vivo 
STO substrates, corresponding to C-terminal sequences –CAVL (active with FTase under 
STO conditions) and –CKAA (active with GGTase-I and FTase under STO conditions) 
(55, 56). In vitro work has shown that an additional substrate can bind to the product 
complex to help facilitate product release (20, 34, 35), and in most cases this additional 
substrate is the FPP or GGPP molecule (34), although peptides have also been proposed 
(20, 35). Therefore, in the cell it is possible that product release for the STO substrates is 
facilitated by another substrate, protein (i.e., a release factor), or small molecule. 
Potentially, facilitation of product dissociation could be a mechanism of regulating 
prenylation. Furthermore, this could be a mechanism to deliver modified proteins to 
particular cellular membranes. Overall, this work suggests that many more proteins are 
geranylgeranylated than originally proposed and will aid us in understanding what 
pathways include geranylgeranylated proteins and may therefore be affected by inhibitors 
of GGTase-I.  
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CHAPTER III 
 
PREDICTING FTASE SUBSTRATES: DEVELOPMENT OF A NOVEL 
COMPUTATIONAL METHOD1 
 
Introduction 
 Protein farnesyltransferase (FTase) and geranylgeranyltransferase-I (GGTase-I) 
catalyze the addition of a farnesyl or geranylgeranyl group to a cysteine near the C-
terminus of a substrate protein (1, 2). These hydrophobic modifications help to locate 
substrates to cellular membranes and promote protein-protein interactions (3, 4). FTase 
and GGTase-I were proposed to recognize a “Ca1a2X” motif on substrates (2, 5, 6), where 
“C” is the cysteine where the prenyl group is attached via a thioether bond, “a1” and “a2” 
are small and aliphatic amino acids, and “X” confers specificity between the two 
enzymes, with FTase typically preferring methionine, alanine, glutamate or serine and 
GGTase-I preferring leucine or phenylalanine (7-10). Although the Ca1a2X motif can 
serve as a model for specificity, many studies have indicated that not all substrates are 
described by this paradigm and that the Ca1a2X model should be expanded (Chapter 2,  
(11, 12)).  
                                                 
1 A portion of this work is published in London, N., Lamphear, C. L., Hougland, J. L., Fierke, C. A., and 
Schueler-Furman, O. (2011) Identification of a novel class of farnesylation targets by structure-based 
modeling of binding specificity. PLoS Comput Biol 7, e1002170.   
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 Inhibitors towards these two prenyltransferases are of great interest for the 
treatment of a multitude of diseases. For example, Ras was an early discovery as a 
prenyltransferase substrate (13) and is mutated in 30% of all human cancers (14). 
Prenyltransferase inhibitors were initially developed to target Ras protein signaling 
pathways implicated in cancer, but it was later determined that inhibitor efficacy is the 
result of modulating prenylation of non-Ras proteins (15). Therefore, inhibitors are being 
studied for the treatment of other diseases besides cancer such as Hutchinson-Gilford 
Progeria syndrome (16) and parasitic infections (17). Because of the potential 
implications of prenylation in cell biology and potential disease treatment, it is necessary 
to define the complete set of in vivo prenylated proteins. Traditional methods to detect 
prenylation in vivo, such as the use of radioactivity and antibodies, have met limited 
success (1, 18-20); therefore, computational methods to predict prenylated proteins are of 
great value.  
 Past computational approaches to predict prenylation have been developed based 
upon already known substrates. The most recent example of an algorithm for prenylation 
prediction is PrePS, developed by the Eisenhaber group (21, 22). They generated a 
learning set of known and homologous substrates, and also included the region of 11 
amino acids upstream of the Ca1a2X sequence in their analysis. Therefore, PrePS predicts 
the likelihood of prenylation of the C-terminal 15 amino acids of a protein. In recently 
published work of peptide library studies with FTase, PrePS had very low false positive 
rate for farnesylated peptides, but had a high false negative rate, about 40% (11). 
Therefore, this method misses a large group of potential substrates. Other predictions 
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have been done with structural studies (23), but overall a more robust prediction program 
is needed.   
 In this work, we collaborated with Nir London and Dr. Ora Schueler-Furman at 
the Hebrew University of Jerusalem to test a program that predicts farnesylation of 
Ca1a2X sequences (24). The Scheuler-Furman lab developed the FlexPepBind method 
using the FTase peptide library work as a training set (11). To test the predictive power of 
this method, we chose a set of 29 peptides predicted to be FTase substrates to test for 
farnesylation activity. I measured the reactivity of FTase with this set of 29 peptides, 
measuring the value of kcat/KMpeptide for peptides with reactivity with FTase under MTO 
conditions. Overall, FlexPepBind is a robust program for predicting a wide range of 
FTase substrates, which is an exciting breakthrough; however, at this time it is unclear 
what catalytic parameter may correlates with FlexPepBind score.  
 
Experimental Methods 
Development of FlexPepBind 
 This program was developed by our collaborators Nir London and Ora Scheuler-
Furman at the Hebrew University of Jerusalem; more specific details of the program are 
in reference (24). A brief summary of the development of this program is as follows. A 
crystal structure of FTase in complex with the peptide CNIQ and a farnesyl diphosphate 
analog (([(3,7,11-trimethyl-dodeca-2,6,10-trienyloxycarbamoyl)-methyl]-phosphonic 
acid) was used as a template (PDB ID: 1tn6, (23)). Varied peptide sequences were 
threaded onto the peptide backbone and the side chains were packed in the best rotamer 
configuration. Three bonds were held constant to preserve the structure of the binding 
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site: 1) the position of sulfur atom of the CaaX cysteine relative to nearby FTase 
sidechains; 2) the structurally conserved hydrogen bond from the C-terminal carboxylate 
of the peptide to FTase Q167; and 3) the hydrogen bond between the backbone 
carbonyl of the a2 residue to the sidechain of FTase R202β. The arrows in Figure 3.1 
show these three constraints for the calculations. The Rosetta FlexPepDock protocol was 
previously developed by Scheuler-Furman lab to model protein-protein interactions (25) 
using the Rosetta modeling suite (26) and based on this, the Shueler-Furman lab 
developed a simpler and less computationally expensive protocol called FlexPepBind to 
model FTase/peptide interactions. The training set for development of FlexPepBind to 
distinguish between FTase substrates and non-substrates was from reactivity of FTase 
with a peptide library (11) using 77 MTO peptide sequences and 51 non-reactive peptide 
sequences. For each peptide, the energy score from the best configuration was chosen. 
Energy cutoff scores of -0.4 and -1.1 were used validate the training set of peptide 
reactivity with FTase. This protocol was then applied to other test sets as detailed in (24) 
and the results section, and applied to the total 8,000 possible CaaX sequences to predict 
FTase substrates and non-substrates.  
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Figure 3.1. Crystal Structure of FTase. Crystal structure of FTase bound to CNIQ 
peptide (green) and an FPP analog (red) (PDB ID 1tn6 (23)). Three bonds were 
constrained: 1) the position of sulfur atom of the CaaX cysteine relative to nearby FTase 
sidechains; 2) the hydrogen bond between the X residue carboxylate and sidechain of 
FTase residue Q167; and 3) the hydrogen bond between the a2 backbone carbonyl 
oxygen to the side chain of FTase R202β.  
 
 
Choosing peptides for experimental validation of FlexPepBind 
 The best scoring 29 sequences of peptides whose reactivity with FTase had not 
previously been measured were chosen to be tested for activity in vitro; 16 of these 
peptides correspond to the C-terminal sequences of human proteins. These peptides were 
purchased from Sigma Genosys (The Woodland, TX) in the PEPscreen™ format in the 
form dns-TKCxxx, where x is any amino acid. The peptides were dissolved in 10% 
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DMSO in EtOH and stored at -80ºC. The peptide concentration was calculated by 
measuring free thiols using a DTNB assay with an extinction coefficient of 14,150  
M-1cm-1 at 412 nm (27). 
 
Multiple turnover screen for FTase activity 
 3 μM dansylated-peptide (dns-TKCxxx) was incubated with 1 μM 3H- 
farnesyldiphosphate and 25 nM rat FTase in 50 mM HEPPSO, pH 7.8, 5 mM TCEP, 5 
mM MgCl2 at 25ºC for two hours. The reaction was quenched with 80:20 
isopropanol:acetic acid and fractionated on a silica TLC plate (8:1:1 
isopropanol:ammonium hydroxide: water). The TLC plates were visualized by 
autoradiography. Peptides that were observed to be at least 10–20% farnesylated, as 
evaluated compared to 3H-farnesyl-dns-GCVLS, were labeled MTO substrates. Using the 
assumptions that [peptide] < KM and [FPP] is saturating, the lower limit of this assay 
200–400 M-1s-1, similar to the limits observed in previous work (11). 
 
Single turnover screen for FTase activity 
 Single turnover assays were carried out as described above for the MTO assays 
except that the enzyme concentration was increase to 1 μM FTase and incubated with 0.8 
μM 3H-FPP and 3 μM dns-TKCxxx peptide for one hour at 25ºC before the reaction was 
quenched. Peptides were considered a STO substrate if at least 10 - 20% of the 3H-FPP 
reacted with the peptide after one hour. The lower limit of the peptide reactivity in this 
assay is estimated to be ≥ 0.0004-0.0006 s-1 and is a similar cutoff as in other work with 
FTase (11).  
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Steady state kinetics 
 Steady state kinetic parameters for the FTase catalyzed farnesylation of the MTO 
peptides predicted by FlexPepBind were using the fluorescent assay described in Chapter 
2. In this case, reactions contained 0.2 – 40 μM dns-peptide, 20 -100 nM FTase, and 10 
μM FPP in 50 mM HEPPSO pH 7.8, 5 mM TCEP and 5 mM MgCl2 at 25ºC. All curve 
fitting was performed using Graphpad Prism (Graphpad Software, San Diego, CA). Both 
the initial rate and the endpoint of the reactions were measured and the fluorescence was 
converted to concentration using a conversion factor, which was generated by dividing 
the change in fluorescence to reach the reaction endpoint by peptide concentration and 
taking the average at several peptide concentrations. The values for the kinetic 
parameters were determined from the fit of the Michaelis-Menten equation (Equation 1) 
to the peptide dependence of Vinitial/[E].  
][
][
][ peptideK
peptidek
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V
M
cat
      (1) 
 
Correlation of parameters with FlexPepBind scores 
 To determine if various physical parameters correlate with FlexPepBind scores, 
the parameter was graphed with FlexPepBind score. A nonparametric (Spearman) 
correlation analysis was used to determine if the values correlate using Graphpad Prism 
(Equation 2, Graphpad Software, San Diego, CA). This analysis assumes that there is not 
a Gaussian distribution of values and that both the variables are independent. A 
correlation coefficient is obtained from this analysis where rs = 0 if the variables are not 
correlated and rs =1 or -1 if the variables are perfectly correlated or anti-correlated. 
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Further, if -1 < rs < 0, for example, one variable increases as the other decreases. A two 
tailed p value was also obtained with the nonparametric (Spearman) correlation, to assess 
if the correlation is real and not due to chance. In the nonparametric (Spearman) 
correlation analysis, rs is the correlation coefficient, N is the number of pairs (XY), and D 
is the difference between each pair (X-Y) (28).  
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Results 
Development of FlexPepBind: a good predictor of FTase substrates 
  FlexPepBind was created by taking structural data for FTase•peptide complexes 
(23), threading different sequences onto the backbone, and finding the optimal rotamers 
using a modified protocol of FlexPepDock (which utilizes the Rosetta modeling suite) 
that is simpler and faster (24). Three bonds were held constant to maintain the integrity of 
the active site: 1) the cysteine-Zn2+ bond (by maintaining the position of the sulfur 
position in the active site); 2) the hydrogen bond between the X group carboxylate and 
the side chain of FTase Q167; and 3) the hydrogen bond between the a2 backbone 
carbonyl and the side chain of FTase R202β. Energy scores were calculated for the 
binding affinity of FTase for the training set peptides including 77 MTO and 51 NON 
(non-substrate) peptide sequences previously tested for reactivity with FTase (11). A 
threshold of -0.4 energy score was set as a cutoff; any peptide below this threshold was 
designated a peptide that would presumably bind and react with FTase while any peptide 
above this threshold was designated a non-binder and hence not a substrate for FTase. 
Overall, this computational analysis of the training set correctly classified 69% of the 
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substrates in the proper reactive or non-reactive pools with FTase (true positive rate); and 
incorrectly categorized 8% of the training set (false positive rate). A more stringent cutoff 
of -1.1 energy score yields a 44% true positive rate and a 2% false positive rate with the 
training set. As the false positive rate of 8% with the -0.4 cutoff is quite low, this 
threshold was used for further work.  
 After FlexPepBind was developed, the program was tested on other published 
data sets (see reference (24) for more details). First, the program was tested on the 
reactivity of a second “targeted” library data set, published in reference (11), that 
contained peptides whose sequences were biased towards canonical a2 and X sequences. 
In this library, 29 peptides were MTO and 15 peptides were non-substrates (NON); 
applying the FlexPepBind protocol yielded an 86% true positive rate and a 12.5% false 
positive rate (a slightly higher true positive rate than the test set, but also a slightly higher 
false positive rate). The FlexPepBind protocol was also applied to analyze an additional 
set of 41 peptides of the form CxxL (a canonical GGTase-I library) where the reactivity  
with FTase was published (29). FlexPepBind yielded an 88% true positive rate and a 12% 
false positive rate when using a cutoff of -0.4. Figure 3.2 shows the distribution of 
peptide scores for this CxxL library grouped into the two categories identified by 
FlexPepBind: binders/substrates (left side) and non-binders/non-substrates (right side). 
Any substrate peptide with a FlexPepBind score >-0.4 and any non-substrate peptide with 
a score <-0.4 (indicated by the arrows) contributes to the 12% false positive rate. The 
opposite results, substrate <-0.4 and non-substrate >-0.4, contribute to the 88% true 
positive rate. Interestingly, FlexPepBind is able to accurately predict FTase peptide 
substrates even when the X group is Leu, the canonical GGTase-I X group. Overall, 
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FlexPepBind gives similar results for predicting FTase substrates tested against a variety 
of peptide sequences. 
 
Application of FlexPepBind to all possible CaaX sequences and analysis of STO 
sequences 
 To identify possible additional FTase substrates and to further explore FTase 
molecular recognition, FlexPepBind was applied to obtain the energy score for all of the 
8,000 possible CaaX sequences. The distribution of peptide scores for this analysis is 
shown in Figure 3.3. Also graphed is the distribution of the MTO, STO, and NON 
substrates from reference (11). Overall, there are 2309 peptides with scores less than the 
threshold of -0.4 that are predicted to be FTase substrates (29% of the 8,000 possible 
sequences). In particular, a new proposed sequence motif was identified, -CaaX 
sequences that contain an acidic (D or E) X residue. For the data sets of known reactivity 
with FTase from reference (11), the scores of MTO and STO pools of peptides are 
skewed to more negative energy scores, as expected for substrates (Figure 3.3, green and 
red lines). The FlexPepBind algorithm identifies 47% of the STO peptides as FTase 
substrates, which is significantly better than the PrePS algorithm, which predicted only 
14% of those sequences as substrates for FTase.  
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Figure 3.2. The distribution of FlexPepBind scores of a set of Ca1a2L peptides tested 
with FTase. The left section of the graph is substrates with FTase while the right section 
of the graph is non-substrates. The horizontal black line is the -0.4 threshold. In general, 
FTase substrates have a score less than -0.4. Overall, there is an 88% true positive rate 
and a 12% false positive rate, with the peptides that contribute to the 12% false positive 
rate noted by arrows.  
  
 
 
Figure 3.3. The energy distribution scores as calculated by FlexPepBind of all CaaX sequences, as well as the MTO, STO, and 
NON data sets from reference (11). The black line indicates the cutoff FlexPepBind score of -0.4. Anything less than this threshold 
is predicted to be a substrate, while those above are predicted to be non-substrates. The scores for the peptides in the MTO and STO 
pools are skewed towards more negative energy values (FTase substrates) while the scores for the peptides in the NON pool are 
skewed towards higher values.  
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Testing substrates of FlexPepBind in vitro 
 To further test the predictive power of the FlexPepBind algorithm, the reactivity 
of FTase was tested with 29 peptides having high FlexPepBind scores. The best scoring 
13 sequences of previously uncharacterized peptides were chosen as well as 16 high 
scoring peptides corresponding to real proteins in the human proteome that have not been 
previously identified as FTase substrates. Seven of these peptides contain an acidic X 
residue, a class of non-canonical X groups. The peptides were screened for MTO and 
STO reactivity with FTase and the results are shown in Table 3.1. 
 FTase catalyzed farnesylation of 26 out of the 29 peptides predicted to be FTase 
substrates using FlexPepBind, despite the inclusion of non-canonical amino acids, such 
as X = D or E. Nineteen of these peptides were MTO substrates of FTase, seven were 
STO substrates, and only three were non-reactive with FTase under the conditions of the 
screen. Generally, a more negative FlexPepBind score correlates with MTO or STO 
FTase reactivity (Table 3.1). Furthermore, six of the seven peptides with acidic X 
residues (bold in Table 3.1) are FTase substrates with three farnesylated under MTO 
conditions (CYVE, CYIE, CYLD) and three are farnesylated under STO conditions 
(CYLE, CFIE, CTTE). Only CLFE was a non-substrate. The MTO, STO, and NON pools 
of substrates had average energy scores of -2.8 ± 0.8, -2.7 ± 0.8, and -1.6 ± 0.1, 
respectively. The modeled structures of peptide substrates with a negatively charged X 
group bound to FTase suggest that this X group is stabilized by an electrostatic 
interaction with FTase residue H149β and hydrogen bonds with W102β and S99β (Figure 
3.5). Overall, this analysis further validates shows that FlexPepBind as a robust method  
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Sequence Score Protein 
MTO Substrates:   
C Y L I -3.96  
C Y L V -3.60  
C F L V -3.60  
C L I I -3.51  
C Y V E -3.43  
C Y I E -3.40  
C L I V -3.33 NACHT and WD repeat domain-containing protein 1 (and isoform 2) 
C Y L L -3.24  
C Y L D -3.13  
C W L V -3.01  
C Y V A -2.88 Isoform 5 of Zinc finger protein 64 homolog, isoforms 3 and 4. 
C F L T -2.74  
C W L S -2.46 Isoform 3 of Ankyrin repeat and BTB/POZ domain-containing protein BTBD11
C C L S -2.37 Isoform 3 of Intersectin-2 
C K L A -2.06 Isoform 6 of Target of rapamycin complex 2 subunit MAPKAP1 
C W T C -1.94 Isoform 3 of Folliculin 
C S L I -1.90 Isoform 5 of Rho GTPase-activating protein 19 
C G V G -1.65 Putative uncharacterized protein ENSP00000347057 
C V C V -1.12  
STO Substrates:   
C Y L E -3.82  
C F I E -3.34  
C W V I -3.03  
C A F I -2.62 Proton-coupled amino acid transporter 1 
C T T E -2.14 Isoform 2 of Decaprenyl-diphosphate synthase subunit 1 
C H F H -2.14 Isoform 2 of Solute carrier family 7 member 13 
C P F F -1.69 Homeobox protein ESX1 
Non-substrates:   
C L F E -1.77 Isoform 2 of C-type lectin domain family 2 member D (& isoforms 4&6) 
C F D I -1.59 Phosphatidate phosphatase PPAPDC1B 
C H C I -1.56 Growth/differentiation factor 15. 
 
Table 3.1. Substrates of FTase predicted by FlexPepBind. Thirteen top scoring, 
previously uncharacterized peptides and 16 high scoring peptides corresponding to 
untested human protein sequences were chosen to be tested for reactivity with FTase in 
vitro. The synthesized peptides of the form dns-TKCxxx and peptides reactive with 
FTase were identified using a radioactive assay under a stopped MTO or STO reaction 
that detects 3H-farnesyl-peptide products fractioned on TLC plates (see Experimental 
Methods). Overall, FTase catalyzed farnesylation of 19 peptides under MTO conditions, 
7 under STO conditions, and 3 were unreactive with FTase under the conditions of the 
assay. Additionally, 6 out of 7 peptides with an acidic X group (bold) were FTase 
substrates. 
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Figure 3.4. Reactivity of peptides with FTase. A) Dns-TKCxxx peptides predicted to be substrates by 
FlexPepBind were screened for reactivity with FTase under MTO and STO conditions using a radioactive 
assay. For the MTO screen, 3 μM dansylated-peptide (dns-TKCxxx) was incubated with 1 μM 3H- FPP and 
25 nM rat FTase in 50 mM HEPPSO, pH 7.8, 5 mM TCEP, 5 mM MgCl2 at 25ºC for 2 hours. For the STO 
screen, 1 μM FTase was incubated with 0.8 μM 3H-FPP and 3 μM dns-TKCxxx peptide for one hour at 
25ºC in the same buffer. Reactions were fractionated on a TLC plate, and peptides were designated MTO 
or STO substrates if they were at least 10-20% reacted as compared to a 10 or 20% positive control. A) 
shows a TLC plate illustrating the separation of 3H-FPP and 3H-farnesylated peptide under STO conditions; 
peptides TKCKLA, TKCSLI, AND TKCGVG are reactive with FTase under STO conditions. B) and C) 
The steady state parameters were measured for peptides reactive with FTase under MTO conditions. In the 
same conditions as in A), 0.2 – 40 μM dns-peptide, 20 -100 nM FTase, and 10 μM FPP were incubated 
together, and the initial velocities of the reaction were measured from the time dependant change in 
fluorescence (λex = 340 nm, λem = 520 nm). The Michaelis-Menten equation was fit to the data to determine 
the values of kcat/KMpeptide (reported in Table 3.2). B) and C) show the plots for dns-TKCYLL and dns-
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TKCWTC, respectively. 
 
 
 
Figure 3.5. Proposed structure of peptides terminating in acidic residues bound to 
FTase. Peptides CYLE (green), CYVE (cyan), CYIE (magenta), and CFIE (yellow) are 
modeled into the binding pocket of FTase (orange). The negatively charged X group of E 
may be stabilized by interaction with positively charged H149β and the formation of 
hydrogen bonds with W102β and S99β.  
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of predicting FTase substrates, and suggests a new class of FTase substrates containing 
an acidic X residue. 
 
Steady state kinetic analysis 
 Next, we measured the steady state kinetic parameters of the novel MTO 
substrates predicted by FlexPepBind with FTase (Tables 3.1 and 3.2) using the 
enhancement in fluorescence of the dansyl group in the dns-TKCxxx peptides upon 
farnesylation. Using the assay, we obtained kinetic parameters for 12 of the peptides with 
MTO activity with FTase. The remaining 5 peptides were below the threshold of activity 
measured by the fluorescence assay. Table 3.2 shows a summary of the kcat/KMpeptide 
values measured for farnesylation of these peptides catalyzed by FTase obtained by this 
analysis.  
 
Peptide kcat/KMpeptide (mM-1s-1) Score: 
CYLV 1.43 ± 0.09 -3.6 
CLII 1.6 ± 0.3 -3.51 
CYIE 0.25 ± 0.01 -3.4 
CLIV 3.3 ± 0.2 -3.33 
CYLL 0.8 ± 0.1 -3.24 
CYVA 32 ± 6 -2.88 
CWLS 21 ± 2 -2.46 
CCLS 39 ± 19 -2.37 
CKLA 2.7 ± 0.2 -2.06 
CWTC 6.2 ± 1.0 -1.94 
CGVG 1.0 ± 0.1 -1.65 
CVCV 0.8 ± 0.2 -1.12 
 
Table 3.2. Steady state parameters for a subset of MTO peptides predicted by 
FlexPepBind. kcat/KMpeptide was measured for FTase catalyzed farnesylation of 12 dns-
TKCxxxx peptides by incubating 0.2 – 40 μM dns-peptide with 20 -100 nM FTase, 10 
μM FPP in 50 mM HEPPSO pH 7.8, 5 mM TCEP and 5 mM MgCl2 at 25ºC. The 
FlexPepBind score for each sequence is also shown.  
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Discussion 
FlexPepBind vs. PrePS 
 The FTase substrate reactivity predicted by PrePS, a computational method 
previously developed by the Eisenhaber lab (21), was compared to FlexPepBind. In a 
study of the reactivity of a peptide library with FTase, PrePS had very low false positive 
rate for farnesylated peptides, but had a high false negative rate, about 40% (11). It also 
poorly identifies peptides with STO reactivity with FTase (14%). One difference between 
the methodologies of these algorithms is that PrePS analyzes the C-terminal 15 amino 
acids to take into account the region upstream of the last four terminal amino acids and 
the flexibility of the C-terminal tail. To examine this, we compared the PrePS and 
FlexPepBind scores for the 29 novel peptide sequences identified by FlexPepBind (Table 
3.3). In column C, the 30 amino acid C-terminal sequence of the 16 peptides 
corresponding to human proteins was scored by PrePS. In all cases, PrePS does not 
predict that these proteins will be FTase substrates (as indicated by “-”, “--”, or “---” 
symbols); however, in vitro analysis shows that 13 out of 19 sequences are farnesylated 
by FTase in vitro (Table 3.3). If a canonical CaaX (the H-Ras CVLS sequence) replaces 
the last four amino acids of each sequence (Figure 3.3 column D), then 9 of the 15 
sequences are predicted to be substrates by PrePS (as indicated by “+” or “++”). 
Furthermore, if the 26 upstream amino acids are replaced by the H-Ras sequence, then 8 
of the 16 sequences are predicted to be farnesylated (Figure 3.3 column E). This analysis 
suggests that PrePS is discriminating against these sequences based on both the –CaaX 
sequence and the upstream sequence. The role of the upstream sequence in substrate 
selectivity and determinants of MTO and STO is unclear, and the relationship of the 
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Cxxx sequence and the upstream region is further explored as in Chapter 4 with in vivo 
work. This issue could be further clarified by additional in vitro studies to characterize 
the relationship between the Cxxx sequence, the upstream region, and FTase reactivity by 
measuring the reactivity of FTase with longer peptides containing varied upstream 
sequences, such as those shown in Table 3.3. 
 
Steady state parameters, KD, and FlexPepBind score 
 The FlexPepBind algorithms are based on the prediction of the affinity of FTase 
for each peptide with the assumption that the high affinity peptides would also react 
readily with FTase. However, the training set was based on a library of peptides that react 
readily with FTase rather than those that bind tightly. To evaluate the physical parameters 
that determine the FlexPepBind score we analyzed the correlation of this score with two 
experimental parameters, kcat/KMpeptide and KD.  The kcat/KMpeptide parameter reflects the 
reactivity of a peptide with FTase•FPP complex and indicates the ability of a peptide to 
compete with other substrates, such as the situation in the cell. Therefore, this parameter 
is termed the “specificity constant” (31). For FTase, kcat/KMpeptide includes all of the 
reaction steps up to the first irreversible step in the reaction, so it includes the rate 
constants of the peptide binding to E•FPP, the FPP conformation change, and the 
formation of the prenylated peptide and pyrophosphate products (32-36). Under these 
conditions, the release of the diphosphate is the first irreversible step (33, 34), so the 
release of the prenylated peptide does not contribute to the value of kcat/KMpeptide. The 
training set identifies substrates based on reactivity under kcat/KMpeptide (MTO) conditions. 
Therefore, we examined whether the FlexPepBind score correlates with the value of 
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Sequence 
(A) 
Derived from 
protein (B) 
PrePS prediction 
Score 
(F)  
Activity  
(G) Full  
(C) 
x26-CVLS 
 (D) 
H-Ras-Cxxx 
(E) 
CYLI    - -3.96 STO 
CYLE    - -3.82 MTO 
CYLV    - -3.60 MTO 
CFLV    - -3.60 STO 
CLII    ++ -3.51 MTO 
CYVE    - -3.43 MTO 
CYIE    - -3.40 MTO 
CFIE    - -3.34 STO 
CLIV    ++ -3.33 MTO 
CYLL    - -3.24 MTO 
CYLD    - -3.13 MTO 
CWVI    - -3.03 MTO 
CWLV    - -3.01 MTO 
CYVA Q9NTW7-3 - - + -2.88 STO 
CFLT O75037 -- - + -2.74 STO 
CAFI Q7Z2H8 -- + - -2.62 MTO 
CWLS A6QL63-3 - + + -2.46 MTO 
CCLS Q9NZM3-3 -- -- ++ -2.37 MTO 
CTTE Q5T2R2-2 -- - - -2.14 MTO 
CHFH Q8TCU3-2 --- + -- -2.14 MTO 
CKLA Q9BPZ7-6 - - + -2.06 MTO 
CWTC Q8NFG4-3 - ++ - -1.94 None 
CSLI Q14CB8-5 - + ++ -1.90 MTO 
CLFE Q9UHP7-3 -- + -- -1.77 STO 
CPFF Q8N693 --- - -- -1.69 MTO 
CGVG A6NHS1 - - + -1.65 None 
CFDI Q8NEB5 -- ++ -- -1.59 None 
CHCI Q99988 -- + - -1.56 STO 
CVCV O75391 - + + -1.12 MTO 
 
Table 3.3. Peptide sequences, score, PrePS prediction, and in vitro activity of 
peptides. A) Peptide sequence; B) Uniprot identifier of human proteins containing the C-
terminal CaaX sequence (30); C) PrePS (21) predictions for the C-terminal 30 amino 
acids; D) PrePS predictions of the 26 amino acids from Column C appended to C-
terminal CVLS (H-Ras CaaX sequence); E) H-Ras C-terminal region with the last four 
amino acids replaced with the Cxxx sequence tested here. F) FlexPepBind peptides score; 
G) in vitro activity with FTase. In summary, Column D shows the amenability of 
farnesylation of the upstream sequence with a good CaaX sequence and Column E shows 
the amenability of farnesylation with a good upstream region with Cxxx sequences 
predicted by FlexPepBind.  
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 kcat/KMpeptide. Additionally, KD is the dissociation constant of the dns-TKCxxx peptide 
from the E•FPP analog•dns-TKCxxx complex and is indicative of how tightly the peptide 
binds to this complex. As FlexPepBind is based on an analysis of protein-peptide 
interactions in the E E•FPP analog•dns-TKCxxx complex, we proposed to see a 
correlation between the FlexPepBind scores and the affinity measurements. However, the 
FlexPepBind algorithm only analyzes interactions of the Cxxx sequence.  
 Figure 3.6 shows a graph of the correlation of kcat/KMpeptide values and 
FlexPepBind score, with kcat/KMpeptide graphed on a log scale. kcat/KMpeptide values were 
obtained from this work (Table 3.2, Figure 3.6 triangles) as well as the previously 
published peptide library studies with FTase (squares, reference (11)).  Overall, there is 
little correlation between kcat/KMpeptide and FlexPepBind score, regardless of the origin of 
the peptide sequence. The reactivity of the peptides generally range between 100-50,000 
M-1s-1 across the range of FlexPepBind scores (-4-6). The majority of the substrates do 
have FlexPepBind scores ≤ -0.04 (44 out of 58 peptides). Furthermore, there appears to 
be “sweet spot” of high reactivity for a few peptides with FlexPepBind score between -
2.5 and -3.0; however, there are plenty of peptides with lower reactivity with the range of 
scores as well. Also, comparing the rate constant for farnesylation under single turnover 
conditions (kfarnesylation) from reference (11) to the FlexPepBind scores does not correlate 
with the FlexPepBind scores for either MTO or STO substrates (rs = -0.26, p = 0.053, not 
significant, data not shown).  
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Figure 3.6. Comparison of kcat/KMpeptide to FlexPepBind scores. The kcat/KMpeptide 
values were obtained from reference (11) (squares) or were obtained in this work from 
peptides predicted by FlexPepBind predictions (triangles, see Table 3.2). Overall, there is 
little correlation between FlexPepBind score and the value of kcat/KMpeptide  (rs = -0.26, p = 
0.053, not significant). 
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 Finally, we analyzed the correlation between log KDpeptide and FlexPepBind score, 
as shown in Figure 3.7. The KD values measuring the dissociation of the dns-TKCxxx 
peptide from the E•FPP analog•dns-TKCxxx complex are taken from reference (11). 
Unexpectedly, there is also no readily identifiable correlation between peptide affinity 
and FlexPepBind score (rs = 0.14, p = 0.407, not significant). As FlexPepBind was 
developed by calculating an “energy score” that correlates with peptide binding to the 
FTase active site, we were surprised by this result; however there may be several reasons 
for the lack of a trend. A caveat of the measurement of the KD values experimentally is 
that the binding of the peptide was to an enzyme complexed with an unreactive FPP 
analog. It is possible that the affinity under these conditions is not reflective of the 
affinity using native substrates (but this is impossible to measure using FPP as the peptide 
would undergo modification); however, the FlexPepBind algorithm was developed from 
a structure with this analog (23). Further, the binding affinity studies are carried out with 
peptides containing an N-terminal dansyl moiety, which may dominate binding affinity. 
These KD values are also for peptides reactive with FTase. In the future, we would like to 
measure the affinity of non-reactive peptides with FTase complexed to the FPP analog. It 
is possible that there may be a shift in FlexPepBind scores, where poor scoring peptides 
may have higher KD values, such that in general there may be a slightly upward slope in 
points going from negative scores to positive scores.  
 These results show that there is no significant correlation between kcat/KMpeptide or 
KD of peptides with FlexPepBind scores, and it is unclear what experimental parameter 
the FlexPepBind score represents. Nonetheless, the data indicate that FlexPepBind is a 
good method of scoring sequences for farnesylation by FTase, yielding a cutoff for 
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prediction of substrates (MTO or STO) or non-substrates. However, the significance of 
the actual value of the FlexPepBind score is currently unclear, as the score does not 
differentiate well between levels of reactivity. Figure 3.3 illustrates this trend, since there 
is overlap in the scores with classes of substrates. For instance, when comparing non-
substrates (NON, purple line) to MTO substrates (green line), there is overlap in 
sequence scores from -1.5 to 0. FlexPepBind is clearly not a perfect prediction program, 
but overall it improves the current computational techniques by enhancing the prediction 
of the reactivity of FTase with non-canonical C-terminal Cxxx sequences as well as with 
the STO peptide substrates. This is highly useful for identifying potential in vivo 
substrates as well as understanding what metabolic pathways might contain farnesylated 
proteins and therefore be affected by inhibitor treatment. 
 
GGTase-I and computational techniques 
 In the future, now that a larger pool of known GGTase-I MTO substrates, STO 
substrates, and non-substrates is available (Chapter 2), it would be interesting to modify 
and apply the FlexPepBind program to predicting GGTase-I substrates. Specifically, it 
would be interesting to compare the score of a particular peptide for FTase vs. GGTase-I 
to see if the program can enhance the prediction of overlapping substrate selectivity 
between the two enzymes. We are currently working with Dr. Ora Scheuler-Furman and 
her lab to score and test GGTase-I to improve GGTase-I substrate predictions.  
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Figure 3.7. Comparison of log KD to FlexPepBind scores. KD values were obtained 
from reference (11). Overall, there does not appear a correlation between KD and 
FlexPepBind scores with FTase (rs= 0.14, p = 0.407, not significant).  
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CHAPTER IV 
 
SPECIFICITY STUDIES OF THE PRENYLATION PATHWAY IN VIVO: 
METHODS TO DETECT IN VIVO POST-TRANSLATIONAL 
MODIFICATIONS1 
 
Introduction 
 Prenylation, an important post-translational modification, aids in targeting 
modified proteins to the membrane and helps to promote protein-protein interactions (1, 
2). Prenylation comes in two forms: the 15-carbon farnesylation and the 20-carbon 
geranylgeranylation and attachment of the lipid to the C-terminus of proteins is catalyzed 
by protein farnesyltransferase (FTase) from the lipid donor farnesyldiphosphate (FPP) 
and protein geranylgeranyltransferase-I (GGTase-I) from geranylgeranyldiphosphate, 
respectively (3, 4). After prenylation, substrates can be further modified in vivo. The 
enzymes zinc metalloprotease Ste24 (ZMPSTE24) or Ras converting enzyme 1 (RCE1) 
catalyze proteolysis of the three C-terminal amino acids of a prenylated protein, and 
isoprenylcysteine methyltransferase (ICMT) can catalyze methylation of the carboxy 
terminus of the substrate (Figure 4.1, (5-7)). These additional modifications can aid in 
targeting the protein to the membrane; however, the full extent of prenylation,
                                                 
1 Construction of several of the vectors and the corresponding microscopy was carried out by Jenna 
Hendershot. The in vitro proof of principle experiments were carried out by Megan Novak.  
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Figure 4.1. The prenylation pathway. A protein with a cysteine four amino acids from 
the C-terminus is modified, with a farnesyl or geranylgeranyl group, catalyzed by either 
FTase or GGTase-I. Next the last three amino acids of the protein can be proteolyzed 
catalyzed by RCE1 or ZMPSTE24, and the carboxy terminus can be methylated, 
catalyzed by ICMT.  
124 
proteolysis, and methylation of the prenylated proteome in vivo is unknown at this time 
(8-12). 
 Besides prenylation, the post-translational modification of S-palmitoylation can 
aid in membrane localization of proteins as well as target proteins to various cellular 
organelles or lipid domains like lipid rafts (13-16). Unlike prenylation, palmitoylation 
forms a thioester and is therefore readily reversible; the addition of palmitate from 
palmitoyl-CoA to a cysteine via a thioester linkage can be catalyzed by protein acyl-
transferases (PATs) and removal can be catalyzed by protein acylthioesterases (APTs, 
(17, 18)). There is no specific consensus sequence for palmitoylation; however, mass 
spectrometry and genetic studies have revealed some trends, including that 
palmitoylation can occur near a prenylation site (19) and that PATs have overlapping 
specificity (19). Therefore, understanding which proteins are modified by both the 
prenyltransferases and the PATs will allow us to understand the role of lipidation in 
cellular processes.  
 The specificity of the enzymes in the prenylation pathway has been studied, but 
more work is needed to further refine the modes of recognition by these enzymes in vivo. 
FTase and GGTase-I were proposed to recognize a canonical “Ca1a2X” motif at the C-
terminus of a substrate protein (4, 20, 21), whereby “C” is the cysteine where the prenyl 
group is attached, “a1” and “a2” are aliphatic amino acids, and “X” is typically 
methionine, alanine, glutamate, or serine for FTase and leucine or phenylalanine for 
GGTase-I. Although the CaaX motif describes many substrates, there is evidence that this 
model excludes a number of important substrates (12, 22, 23), and that a pool of 
substrates undergo modification catalyzed by both enzymes, i.e., “dual substrates” (24). 
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Specificity studies of RCE1 and ZMPSTE24 have been more limited, but it is known 
these enzymes require a prenylcysteine for recognition and that the substrate selectivity 
may overlap (7, 25-31). Understanding the molecular recognition of these enzymes will 
aid in determining the modifications that occur in vivo.  
 Methods to determine global prenylation within the cell have been met with 
limited success thus far. Historically, substrates of FTase and GGTase-I were primarily 
determined by studying one protein at a time. One method for identifying prenylated 
proteins is to treat cells with a radiolabeled metabolite, such as mevalonate which is a 
precursor of FPP and GGPP (32-34) and then identify the radiolabeled proteins; however 
this method yields low signal (3, 35, 36). Antibodies have been raised to the farnesyl and 
geranylgeranyl modifications for detection by Western blotting but these antibodies can 
cross react with other lipid modifications and are unable to distinguish between the two 
types of prenyl groups (37-40). FPP and GGPP donor analogs, which are specifically 
recognized by FTase or GGTase-I as substrates, have been utilized to aid in modified 
protein isolation and identification. These analogs have either immunogenic properties 
(41, 42), an affinity tag (43), or a group amenable to bioorthogonal ligation (8, 44). 
Although the techniques using these analogs show promise, the whole complement of 
prenylated proteins in vivo still remains to be identified. 
 In this work, we are developing methods to identify prenylated proteins in vivo. 
We began using the FPP and GGPP analogs azido-farnesol and azido-geranylgeraniol to 
label and then identify the labeled proteins. This method led to only a subset of proteins 
tagged in vivo. We then developed a procedure that involves transfecting a vector library 
into mammalian cells corresponding to potentially modified proteins, using fluorescence 
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microscopy to observe protein localization, and mass spectrometry to detect 
modifications. We first generated a library of tagged green fluorescent protein (GFP) 
constructs attached to C-terminal sequences hypothesized to signal prenylation. We 
transfected these constructs into several mammalian tissue culture cell lines and observed 
localization, demonstrating that the GFP localized to different parts of the cell depending 
on the C-terminal sequence and, presumably, modification status. In the future, the 
specific modifications on the GFP-fusion proteins can be analyzed by mass spectrometry 
techniques.  
 
Experimental Methods 
Vector construction  
 To begin preparing a library of mammalian expression vectors, the His6-EGFP-
TEV-X11-Cxxx gene was constructed using two rounds of primer extension polymerase 
chain reaction (PCR) to add a BamHI site and a His6 tag to the 5’ end of the gene and a 
TEV cleavage site followed by a C-terminal tail flanked by a KasI site and an EcoRI site 
to the 3’ end of the EGFP (Figure 4.2 A). The KasI site and EcoRI site allow for easy 
interchange of the C-terminal amino acids of the gene. Unless noted, all enzymes used in 
this work were purchased from New England BioLabs (Ipswich, MA). For the parent 
vector construction, the overall gene was His6-EGFP-TEV-myc. The myc sequence is 
EQKLISEEDL; this sequence can be detected by Western blotting with an anti-myc 
antibody and is not prenylated, serving as a negative control. The template for the EGFP 
sequence was the CS2+EGFP vector and was a gift from Dr. Anne Vojtek’s lab. A 
FailSafe PCR kit (Epicentre, Madison, WI), which contains multiple solutions that vary 
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PCR conditions, was used with the following thermocycler program for the first round of 
primer extension PCR: 1) 94ºC for 2 minutes; 2) 30 cycles of 94ºC for 45 seconds, 55ºC 
for 45 seconds, 72ºC for 1 minute; 3) 72ºC for 4 minutes; and 4) hold at 4ºC. Each tube 
contained 200 ng of the CS2+eGFP template, 50 μM primer A (Figure 4.3), and 50 μM 
primer B (Figure 4.3) in 1X Fail Safe Enzyme Mix and 1X Fail Safe Buffer (each A 
through L). This method yielded the correct DNA fragment around 850 base pairs with 
FailSafe buffers A, B and C, and these PCR products were gel purified. This PCR 
product encodes the BamHI site, the His6 tag, the EGFP gene, the TEV site, and a portion 
of the myc tag. A second round of primer extension PCR was carried out using PFU 
Turbo enzyme (0.4 U/μL, Stratagene, Santa Clara, CA), 1 X PFU buffer, 0.8 mM dNTP 
mix, 0.4 ng/μL PCR product, and 2.5 ng/μL primers C and D (Figure 4.3). The same 
thermocycler program as above was used and a band around 900 bases was seen on a gel 
which encodes the entire gene as seen in Figure 4.2 and 4.3. The band was cut out, gel 
purified and the inserts were double digested with EcoR1 and BamHI, and then ligated 
using T4 DNA ligase into the pcDNA4/TO mammalian expression vector (Invitrogen) 
digested with the same restriction enzymes (Figure 4.2 B, with the Ras15 tail as an 
example). The vector sequence was verified by sequencing (DNA Sequencing Core, 
University of Michigan).  
 
 
 
 
 
 
128 
Figure 4.2. Gene insert scheme and plasmid maps. A) To construct a parent vector for the 
His6-EGFP-TEV-X11-CaaX expression library, primer extension PCR was used to generate the 
above insert, flanked by a BamHI site and an EcoR1 site. A KasI site was added between the 
TEV protease site and the C-terminal tail to allow for the C-terminal sequences to easily be 
swapped. The plasmid maps for the His6-EGFP-TEV-Ras15 gene are shown in the PCDNA4/TO 
mammalian vector (B) and the pET23a E. coli expression vector (C). The maps were generated 
using the PlasmaDNA program.  
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His6-EGFP-TEV-myc gene sequence 
 
 
ATGAAACATCACCATCACCATCACGGCTCCATGGTGAGCAAGGGCGAGGAGCTGTTCACCG
GGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGT
CCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA
CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGT
GCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGA
AGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCC
GAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTC
AAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT
ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACAT
CGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGG
CCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCC
CAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTC
GGCATGGACGAGCTGTACAAGGGCGGTGGAGAGAATCTTTATTTTCAGGGCGCCGAGCAGA
AGCTCATCAGCGAGGAGGACCTGTGAATTC 
 
Key:  
1. ATGAAA is the sequence for start codon (coding methionine) and a lysine linker 
2. CATCACCATCACCATCACGGCTCC is the His6-tag plus and an extra linker sequence of 
glycine and serine 
3. ATGGTGAGC ….  is the EGFP gene 
4. GAGAATCTTTATTTTCAGGGCGCC  is the TEV protease site sequence and an alanine linker 
5. GAG……CTG TGA is the C-terminal amino acids of gene encoding the myc tag and the stop 
codon 
6. GGCGCC is the KasI site 
7. GAATTC is the EcoRI site 
8. The lavender bases correspond to vector sequence.  
 
 
Primer A TGCAGGATCCATGAAACATCACCATCACCATCACGGCTCCATGGTGAGCAAGGGCGAG 
Primer B TGATGAGCTTCTGCTCGGCGCCCTGAAAATAAAGATTCTCTCCACCGCCCTTGTACAG 
Primer C TGCAGGATCCATGAAACATCA 
Primer D CCTTGAATTCTGATCACAGGTCCTCCTCGCTGATGAGCTTCTGCTCGGC 
 
 
Figure 4.3. The DNA sequence of the His6-EGFP-TEV-myc gene and primers for 
primer extension PCR. Two rounds of primer extension PCR using primers A-D (table) 
following the procedure detailed in the experimental methods section yielded the correct 
product for the His6-EGFP-TEV-myc gene. The sequence for the gene and the key for the 
color coding of each portion of the gene are above.  
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 Next, a library of expression pcDNA4/TO-EGFP expression vectors was created 
by altering the C-terminal tails, and part of this work was done in collaboration with a 
rotation student, Jenna Hendershot.  The parent vector was double digested with KasI and 
EcoRI to create two sticky ends. The C-terminal tail insertions were constructed from two 
synthetic complementary DNA oligonucleotides (Integrated DNA Technologies), such 
that when two strands are annealed together, the oligonucleotides have overhangs that 
correspond to KasI and EcoRI sites sot that this sequence can be readily ligated with the 
EcoRI/KasI digested parent vector (see Figure 4.8). For this procedure, oligonucleotides 
were dissolved in water and diluted to 5 pmols/μL in 1X Quick Ligase buffer. The 
oligonucleotides were annealed by heating to 94ºC and slowly cooling them using a 
thermocycler and the program shown in Table 4.1. The annealing reactions were then 
diluted 100-fold in 1X Quick T4 DNA Ligase buffer and water. The ligation reaction 
included 50 pmols total of the annealed insert was incubated in 1X Ligase buffer, 50 ng 
of digested pCDNA4/TO His6-EGFP-TEV-myc vector, and 1 μL Quick T4 Ligase (per 
20 μL). The ligation reaction was incubated at room temperature for 5 minutes and then 
stored on ice until it was transformed into XL1-Blue chemically competent or Z-
competent E. coli cells. If the cells used were chemically competent, 5 μL of the ligation 
mix was added to 100 μL of cells, incubated on ice 30 minutes, heated for 45 seconds at 
42ºC, and incubated on ice for 2 minutes. Then 250μL of 2xYT media was added to the 
tubes and incubated 37ºC for 1 hour. Finally, 100 μL of cells were added to a pre-warmed 
LB agar plate with 100 μg/mL ampicillin and incubated at 37ºC overnight. If the cells 
were Z-competent, 5 μL of the ligation mix was added to 100 μL of cells and incubated 
on ice for 20 minutes. Then, 100 μL of the cells were added to LB agar plate with 100 
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ug/mL ampicillin and incubated at 37ºC overnight. The cells from single colonies on the 
plates were inoculated into 5 mL of 2xYT media with 100 μg/mL ampicillin, grown 
overnight at 37ºC shaking at 225 rpm, and then the DNA was purified using a QIAprep 
Spin Miniprep Kit (Qiagen) or a Wizard® Plus Minipreps DNA Purification System 
(Promega). The sequences of the EGFP fusion genes were verified by sequencing (DNA 
Sequencing Core, University of Michigan). 
 
 
Segment Temperature Time Number of Cycles 
1 94ºC 5 minutes 1 
2 94ºC 30 seconds 2 
 80ºC 5 minutes  
3 72ºC 7 minutes 1 
4 66ºC 7 minutes 1 
5 60ºC 3 minutes 1 
6 52ºC 3 minutes 1 
7 46ºC 3 minutes 1 
8 37ºC 20 minutes 1 
9 4ºC hold  
 
 
Table 4.1. Annealing program. The thermocycler (Eppendorf) program to anneal two 
complementary DNA oligonucleotides together.   
 
 
 Additionally, the His6-EGFP-TEV-Ras15 gene was cloned into the E. coli 
expression vector pET24a. The Ras15 sequence is the C-terminal 15 amino acids of 
DESGPGCMSCKCVLS in the H-Ras gene (DNA sequence: 
GATGAGAGTGGCCCCGGCTGCATGAGCTGCAAGTGTGTGCTCTCCTGA) This 
work was done in collaboration with an undergraduate student, Megan Novak. Using 
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similar primer extension PCR techniques as outlined above catalyzed by PFU Turbo 
polymerase, BamHI and NdeI sites were added to the 5’ end of the gene while an EcoRI 
site was added to the 3’ end of the gene. After PCR amplification, the DNA band was cut 
out, gel purified, and digested with NdeI and EcoRI, it was ligated with the NdeI/EcoRI 
digested pET23a vector catalyzed by Quick T4 DNA Ligase (Figure 4.2C). The sequence 
of the His6-EGFP-TEV-Ras15 gene was verified by DNA sequencing (DNA Sequencing 
Core, University of Michigan). 
 Additionally, dual mammalian expression vectors were constructed that contain 
genes for both FTase and His6-EGFP-TEV-X11-CaaX sequences (see Figure 4.14). 
Previously, Dr. James Hougland constructed a mammalian expression vector starting 
form the pACT vector that contained the two subunits of FTase either under the CMV or 
SV40 promoters and a red fluorescent protein under the other promoter. The plasmid 
pCAF1 contains the FTase gene under the SV40 promoter (with the Tag-RFP gene under 
the CMV promoter) and pCAF2 plasmid contains the FTase gene under the CMV 
promoter (with the TagRFP under the SV40 promoter). Primer extension PCR was used 
to add restriction sites to the EGFP genes. To insert the His6-EGFP-TEV-X11-CaaX gene 
into pCAF1, NheI and BamHI sites were added to the 5’ end and EcoR1 and NotI sites 
were added to the 3’ end. Similarly, to insert the EGFP fusion gene into pCAF2, HindIII 
and BamHI sites were added to the 5’ end of the gene and EcoRI and SacII sites were 
added to the 3’ end. Insert 1 and the pCAF1 vector were digested with NheI and NotI 
while the insert 2 and pCAF2 were digested with HindIII and SacII. These digested DNA 
fragments were gel purified and then insert 1/pCAF1 and insert 2/pCAF2 were incubated 
with Quick T4 DNA Ligase to ligate the genes with the vector. These plasmids were 
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transformed into XL-Blue E. coli cells, grown, purified, and sequenced as described 
above.   
 
Tissue culture 
 HeLa, HEK-293 and NIH-3T3 cells were purchased from ATCC (Manassas, VA) 
and unless otherwise noted, all medium and supplements were purchased from Gibco 
(Life Technologies, Grand Island, NY). HEK-293 and HeLa cells were grown in 12 mL 
DMEM medium supplemented with 10% FBS in flasks at 37ºC in 5% CO2, and NIH/3T3 
cells were grown in 12 mL DMEM medium with 10% calf serum in flasks at 37ºC in 5% 
CO2. If needed, the medium was also supplemented with 1% penicillin/streptomycin. To 
passage cells, the medium was removed and 2 mL of 0.25% (w/v) Trypsin-EDTA was 
incubated with the cells for 10 minutes at 37ºC to remove the cells from the plate. Then 
the cells were diluted to 12 mL in fresh medium in a flask. For the analog work, HeLa 
cells were split into 6-well plates, with 50,000 cells per well. After growing for 48 hours, 
the cells were incubated for 24 hours with either 40 μM azido-farnesol or azido-
geranylgeraniol, DMSO, or nothing. The medium was removed and cells were lysed by 
addition of 300 μL lysis buffer (1.0% NP-40, 150 mM NaCl, and 50 mM Tris pH 8.0 
with a mini protease inhibitor tablet (1 tablet/10 mL buffer, Roche)) to each of the wells 
and rocking the plates for 30 minutes at 4ºC. The lysates were transferred to chilled 
microcentrifuge tubes, centrifuged at 12,000 rpm at 4ºC for 20 minutes to remove the 
cellular debris, and the lysates were stored at -20ºC.  
 
 
134 
Click chemistry, fluorescence scanning, and Western blotting 
 Click chemistry of azido-farnesol or azido-geranylgeraniol treated lysates was 
carried out using the Click-iT® Kit (Invitrogen, Carlsbad, CA) to conjugate the azido 
modified proteins to tetramethylrhodamine-alkyne (TAMRA-alkyne, Invitrogen, 
Carlsbad, CA). The analogs were obtained as a gift from Invitrogen. A Bradford assay 
was used to normalize the protein concentration in each sample. The click reaction, 
which uses a copper catalyst to form a triazole conjugate from the reaction of an azide 
with an alkyne (Figure 4.5), was carried out as outlined in the kit protocol. To prepare 
samples for SDS-PAGE analysis, a methanol/chloroform extraction was used to remove 
the reaction components and precipitate the proteins. The samples were dried and 
resolubilized in SDS-PAGE loading buffer and fractionated on 12% Tris-HCl gels.  
 To visualize the fluorescently labeled proteins, a Typhoon phosphoimager was 
used. The gel was scanned using the green laser (532 nm excitation, 580 nm emission). 
The Typhoon PMT was set between 600 and 800 V and 200 pixels were used with 
normal to medium sensitivity.  
 Western blotting was also used in some cases to visualize the azide modified 
proteins. The anti-TAMRA antibody (Invitrogen) and anti-rabbit-HRP (Thermo) were 
used as primary and secondary antibodies. SDS-PAGE, transferring proteins to 
nitrocellulose membranes from the gel, Western blotting, and film developing were 
carried out using standard conditions (45-47).  
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Transfections and fluorescence microscopy 
 HeLa, HEK-293, and NIH/3T3 cells were used for transfections. For all 
transfections, cells were split, allowed to grow for 24 hours, transfected, and then 
visualized 24 hours later by microscopy (or if necessary, Western blotting). There was no 
improvement in expression if the cells were grown 48 hours after transfection. For the 
analog work, the Effectene reagent (Qiagen) was used for transfections of the myc-Rheb 
protein (in the pRK5 vector, gift from Dr. Kun-Liang Guan). For a 6-well plate with 80% 
confluent cells at the time of transfection, 0.4 μg DNA: 3.2 μL enhancer and 10 μL 
Effectene were added to each well and cells were grown at 37ºC for 24 hours. For a 
negative control, a “mock” transfection was carried out using Effectene and the enhancer, 
but without addition of the DNA. To enhance the EGFP-fusion expression in each of the 
cell lines, the FuGENE 6 reagent (Promega) was used. For most pcDNA4/TO based 
plasmids, the optimal FuGENE 6 to DNA ratio was 6:1, although with some constructs 
the transfection efficiency was higher using a 3:2 FuGENE 6:DNA ratio. Generally, cells 
were split to 40,000 – 80,000 cells per well for a 12-well plate and 100,000 cells per well 
for a 6-well plate 24 hours before transfection and the cells were grown for 24 hours after 
transfection.  
 Fluorescence microscopy was used to visualize the localization of the EGFP 
fusion proteins. A Nikon Eclipse TE2000 U inverted epifluorescence microscope with the 
MetaMorph software (Molecular Devices) was used to obtain fluorescent images. The 
470 nm emission and a 525 emission cubes were used with a 5-100 ms exposure to obtain 
EGFP fluorescent protein localization images.  
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In vitro farnesylation reaction: labeling a peptide 
 Rat FTase was recombinantly expressed in BL21(DE3)•pET23aPFT cells and 
purified as described previously (22, 48, 49). The dns-SKTKCVIM peptide (10 μM) was 
incubated with 40 nM FTase, 10 μM FPP, 50 mM HEPPSO pH 7.8, 5 mM TCEP, and 5 
mM MgCl2 at 25ºC for 3.5 hours. The peptide was estimated to be greater than >90% 
farnesylated according to the change in fluorescence signal. The farnesylated peptide was 
stored at -20ºC.  
 
Mass spectrometry of a farnesylated peptide 
 In collaboration with Dr. Eric Simon and Dr. Phil Andrews at the University of 
Michigan, mass spectrometry was used to analyze the farnesyl modification on the 
prenylated peptide dns-SKTKC(F)VIM. Contaminants were removed form the peptide 
solution using a ZipTip (Millipore). A Maldi-TOF-TOF instrument was used to detect a 
farnesyl-cysteine residue with a 307 m/z.  
 
Recombinant His6-EGFP-TEV-Ras15 expression and purification 
 The His6-EGFP-TEV-Ras15 gene in the pet23a vector was transformed into 
BL21(DE3) cells and grown in a 1 L culture of autoinduction media at 30ºC for 24 hours. 
Cells were pelleted and resuspended in 50 mM Tris pH 8.0 and 100 mM KCl. Cells were 
lysed and clarified as described in Chapter 2.  
 A batch purification method with TALON cobalt affinity resin (Clontech, 
Mountain View, CA) was used to purify the protein. In short, the lysate was incubated 
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with resin (1 mL of packed resin per 15 mg total protein as estimated by absorbance at 
280 nm) for 20 minutes agitating at room temperature and washed three times with 10 
column volumes of Buffer A (50 mM Tris pH 8.0, 100 mM KCl, and 2 mM imidazole). 
To elute the protein, the resin was transferred to a gravity column, washed with 5 column 
volumes of Buffer A, and eluted in fractions with 5 column volumes of Buffer B (50 mM 
Tris pH 8.0, 100 mM KCl, and 200 mM imidazole). Fractions were analyzed by SDS-
PAGE and Coomassie blue staining, pooled, concentrated using 10,000 MWCO Amicon 
filter devices (Millipore), and dialyzed against 2 L of 20 mM Tris pH 8.0 for about 2.5 
hours at 4ºC and then 4 L of 20 mM Tris pH 8.0 with 1 mM TCEP overnight. The protein 
was then separated into aliquots, frozen using a Nalgene “Mr. Frosty” Freezing device 
containing isopropanol (which cools the samples 1ºC/min when placed in -80ºC freezer), 
and stored at -80ºC.  
 
Digestion with TEV protease  
 Conditions for proteolysis of the recombinantly purified His6-EGFP-TEV-Ras15 
protein were optimized by Megan Novak. The best results were obtained by incubating 
588 μg of purified His6-EGFP-TEV-Ras15 with 360 μg TEV protease in 50 mM Tris pH 
8.0 and 1 mM TCEP for 3 hours at room temperature. Purified His6-EGFP-TEV-Ras15 
alone and TEV protease alone were used as negative controls. To verify digestion by a 
gel shift, samples were run on a 12% SDS-PAGE gel and stained with Coomassie blue 
dye.  
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Results 
Azido FPP and GGPP analogs to detect in vivo prenylated proteins 
 Prenylated proteins are difficult to detect using traditional radio-labeling methods. 
A method that has been gaining popularity to detect prenylation and other post-
translational modifications (PTM) is to incorporate functional groups into the PTM that 
are amendable to bio-orthogonal conjugation chemistry (also called “tagging-via-
substrate” (8)). Staudinger ligation or “click” chemistry reactions allow for the selective 
labeling of an azide group to an alkyne (50, 51). We chose to use the “click” chemistry 
approach, as it is conveniently carried out at room temperature and in aqueous solution 
(51). 
 FTase and GGTase-I have been previously shown to catalyze the modification of 
substrates onto proteins using azido-FPP or azido-GGPP (8, 44) (Figure 4.4). For labeling 
in cells, the azido-farnesol and azido-geranylgeraniol readily cross the cellular membrane 
and are converted to FPP or GGPP in vivo (8, 52). After cell lysis, the azido-modified 
proteins are labeled using tetramethylrhodamine-alkyne (TAMRA-alkyne, Figure 4.5) 
which can be detected by fluorescence or Western blotting.  
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Figure 4.4. Structures of lipid substrates and analogs. A) farnesyl diphosphate (FPP); 
B) geranylgeranyl diphosphate (GGPP); C) azido-FPP; D) azido-GGPP. 
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Figure 4.5. The “click” reaction. FTase catalyzed the labeling of proteins in vivo with 
the azido-farnesyl analog. In the presence of copper(I), the azido-farnesyl group on the 
proteins reacts with an alkyne attached to tetramethylrhodamine (TAMRA) to form a 
stable triazole conjugate. 
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 A number of cellular proteins were detected using this method (Figure 4.6A). 
However, the background was high and a quantity of known prenylated proteins of low 
molecular mass was not observed. Figure 4.6 A) shows an anti-TAMRA Western blot of 
azido-farnesol treated HeLa cells with or without a myc-Rheb transfections. Rheb is a 
known substrate of FTase (53), so it should become azido-modified. Overall, slightly 
more bands corresponding to farnesylated proteins are observed in azido-farnesol treated 
cells (lane 3) compared to the control (lane 1). Furthermore, the analog was transferred to 
a known FTase substrate (myc-Rheb) that was overexpressed from a plasmid transfected 
into the cells (lane 4). A high background is observed in the control lane. This experiment 
was then repeated using either azido-farnesol (N3-FOH) or azido-geranylgeraniol (N3-
GGOH) (Figure 4.6 B). In general, the Western blots did not indicate that additional 
proteins were labeled in the azido-analog treated cells (lanes 3 and 9). Fluorescence 
scanning was used to analyze labeling (Figure 4.6 B) and the method was more sensitive 
and faster. Lanes 6 and 12 show that proteins are modified with azido-farnesyl and azido-
geranylgeranyl modifications (arrows) compared to the untreated cells; however, there is 
still high background. It was promising that low molecular weight proteins that likely 
correspond to known prenylated proteins such as the GTPases were modified with azido-
geranylgeranyl groups. This behavior was not observed for the azido-farnesol modified 
group in our experiments. As this was not a robust method to detect prenylated proteins, 
we chose to employ a different method to understand the specificity of FTase and 
GGTase-I in vivo.  
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Figure 4.6. Fluorescence scans and Western blotting. A) HeLa cells were treated with 40 μM 
azidofarnesol (N3-FOH) or DMSO for 24 hours before cell lysis. Using “click” chemistry, azido-
farnesylated proteins were conjugated to tetramethylrhodamine-alkyne (TAMRA-alkyne). The TAMRA-
farnesyl conjugated proteins were fractionated using SDS-PAGE and visualized using Western blotting 
with an anti-TAMRA antibody. There is a slight increase in bands observed in the N3FOH treated cells 
(lanes 2-4) compared to the DMSO treated control (lane 1). The overexpressed myc-Rheb protein was also 
labeled (arrow, lane 4). B) HeLa cells were treated with nothing, DMSO, 40 μM azidofarnesol, or 40 μM 
azido-geranylgeraniol (N3-GGOH) and “click” chemistry was used to conjugate the azide to TAMRA-
alkyne. The proteins are fractionated using SDS-PAGE and visualized by either anti-TAMRA Western blot 
(lanes 1-3 and 7-9) or fluorescence scans (lanes 4-6 and 10-12, excitation 532 nm, emission 580 nm). In 
this case, little increase in labeling of cells was observed by Western blot in the lysates treated with N3-
FOH or N3-GGOH compared to the control (lanes 2/3 and lanes 8/9). The fluorescence scans look more 
promising as several protein bands are apparent in N3-FOH or N3-GGOH lysates compared to the control 
(lanes 5/6 and 11/12, respectively; arrows indicate bands of labeled proteins).  
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A new method: transfections, microscopy, and mass spectrometry 
 We developed a new and hopefully more informative method to test the 
specificity of the prenylation pathway in vivo, by combining transfection of a library of 
expression vectors, fluorescence microscopy, and mass spectrometry techniques. Figure 
4.7 shows the overall scheme. Libraries of mammalian expression vectors encoding 
proteins with variable CaaX sequences are transfected into various mammalian cells. 
These expression vectors contain a His6 tag appended to the N-terminus of the enhanced 
green fluorescence protein (EGFP). Attached to the C-terminus of this EGFP are 15 
amino acids that correspond to a proposed prenylated protein that contains both the 
putative CaaX sequence and upstream regions, since it is proposed that the upstream 
flexible linker region may contribute to selectivity. Between the C-terminal sequence and 
the EGFP is a TEV protease cleavage site, so overall, the protein is His6-EGFP-TEV-X11-
CaaX. After this plasmid is transfected into mammalian tissue culture cells and the 
protein is expressed, the localization of fusion protein is observed by fluorescence 
microscopy, which may indicate its prenylation status. Additionally, the protein can be 
purified from the lysates by utilizing the His6 tag and, potentially, the 15 amino acid 
modified tail can be cleaved from the protein by TEV protease. The modification status 
of either the entire protein or the cleaved peptide can then be determined using mass 
spectrometry. This analysis provides information about whether a given CaaX sequence 
is prenylated, proteolyzed, and/or methylated (Figure 4.1) as well as determining whether 
a farnesyl, geranylgeranyl, or either moiety is incorporated. Finally, some prenylated 
proteins are also palmitoylated at a cysteine near the prenylation site (19) and upstream 
lysines may also be acetylated or methylated, so mass spectrometry will indicate whether 
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these modifications occur as well. The expected mass changes for some of the various 
modifications are shown in Table 4.2.  
 
 
 
 
 
Figure 4.7. Overall method scheme. Cells are transfected with vectors containing His6-
EGFP-TEV-X11-CaaX genes under the CMV promoter and expression and localization of 
EGFP fusion proteins are analyzed by fluorescence microscopy. If a protein is localized 
to the membranes, this suggests that it is modified. Additionally, cells can be lysed and 
the proteins can be pulled down using the His6 tag and digested by incubation with TEV 
protease. The 15 amino acid tail or full length protein can then be analyzed by mass 
spectrometry to determine the various post-translational modifications.  
 
 
145 
 
Mass changes with associated modifications 
Modification Mass change (Da) 
Farnesylation 204 
Geranylgeranylation 272 
Palmitoylation 238 
Methylation 14 
Proteolysis 213-558 
 
Table 4.2. Post-translational modification mass changes. The expected mass changes 
for various post-translational modifications in the prenylation pathway when using mass 
spectrometry.  
 
Development of the method 
 The first step in this technique was to quickly and efficiently generate a library of 
mammalian expression vector constructs. To this end, we developed a molecular biology 
method using restriction enzymes and DNA oligonucleotides to easily alter the sequence 
of the 15 amino acid C-terminal tails of the fusion proteins (Figure 4.8). In a parent 
vector, the C-terminal region was flanked by KasI and EcoRI restriction enzyme site; 
digestion of the plasmid with these two restriction enzymes creates a linear vector with 
two overhangs. To add the tails, DNA oligonucleotides were purchased corresponding to 
sequences of interest and were designed such that when two oligonucleotides are 
annealed together, overhangs are formed that match the KasI and EcoRI sites of the 
parent vector. The vector and annealed oligonucleotides are then ligated, transformed into 
E. coli, and purified to obtain a library of vector constructs. We evaluated this method on 
one test vector, and as it was successful, we could apply the method to readily obtain all 
of the new vectors.  
146 
  
 
Figure 4.8. Ligation scheme. A parent vector was constructed (His6-EGFP-TEV-myc) 
such that the C-terminal region is flanked by KasI and EcoRI restriction sites, and when 
the vector is digested with these enzymes, sticky ends are created. Two complementary 
DNA oligonucleotides that correspond to a 15 amino acid C-terminal tail are purchased 
(blue). The oligonucleotides are designed such that when the two strands are annealed 
together, overhangs are created. Then, the annealed oligonucleotides and digested parent 
vector can be ligated to form a unique complete vector. This method is an efficient way 
to create a library of different mammalian expression vectors.  
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 Next, we verified that mass spectrometry techniques could be used to detect a 
farnesyl modification in collaboration with Dr. Eric Simon and Dr. Phil Andrews at the 
University of Michigan. The peptide dns-SKTKCVIM was farnesylated to ≥90% by 
incubation with FPP and FTase in vitro. This peptide was purified from other reaction 
components using a ZipTip, and a MALDI-TOF-TOF mass spectrometer was used to 
analyze the mass of the peptide. Figure 4.9 shows the spectrum obtained, and there is a 
mass difference of around 307 m/z between two peaks, corresponding to a farnesyl 
modification on a cysteine residue on the peptide. This suggests that mass spectrometry 
can be applied to modified proteins and peptides obtained from in vivo samples.  
Figure 4.9. Mass spectrometry of a farnesylated peptide. The peptide dns-
SKTKCVIM was labeled in vitro with a farnesyl group. A MALDI-TOF-TOF instrument 
was used to measure the mass of the protein. This spectrum shows a change in mass of 
about 307 m/z which corresponds to the farnesyl (204 m/z) modification on a cysteine 
residue.  
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 Additionally, a His6-EGFP-TEV-Ras15 protein was recombinantly expressed and 
purified in BL21(DE3) E. coli cells and this work was done in collaboration with an 
undergraduate student in the lab, Megan Novak. By expressing and purifying this protein, 
large amounts of this protein could be obtained as a negative (unmodified) control and 
the TEV digestion could be optimized. Megan was able to successfully express and 
purify the His6-EGFP-TEV-Ras15 protein (Figure 4.10 A, fractions 2-4). She was also 
able to successfully digest the protein as indicated by a gel shift in Figure 4.10 B, lane 1. 
Since the library construction, mass spectrometry, and TEV digestion protocols were 
each verified in various proof of principle tests, I then began to optimize the whole 
protocol for use in mammalian tissue culture cells.  
 
Expression vector library construction 
 A library of vectors that corresponds to previously tested in vitro peptides was 
constructed, and rotation student Jenna Hendershot helped with some of this work. As 
controls, sequences corresponding to the C-terminus of H-Ras (a known farnesylated and 
palmitoylated protein) and the myc tag (non-substrate) were generated as positive and 
negative controls. Then, CaaX sequences were chosen that had a variety of in vitro 
activity, including MTO FTase substrates, GGTase-I MTO substrates, dual substrates for 
both FTase and GGTase-I, FTase STO substrates, and non-substrates (12). Additionally, 
the Rab-18 is suggested to be palmitoylated at a cysteine four amino acids upstream of 
the CaaX sequence (by similarity, (54)). The last 15 amino acids of the protein (including 
the CaaX sequence) were appended to the C-terminus of the His6-EGFP-TEV proteins. 
Additional substrates were chosen based on high scoring peptides predicted to be FTase 
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substrates from the FlexPepBind studies in Chapter 3. Table 4.3 shows a summary of the 
sequences in the C-terminal tail and the reactivity of the peptide with FTase and GGTase-
I in vitro.  
 
 
 
Figure 4.10. Purification and digestion of the His6-EGFP-TEV-Ras15 protein. A) 
SDS-PAGE gel showing fractions eluted from a Talon Cobalt metal affinity column 
using imidazole. Purification of the His6-EGFP-TEV-Ras15 recombinant protein (30,760 
Da) eluted in fractions 2-4 and runs between 30 and 40 kDa ladder bands on an SDS-
PAGE gel stained with Coomassie blue dye. The gel has been darkened to more easily 
visualize the bands. B) SDS-PAGE gel analyzing TEV–protease digestion of His6-EGFP-
TEV-Ras15 recombinant protein. Lane 1 is the digestion of His6-EGFP-TEV-Ras15 plus 
TEV protease, lane 2 is undigested His6-EGFP-TEV-Ras15, and lane 3 is TEV protease 
alone. Lane 4 is blank. The TEV digestion alters the apparent mass of the His6-EGFP 
protein (Lane 1).  
 
 
 Table 4.3. Mammalian expression vector sequences and in vitro activity. His6-EGFP-TEV-X11-CaaX genes were constructed in the pCDNA4/TO vector. The 
last 15 amino acid tail and corresponding in vivo protein is shown on the left. If available, the in vitro steady state parameters are indicated. Steady state data and 
activity is either from aunpublished data, from  breference (12), or from cChapter 3..  
High activity in vitro peptides 
Protein Sequence (Last 15 aa) CaaX GGTase-I kcat/KM
peptide  
(mM-1s-1)a 
FTase kcat/KMpeptide  
(mM-1s-1)b In vitro  activity
a,b 
Cell Division Control Protein 42 Homolog AALEPPETQPKRKCCIF CCIF 15 ± 1 3.0 ± 0.3 Dual substrate 
Type I inositol- 1,4,5-trisphosphate 5-phosphatase AGKPHAHVHKCCVVQ CVVQ   MTO farnesylated 
Aldehyde dehydrogenase family 3 member B1 RMLLVAMEAQGCSCTLL CTLL 14 ± 4  MTO Geranylgeranylated 
Neuronal membrane glycoprotein M6-b (transmembrane) NYAVLKFKSREDCCTKF CTKF 1.12 ± 0.07 4.4 ± 0.4 Dual substrate 
Interferon-induced guanylate-binding protein 2 WDIQMRSKSLEPICNIL CNIL 33 ± 2  MTO Geranylgeranylated 
Many possibilities. Ras-related protein Rab-8A PPSAPRKKGGGCPCVLL CVLL 38.6 ± 0.4  Dual substrate 
Rho-related GTP-binding protein Rho6 LGNSSPRTQSPQNCSIM CSIM 1.22 ± 0.08 14 ± 1 Dual substrate 
Ras-related protein Rab-18 REEGQGGGACGGYCSVL CSVL 4 ± 4  MTO Geranylgeranylated + Palmitoylation 
Extracellular superoxide dismutase [Cu-Zn] EHSERKKRRRESECKAA CKAA   STO  farnesylated 
Rho-related GTP-binding protein RhoC AGLQVRKNKRRRGCPIL CPIL   STO farnesylated 
Zinc Finger Protein 124 KHKKTHTGEKPYKCKKM CKKM   CAAX non-substrate 
Forkhead box protein C2 PPLYRHAAPYSYDCTKY CTKY   CAAX non-substrate 
Peptides predicted by FlexPepBind 
Protein Sequence (Last 15 aa) CaaX GGTase-I kcat/KM
peptide  
(mM-1s-1) 
FTase kcat/KMpeptide  
(mM-1s-1) In vitro  activity
c 
Zinc finger protein 64 homolog, isoform 5 LTVHLRSHTGCCYVA CYVA   MTO farnesylated 
Intersectin-2 (Isoform 3) WRLLLASSRGICCLS CCLS   MTO farnesylated 
Folliculin isoform 3 RLPCPELREESCWTC CWTC   MTO farnesylated 
Homeobox protein ESX1 TWAPVINSYYACPFF CPFF   STO farnesylated 
Decaprenyl-diphosphate synthase subunit 1 (2nd isoform) FAWRCRQSSTVCTTE CTTE   STO farnesylated 
Growth/differentiation factor 15 LQTYDDLLAKDCHCI CHCI   CAAX non-substrate 
Phosphatidate phosphatase PPAPDC1B LSTAQKPGDSYCFDI CFDI   CAAX non-substrate 
K-Ras (2B isoform) GKKKKKKSKTKCVIM CVIM   MTO farnesylated control 
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  Overall, 19 vectors and 3 vector controls were successfully made in the 
pcDNA4/TO expression system. The ligation method developed by using DNA 
oligonucleotides proved very successful. For example, for the “high activity” vectors, the 
construction of 13 plasmids was initiated, and 12/13 plasmids were successfully 
generated on the first attempt (a 92% success rate).  
 
Fluorescence microscopy 
 Each vector in the library was transfected into mammalian tissue cultures cells to 
visualize the fusion protein localization. If a protein localizes to cellular membranes, this 
observation suggests that the protein is modified; however, it is not known for certain that 
all prenylated proteins localize to the membranes. To begin, the positive and negative 
controls of H-Ras and myc tag EGFP fusion proteins were transfected into NIH/3T3 and 
HEK-293 cells. As predicted, the H-Ras EGFP fusion protein localizes to the membrane 
where the myc fusion showed diffuse localization, showing that these are good controls 
(Figure 4.11 shows images from the HEK-293 cells transfected with the control 
plasmids). Next, both the NIH/3T3 and HEK-293 cell lines were transfected with 
plasmids expressing EGFP fusion proteins containing C-terminal tails that showed high 
in vitro MTO activity. Some of this work was carried out by Jenna Hendershot. Figure 
4.12 shows a representation of some of the fluorescence images obtained for a subset of 
the vectors, and Table 4.4 (the top panel) also shows a summary of the observed 
localization, with “n/a” meaning that the vector did not transfect efficiently. 
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Figure 4.11. Brightfield and GFP fluorescence microscopy of HEK-293 cells 
transfected with positive and negative control plasmids. A Nikon Eclipse TE2000 U 
inverted epifluorescense microscope (470 excitation and 525 emission cubes) was used to 
obtain fluorescent images of the EGFP. A) Positive control: The plasmid encodes His6-
EGFP-TEV-Ras15 (with DESGPGCMSCKCVLS corresponding to the C-terminus of H-
Ras, a known farnesylated and palmitoylated protein). The fusion protein localizes to the 
plasma membrane. B) Negative control: The plasmid encodes His6-EGFP-TEV-myc 
(sequence EQKLISEEDL is the myc tag). The fluorescence is diffuse and evenly 
localizes throughout the cell, consistent with cytosolic localization and no lipid 
modification on the protein.  
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Figure 4.12.  Brightfield and GFP fluorescence microscopy of His6-EGFP-TEV-X11-
CaaX fusion proteins. The left two panels are images of NIH/3T3 cells and the right 
panels are images of HEK-293 cells including both brightfield and fluorescence images. 
In each row, the transfected plasmid contains a different sequence from: A) Cell Division 
Control Protein 42 Homolog, CaaX=CCIF, predicted dual substrate; B) Type I inositol- 
1,4,5-trisphosphate 5-phosphatase, CaaX=CVVQ, predicted farnesylated; C) Interferon-
induced guanylate-binding protein 2, CaaX=CNIL, predicted geranylgeranylated; D) 
Forkhead box protein C2, CaaX=CTKY, predicted non-substrate; E) Ras-related protein 
Rab-8A, CaaX=CVLL, predicted dual substrate; F) Rho-related GTP-binding protein 
Rho6, CaaX=CSIM, predicted dual substrate. 
 Table 4.4. In vivo localization of fusion proteins and computational algorithm predictions. His6-EGFP-TEV-X11-CaaX genes in the pCDNA4/TO vector 
were transfected into cells, and localization was observed by fluorescence microscopy. The “high in vitro activity” library was transfected into both NIH/3T3 
cells and HEK-293 cells, while the “FlexPepBind” library was solely transfected into HEK-293 cells. A summary of the observed localization for each gene is 
shown. “Membrane” indicates either plasma membrane or plasma membrane/organelle membrane localization. If a gene did not transfect well, it is indicated by 
“n/a.” PrePS predictions are from reference (9) and FlexPepBind predictions are from reference (23) and Chapter 3.  A “+”, “++,” or “+++” symbol from the 
PrePS algorithm indicates that a protein is predicted to be prenylated; a score ≤ -0.4 indicates FlexPepBind prediction of farnesylation. 
 
High activity in vitro peptides 
Protein Sequence (Last 15 aa) 
PrePS 
FTase 
prediction 
PrePS 
GGTase-I 
prediction 
FTase FlexPepBind 
score (≤ -0.4 
predicted substrate) 
In vitro  activity In vivo localization 
Cell Division Control Protein 42 Homolog AALEPPETQPKRKCCIF ++ ++ -0.55 Dual substrate membrane 
Type I inositol- 1,4,5-trisphosphate 5-phosphatase AGKPHAHVHKCCVVQ ++ --- -1.32 MTO farnesylated membrane 
Aldehyde dehydrogenase family 3 member B1 RMLLVAMEAQGCSCTLL - + -2.02 MTO Geranylgeranylated diffuse 
Neuronal membrane glycoprotein M6-b (transmembrane) NYAVLKFKSREDCCTKF -- --- 5.42 Dual substrate diffuse 
Interferon-induced guanylate-binding protein 2 WDIQMRSKSLEPICNIL - ++ -0.28 MTO Geranylgeranylated membrane 
Many possibilities. Ras-related protein Rab-8A PPSAPRKKGGGCPCVLL ++ +++ -0.66 Dual substrate membrane 
Rho-related GTP-binding protein Rho6 LGNSSPRTQSPQNCSIM ++ +++ -1.29 Dual substrate membrane 
Ras-related protein Rab-18 REEGQGGGACGGYCSVL + +++ -1.22 MTO Geranylgeranylated + Palmitoylation membrane 
Extracellular superoxide dismutase [Cu-Zn] EHSERKKRRRESECKAA - --- -0.45 STO  farnesylated n/a 
Rho-related GTP-binding protein RhoC AGLQVRKNKRRRGCPIL + +++ -0.94 STO farnesylated membrane 
Zinc Finger Protein 124 KHKKTHTGEKPYKCKKM -- --- 2.92 CAAX non-substrate n/a 
Forkhead box protein C2 PPLYRHAAPYSYDCTKY -- --- 4.83 CAAX non-substrate diffuse 
Peptides predicted by FlexPepBind 
Protein Sequence (Last 15 aa) 
PrePS 
FTase 
prediction 
PrePS 
GGTase-I 
prediction 
FTase FlexPepBind 
score (≤ -0.4 
predicted substrate) 
In vitro  activity In vivo localization 
Zinc finger protein 64 homolog, isoform 5 LTVHLRSHTGCCYVA - --- -2.88 MTO farnesylated diffuse 
Intersectin-2 (Isoform 3) WRLLLASSRGICCLS - --- -2.37 MTO farnesylated possible membrane 
Folliculin isoform 3 RLPCPELREESCWTC - --- -1.94 MTO farnesylated diffuse 
Homeobox protein ESX1 TWAPVINSYYACPFF --- --- -1.69 STO farnesylated diffuse 
Decaprenyl-diphosphate synthase subunit 1 (2nd isoform) FAWRCRQSSTVCTTE -- --- -2.14 STO farnesylated diffuse 
Growth/differentiation factor 15 LQTYDDLLAKDCHCI -- --- -1.56 CAAX non-substrate diffuse 
Phosphatidate phosphatase PPAPDC1B LSTAQKPGDSYCFDI -- --- -1.59 CAAX non-substrate diffuse 
K-Ras (2B isoform) GKKKKKKSKTKCVIM +++ +++ -0.37 MTO farnesylated control membrane 
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 Overall for the peptides characterized as having “high in vitro activity,” the 
EGFP-CaaX protein localized to the membranes in both cell lines, despite being 
overexpressed. For instance, in Figure 4.12 row A, which corresponds to the C-terminus 
of CDC42 homolog with a CaaX sequence of CCIF, shows non-diffuse localization at the 
cellular membranes. Additionally, Figure 4.12 B which corresponds to Type I inositol- 
1,4,5-trisphosphate 5-phosphatase (CaaX=CVVQ, predicted to be farnesylated) appears 
to localize to both the plasma membrane and punctuate spots within the cells. Figure 4.12 
rows C, E, and F which are predicted to be geranylgeranylated or dual substrates appear 
to localize to a bright spot, presumably outside of the nucleus as well as perhaps the 
nuclear membranes. Two proteins that did not follow the trend were the CTLL (images 
not shown) and CTKF proteins (not shown), that showed diffuse localization. These C-
terminal tails were predicted to be geranylgeranylated, or dual substrates, respectively 
based on the in vitro reactivity with FTase and GGTase-I. However, the lack of 
localization does not prove that the proteins are not modified. A protein that is expected 
to be a non-substrate, Forkhead box protein C2 (CaaX=CTKY), shows completely 
diffuse and even localization throughout the cell, as predicted (Figure 4.12 D). To further 
investigate the localization of these EGFP-fusion proteins, confocal microscopy, 
inhibitor, and co-localization experiments with organelle markers would reveal more 
information about the exact cellular localization and modification status of each of these 
proteins (more details in the Discussion section).  
 The plasmids containing CaaX sequences identified from the “FlexPepBind” 
analysis (Chapter 3) were also transfected into HEK-293 cells (Figure 4.13, Table 4.4 
bottom panel). Of these EGFP-CaaX proteins, only intersectin-2 isoform 3 (CaaX = 
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CCLS) was observed to have some membrane localization (Figure 4.13 A). The rest of 
expressed proteins showed diffuse localization, including sequences proposed to be 
substrates and non-substrates. Figure 4.13 A shows localization of the intersectin-2 GFP 
fusion which appears to localizes to a spot within the cell. A predicted non-substrate 
Growth/differentiation factor 15 (CaaX = CHCI, Figure 4.12 B) showed diffuse 
localization. Row C) is a positive control, K-Ras, which clearly shows membrane 
localization. Again, the lack of membrane localization does not prove the protein is 
unmodified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13.  Brightfield and GFP fluorescence microscopy of HEK-293 cells 
expressing His6-EGFP-TEV-X11-CaaX fusion proteins with C-terminal sequences 
predicted by FlexPepBind. Each row is transfected with a plasmid containing different 
C-terminal sequences. A) Intersectin-2 (Isoform 3, CaaX = CCLS). The peptide has MTO 
activity with FTase. B) Growth/differentiation factor 15 (CaaX = CHCI). The peptide has 
no reactivity with FTase. C) K-Ras (2B isoform, CaaX = CVIM). The peptide has MTO 
reactivity with FTase. C) is a positive control.  
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 These studies show that by changing the C-terminal sequence of the fusion 
proteins, the cellular localization can be altered. Even small changes in the last 15 amino 
acids can aid in localizing proteins to different regions of the cell. Also, the localization is 
maintained in multiple cells lines. In general, for the sequences obtained from peptides 
that react rapidly with FTase or GGTase-I, the expressed proteins localize to the 
membranes as predicted. For the “FlexPepBind” library, the results were less clear, as 
only one sequence localized to membranes. A potential explanation for this behavior is 
that as sequences from the first library have higher in vitro activity, these proteins are 
also more readily modified in vivo. The activity of the FlexPepBind peptides is likely 
significantly lower, as the activity was measured using a single timepoint radioactive 
assay which is highly sensitive. Possibly, a low percentage of the pool of the EGFP-CaaX 
protein is modified in vivo, but this level is below the level of detection in this whole cell 
fluorescence microscopy assay. Alternatively, it is possible that the non-canonical side-
chains in the CaaX sequence (such as X= E) do not allow membrane localization even if 
the proteins are modified.  
 A route to potentially increase the fraction of membrane localization of the 
overexpressed substrate proteins (and perhaps improve transfection efficiency as well) 
would be to generate expression vectors that dually express both subunits of FTase or 
GGTase and the fluorescent protein substrate. If the level of the prenyltransferase is 
increased, the pool of modified protein may increase thereby enhancing detection of 
membrane localization. Preliminary work done by Dr. James Hougland, a previous 
postdoctoral fellow in the lab, has indicated that this type of vector may improve the 
membrane visualization and localization of proteins with weaker CaaX sequences A 
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scheme of vectors that are constructed and ready to be tested is shown in Figure 4.14. By 
switching the promoters the genes are under, the protein expression may be tuned.   
 
 
 
 
Figure 4.14. Dual expression vectors. Vectors were made that co-express both subunits 
of FTase and the His6-EGFP-TEV-X11CaaX or Flag-EGFP-TEV-X11CaaX genes. The 
genes are under either the CMV or SV40 promoters.  
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Discussion 
FPP and GGPP analogs 
 In this study, we had only modest success detecting prenyl modifications using 
the azido-farnesol and azido-geranylgeraniol analogs. High background was observed, 
which could possibly be minimized by optimizing the “click” chemistry conditions. The 
larger issue, however, is the low incorporation of the analogs onto proteins. One way to 
increase analog incorporation would be to treat cells with an HMG-CoA reductase 
inhibitor such as lovastatin, that will block the cholesterol biosynthesis pathway and stop 
the production of endogenous FPP and GGPP (55, 56). If the levels of the native lipid 
substrates are decreased, it is more likely that the analogs will be incorporated onto the 
proteins. This method enjoys support from previous work in the literature (8, 44). 
Blocking FPP and GGPP synthesis would not fix this low incorporation issue if the 
modified proteins are in too low of a concentration to be visualized (or exist in an only 
partially modified pool).  
 A disadvantage of the use of FPP or GGPP analogs is that the analogs may alter 
the protein specificity of the prenyltransferases (57-59), as the prenyl group forms a 
portion of the protein substrate binding site (11). Crystal structures have revealed that the 
a2 residue of the peptide/protein is contacted by the lipid substrate in both FTase and 
GGTase-I (11). Therefore, altering the FPP or GGPP moieties may change the 
interactions with the peptide or protein substrate and alter the overall enzyme selectivity. 
Studies using the FPP analog 3-MeBFPP (3-(3-Methyl-2-butenyl)-7,11-dimethyldodeca-
2(Z),6(E),10-triene 1-Diphosphate) demonstrated this. When 3-MeBFPP was incubated 
with FTase and various peptides in vitro, different FTase reactivity was observed 
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depending on peptide sequence (57). Another study utilized biotin-FPP or GGPP analogs 
to identify potential prenyltransferase substrates in compactin-treated (unmodified) cell 
lysates. Interestingly, FTase and GGTase-I could not tolerate these lipid substrates unless 
the enzymes were engineered at positions W102T/Y154T or W102T/Y154T/Y205T for 
FTase and F53Y/Y126 or F52Y/F53Y/Y126 for GGTase-I (43). The residues mutated in 
this work include contacts to the peptide substrate, which are known to affect 
prenyltransferase selectivity (22). Taken together, recent work with azido-FPP, azido-
GGPP, anilinogeraniol, and C10-alkyne to identify FTase and GGTase-I substrates in 
vivo has indicated that different analogs pull down different substrates (43, 60-62), which 
agrees with the hypothesis that alteration to the lipid donor can change selectivity. 
Overall, these studies explain why some expected and known substrates are not modified 
with the analogs and are not detected. This caveat should be taken into account when 
using analogs as FTase and GGTase-I substrates.  
  
Comparison to prenylation prediction programs 
 Computational tools have aided in predicting prenylated proteins. PrePS was 
developed to predict the likelihood of prenylation by FTase and GGTase-I (as well as 
GGTase-I) based on a training set of known prenylated proteins and the linker amino 
acids upstream of the CaaX sequence (9). FlexPepBind, a program that predicts FTase 
substrates, was developed based on “energy” binding scores with structural modeling of 
CaaX peptide structures in the FTase active site (Chapter 3, (23)). Table 4.4 shows the 
PrePS and FlexPepBind scores for each C-terminal region of the His6-EGFP-TEV-X11-
CaaX proteins. In general, the observed localization of the EGFP-CaaX proteins in this 
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work correlates with computational predictions. For the His6-EGFP-TEV-X11-CaaX 
sequences chosen for high peptide in vitro activity with FTase and GGTase-I, all 
substrates with MTO or STO in vitro prenyltransferase activity are predicted to be 
prenylated by PrePS and FlexPepBind; however exceptions are the neuronal membrane 
glycoprotein M6-b (CaaX = CTKF) and the extracellular superoxide dismutase [Cu-Zn] 
(CaaX = CKAA) fusion proteins which are both predicted to be non-substrates by PrePS 
and FlexPepBind. Additionally, the interferon-induced guanylate-binding protein 2 fusion 
protein (CaaX = CNIL) is predicted as a non-substrate by FlexPepBind. Furthermore, all 
of the His6-EGFP-TEV-X11-CaaX proteins constructed based on FlexPepBind scores 
were predicted as non-substrates by the PrePS algorithm, but had exceptionally good 
scores with FlexPepBind. Interestingly, the extracellular superoxide dismutase [Cu-Zn] 
(CaaX = CKAA) fusion protein poorly transfected and the neuronal membrane 
glycoprotein M6-b (CaaX = CTKF) fusion displayed diffuse localization, but the 
remainder of the EGFP-CaaX proteins predicted as substrates by PrePS and FlexPepBind 
localized to the membranes. Additionally, with the exception of the intersectin-2 fusion 
protein (CaaX = CCLS), all of the His6-EGFP-TEV-X11-CaaX proteins based on high 
FlexPepBind scores showed diffuse localization in vivo. Therefore, EGFP-CaaX proteins 
were more likely to display membrane localization if predicted to be prenylated by 
PrePS. Again, this suggests that high reactivity with the prenyltransferases and a certain 
level of modification must occur in vivo in order to observe membrane localization by 
this technique. It is likely that the PrePS algorithm predicts more reactive substrates with 
FTase and GGTase-I since it was developed based on known prenyltransferase substrates 
and the in vitro activity of peptides with good FlexPepBind scores is lower.  
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Future in vivo work 
 Now that a method of observing the localization of various CaaX sequences has 
been developed, further work can be done to gain more information about the behavior 
and modification status of proteins in the prenylation pathway. In the future, it would be 
interesting to carry out co-localization studies in order to determine to which cellular 
organelles the fusion proteins localize, since not all prenylated proteins localize solely to 
the plasma membrane to carry out their functions. For instance, Rheb 1 and Rheb 2 
(known farnesylated proteins) which activate mTOR signaling have been shown to 
localize primarily to the ER and Golgi (63). The additional modifications of proteolysis 
and methylation after prenylation are required for proper Rheb localization, but are not 
essential for activation of the signaling pathway (potentially due to an unknown protein 
activating the pathway) (63). Comparison of Rheb studies with the work here suggests 
that several of the EGFP constructs (specifically Figure 4.12 C CaaX=CNIL, Figure 4.12 
E CaaX=CVLL, and Figure 4.12 F CaaX=CSIM) may also locate to the Golgi and/or the 
ER. Co-localization studies using confocal microscopy, EGFP-CaaX transfections, and 
cellular compartment stains to the endoplasmic reticulum (ER-Tracker Red, Life 
Technologies), Golgi complex (BODIPY® TR C5 ceramide complexed to BSA, Life 
Technologies) and the plasma membrane (Alexa Fluor® 350 conjugate of WGA, Life 
Technologies) will aid in determining the localization of EGFP proteins. Furthermore, 
some proteins require a “secondary signal” in order for proper cellular localization. For 
example, the prenylated N-Ras and H-Ras proteins localize to the ER and Golgi 
membranes instead of the plasma membrane unless they are palmitoylated; conversely K-
Ras contains an upstream polybasic region that directly aids in membrane localization 
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(64-66). It is possible that the potential organelle localization of EGFP fusion proteins in 
this work are not modified with the necessary secondary modifications after prenylation 
like palmitoylation, proteolysis, and methylation by the respective enzymes due to 
overexpression of the EGFP proteins or because they lack the necessary consensus 
sequence for the modification. Using inhibitors against FTase, GGTase-I, RCE1, 
ZMPSTE24, ICMT, and the PATs will help to isolate the steps in the prenylation 
pathway that impact protein localization, but it is possible that some modified proteins do 
not display membrane localization. Further, studies using immunostaining against the 
specific endogenous proteins that are potentially prenylated would help in understanding 
the protein localization under native conditions. 
 Overall, more optimization is still needed to help determine and understand the 
substrates of the prenylation pathway. Likely the most informative tool to use in the 
future will be mass spectrometry, as the various modifications of farnesylation, 
geranylgeranylation, proteolysis, methylation, and palmitoylation can be observed. It will 
be very interesting to see if all prenylated proteins get proteolyzed and methylated, as this 
is currently unknown. Additionally, it will be interesting to observe the level of 
modification as well as the combination of modifications. For instance, some substrates 
may exist in a pool that is only partially modified in vivo. Using this method to 
investigate prenylation will also enhance the understanding of the pathways affected by 
the FTIs and GGTIs and which proteins are alternatively modified under treatment with 
the prenyltransferase inhibitors. Pull-downs using the tag and TEV-digestion of in vivo 
samples remain to be optimized, but these methods will aid in enriching concentration of 
the modified protein in the samples. Overall, this work is a good first step towards 
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detecting and observing post-translational modifications and understanding the 
prenylation pathway in vivo.  
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CHAPTER V 
 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 
Summary and Conclusions 
 In this work, we investigated the substrate specificity of GGTase-I and FTase 
using a variety of methods. The proteins modified by the prenyltransferases are involved 
in a variety of important signaling pathways within the cell, and inhibitors towards FTase 
and GGTase-I are being assessed for the treatment of diseases ranging from cancer to 
parasitic infections. Therefore, identifying the prenyltransferase substrates is an important 
goal. Two approaches can be used for identifying prenyltransferase substrates. First, we 
can strive to understand how an enzyme recognizes substrates by determining the 
elements of molecular recognition. We followed this approach using peptide library 
studies and by testing and developing a new computational method. Secondly, we can 
directly identify an enzyme’s substrates in vivo; this method was carried out by using a 
vector expression library, transfections, and fluorescence microscopy.  
 
GGTase-I substrate recognition and peptide library studies 
 The prenyltransferases can recognize peptides as substrates (1-5), allowing for the 
quick and efficient testing of a wide array of sequences. In this study, we improved the 
expression of mammalian GGTase-I using auto-induction media supplemented with 
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ZnSO4. Then, 402 peptides of the form dns-TKCxxx or dns-GCxxx were tested for 
activity with mammalian GGTase-I. 111 of these peptides were substrates with GGTase-I 
(28% of the library) under MTO conditions. Additionally, 178 (44%) of the peptides 
displayed STO-only behavior with GGTase-I. Statistical analysis was used to determine 
amino acids that were over-represented or under-represented in each pool of substrates as 
compared to its presence in the overall library. In this analysis, we found that GGTase-I 
prefers I and L at the a2 position and F, L, M, and V at the X position. There is little 
sequence preference at the a1 position. For STO-only substrates, GGTase-I prefers P and 
S at the X position and has little sequence preference at the a1 and a2 positions.  
 Interesting patterns appear when comparing the results of the sequence 
preferences for GGTase-I with similar studies of FTase selectivity (6). For MTO activity, 
FTase and GGTase-I both prefer substrates with residues I, L, and (to a lesser extent) V at 
the a2 position; however, there are not overlapping preferences at the a2 residue for STO 
substrates. Both enzymes contact the a2 side chain with hydrophobic residues and were 
predicted to select a wide range of small and hydrophobic residues, as evaluated by 
crystallographic work (7), so these substrate analyses agree with and refine these studies. 
Further, at the X position for MTO substrates, FTase and GGTase-I are similar in their 
preference for both F and M, but differ in that FTase also prefers substrates terminating in 
I, L, and V and GGTase-I prefers substrates terminating in Q. This is additional evidence 
of dual substrates for the prenyltransferase enzymes and is in agreement with other work 
(7, 8). 
 Finally, a small comparison of a group of dns-GCxxx peptides and dns-TKCxxx 
peptides was carried out by measuring the steady state parameters. In general, dns-GCxxx 
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peptides were 1-3 times more reactive with GGTase-I than the dns-TKCxxx peptides. 
One explanation for this behavior is that the presence of a charged lysine may interact 
with the GGTase-I residues and affect the reactivity.  
 
Development and analysis of FlexPepBind: a computational method to predict FTase 
substrates 
 In this work, we collaborated with Dr. Ora Schueler-Furman and Nir London at 
the Hebrew University of Jerusalem to develop and test a new computational method 
called FlexPepBind that predicts FTase substrates. The Schueler-Furman lab calculated 
binding scores based on the Rosetta modeling suite (9, 10) by threading various Ca1a2X 
sequences onto a peptide backbone in the FTase active site, based on data from a crystal 
structure (7). Two hydrogen bonds between FTase and the peptide substrate as well as the 
Zn2+-sulfur bond from the peptide cysteine were held constant. This method performed 
very well on predicting FTase substrates in test data sets. For example, FlexPepBind was 
applied to a CxxL library that was tested for activity with FTase (11) and gave an 88% 
true positive rate and a 12% false positive rate when using a cutoff of -0.4 for 
FlexPepBind scores. Another benefit of this method is that it better predicts STO 
substrates. For instance, 47% of STO peptides are predicted by FlexPepBind compared to 
the 14% prediction rate by the previous prenyltransferase prediction algorithm PrePS (12, 
13).   
 After analysis of the affinity of all 8,000 possible Cxxx sequences, a group of 29 
peptides predicted by FlexPepBind to bind to FTase was tested for activity with FTase in 
vitro. The peptides fell into two groups: 1) those that had exceptionally good 
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FlexPepBind scores and 2) those that correspond to in vivo proteins and were previously 
uncharacterized. Of these 29 peptides, FTase catalyzed farnesylation of 26 peptides under 
MTO or STO conditions. This group included peptides with a negatively charged X 
group, such as E or D, which had not previously been observed in any FTase substrates 
(14).  
 Further work was done to characterize these peptides and the relationship of 
physically measurable parameters with FlexPepBind score. The kcat/KMpeptide values were 
measured for some of the MTO peptides.  No correlation was observed between the value 
of kcat/KMpeptide (6) and FlexPepBind scores. Additionally when comparing KDpeptide 
measurements for FTase substrates to FlexPepBind scores, no obvious pattern is observed 
Overall, it is unclear at this time what physically measureable parameter correlates with 
and explains the predictive power of the FlexPepBind algorithm. Nonetheless, this 
program is very successful at identifying a wider range of FTase substrates than 
previously developed algorithms.  
  
Investigation into the in vivo prenylation pathway 
 The full complement of in vivo substrates of FTase and GGTase-I is unknown at 
this time. Furthermore, after prenylation catalyzed by FTase or GGTase-I, substrates can 
undergo additional modification catalyzed by enzymes ZMPSTE24 or RCE1 and ICMT 
to proteolyze and carboxy-methylate the C-terminus. Currently, it is also unknown 
whether all proteins undergo each of these modifications. It is important to understand the 
prenylation pathway in vivo to not only appreciate cellular signaling and localization 
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processes, but also to comprehend which proteins may modulate the effect of 
prenyltransferase inhibitors.  
 One approach to identifying FTase and GGTase-I substrates is to use FPP and 
GGPP analogs that allow for the tagging and pull-down of modified proteins. We 
evaluated the efficacy of treating cells with azido-farnesol and azido-geranylgeraniol 
substrates (15, 16). These analogs can be “tagged” using Click chemistry techniques 
which react the azide with an alkyne  (17); in our case, we used TAMRA-alkyne. We 
then could detect azido-prenylated proteins using Western blotting and fluorescence 
scanning techniques. Overall, we were able to detect prenylated proteins; however the 
level of incorporation was very low, proteins of molecular weight that were known 
substrates were not labeled with high efficiency, and there was high background. 
Although the low analog incorporation and high background issues could likely be fixed 
by further optimization, a tremendous caveat to using these analogs is that they may 
change the specificity of the enzyme. We therefore chose to investigate the prenylation 
pathway using a different approach.  
 To explore the substrate selectivity in the prenylation pathway, we developed a 
method using a library of GFP mammalian expression vectors, transfections, and 
fluorescence microscopy. We prepared a vector system that contains His6-EGFP-TEV-
X11-CaaX genes. The His6 tag allows for protein pull-down, EGFP is the green 
fluorescent protein, TEV is a protease site, and the C-terminal tail contains 15 amino 
acids that correspond to a protein of interest. This tail contains the CaaX sequence as well 
as the upstream region which may be important for substrate selectivity (12, 18) and, in 
some cases, is a potential palmitoylation site. These vectors were also designed such that 
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the 15 C-terminal DNA sequences are flanked by KasI and EcoRI restriction enzyme 
sites. DNA oligonucleotides corresponding to C-terminal sequences of interest were 
annealed together and included overhangs that match the KasI and EcoRI sticky ends. 
The sequences in the C-terminal tail can be quickly interchanged using digestions and 
ligations to create each plasmid. Overall, the method is to transfect cells with the His6-
EGFP-TEV-X11-CaaX genes, observe the localization using fluorescence microscopy, 
and ultimately pull-down the proteins, digest with TEV protease to obtain the modified 
C-terminal tail, and analyze the post-translational modifications using mass spectrometry.  
 We have made progress on this technique in both in vitro proof-of-principle 
experiments as well as some in vivo work. We successfully constructed a small library of 
His6-EGFP-TEV-X11-CaaX vectors as well as a bacterial expression vector with the His6-
EGFP-TEV-Ras15 gene. As a test, we expressed the gene in E. coli, purified the protein, 
and tested TEV protease digestion conditions. We were able to successfully digest the 
recombinant protein. Additionally, we detected a farnesyl modification on an in vitro 
modified peptide using mass spectrometry. These experiments suggest that the overall 
method can be applied to a mammalian system.  
 We tested two small libraries of His6-EGFP-TEV-X11-CaaX genes in vivo. A 
library with C-terminal tail sequences that corresponded to high activity in vitro peptides 
generally showed membrane localization in vivo.  Furthermore, the in vivo localization 
changed depending on the C-terminal sequence of the protein, with some localizing to the 
plasma membrane and others localizing to various organelles. A library of constructs that 
contain C-terminal tail sequences that correspond to peptides predicted to be substrates 
by FlexPepBind generally showed diffuse localization in vivo. A hypothesis explaining 
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this behavior is that the FlexPepBind peptides had lower activity in vitro with FTase, so a 
lower fraction of the protein is modified within the cell and therefore difficult to see 
localization. In the future, it is likely that the mass spectrometry will be the most 
informative technique in identifying the various modifications or combination of 
modifications on proteins. Overall, this work is a good first step towards understanding 
and testing the relationship of substrate specificity and the prenylation pathway.   
 
Future Directions 
Investigation of the region upstream of the CaaX sequence 
 Preliminary experiments in this work with GGTase-I has indicated that the 
sequence upstream of the CaaX sequence may affect the peptide reactivity. In general, 
dns-GCxxx peptides were 1-3 times more reactive than dns-TKCxxx peptides. We have 
obtained more dns-GCxxx peptides that match the “CaaX” sequence of dns-TKCxxx 
peptides in our current library. A future experiment would be to test the reactivity of the 
dns-GCxxx peptides with GGTase-I. We could then have a larger sample size of peptides 
with matching CaaX sequences to compare reactivity and obtain a clearer picture of the 
overall trend. Furthermore, we could test longer peptides with longer upstream regions in 
vitro that more closely correspond to protein sequences to compare reactivity. As we 
have an in vivo system using the His6-EGFP-TEV-X11-CaaX vectors, we could easily test 
the amenability of prenylation for CaaX sequences with upstream regions in the cell. 
Different upstream sequences could be swapped with various CaaX sequences. Besides 
just testing the effect of the upstream region, we could also test the effect of 
palmitoylation on membrane localization since many palmitoylation sites are found near 
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prenylation sites (19). Palmitoylation has been suggested to be a method of regulating 
localization to and from the plasma membrane, so understanding the interplay of 
palmitoylation, prenylation, and localization would be interesting and informative.  
Furthermore, additional upstream modifications, such as acetylation and methylation, 
may regulate the reactivity of these substrates with FTase/GGTase-I.  
 
Computational methods: predicting GGTase-I substrates 
 Now that the new and improved computational method, FlexPepBind, has been 
established (14) to predict FTase substrates, it would be useful to develop a similar 
method for the prediction of GGTase-I substrates. A large amount of in vitro reactivity 
data with GGTase-I is now available from this work, so training and test sets could be 
established. Crystal structures of the GGTase-I enzyme and substrates are also available 
for the threading experiments (7, 20). We are in fact currently working with the Scheuler-
Furman lab to develop a program predicting GGTase-I substrate selectivity.  
 An interesting aspect of a program to predict GGTase-I substrates is that the 
outcome of FlexPepBind with FTase and GGTase-I could be compared to enhance the 
prediction of the overlap between substrates for the prenyltransferases.  These predictions 
could then be tested in vivo and in vitro. We could also compare the overall number of 
modified proteins by each enzyme. Furthermore, it would be interesting to develop a 
similar computational method for the parasitic enzymes; crystal structures of GGTase-I 
from C. albicans and FTase from C. neoformans (both pathogenic fungi) have recently 
been solved (21, 22).  
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Determining in vivo substrates of the prenylation pathway 
 We have established a method using His6-EGFP-TEV-X11-CaaX mammalian 
vectors to probe the in vivo localization of proteins that may be modified by enzymes in 
the prenylation pathway. There is additional work that could be done to further 
investigate this system in vivo. As mentioned previously, mass spectrometry methods will 
be highly informative in identifying the post-translational modifications and combination 
of modifications of proteins; however, this method must still be optimized. Another 
method to potentially improve the expression and localization of low activity His6-EGFP-
TEV-X11-CaaX genes is to use expression vectors that dually express both the FTase (or 
GGTase-I) protein as well as the His6-EGFP-TEV-X11-CaaX gene. A previous lab 
member had some success in improving the localization of a gene using this technique, so 
a similar method could be applied to this technique. These plasmids are already cloned; 
the next step is to optimize gene transfection and expression in vivo.  
 In the future, several deeper aspects of the prenylation pathway could be studied. 
Various inhibitors could be tested to evaluate which proteins are affected by blocking 
prenylation. Testing the effect of the inhibitors would aid in understanding what cellular 
pathways are affected with drug treatment. Further, it was recently discovered that the 
bacteria Legionella pneumophila hijacks the host prenyltransferase machinery to catalyze 
prenylation of bacterial proteins (21, 23). The effect of inhibitors on the prenylation of 
the bacterial machinery could be determined; inhibitors towards FTase and GGTase-I 
could be potential antibiotic drugs.  
 A long term goal is to determine the entire prenylated proteome, and this could be 
carried out by mass spectrometry as it would identify both the proteins and the 
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modifications. Advantages of this approach would be that native protein substrates and 
lipid donors would be used, and endogenous prenyltransferase enzymes would catalyze 
the prenylation. No inhibitors would be necessary for the incorporation of FPP or GGPP 
analogs. This method would entirely reflect the native conditions and states of the 
proteins and modification status in the cells. A technique to make this goal a reality 
would be to enrich for the prenylated proteins after cell lysis so that the concentration 
would be high enough for mass spectrometry detection. First, membrane cellular 
fractions could be isolated since presumably most of the prenylated proteins would reside 
in cellular membranes. Then, an affinity column that binds to the hydrophobic prenyl 
modifications could isolate the prenylated proteins. Specifically, a modified β-
cyclodextrin resin has been shown to bind to prenyl groups (24, 25), so a column such as 
this could be used to further enrich for farnesylated and geranylgeranylated proteins from 
the membrane fractions. Then, proteins could be identified by mass spectrometry, only if, 
of course, they are expressed at a high enough level. Once this method is established, we 
could monitor the whole complement of prenylated proteins under inhibitor treatment, in 
different cells lines that model various diseases (such as the HGPS cells), and potentially 
move to identifying prenyl modifications in specific organs in animal systems. 
Prenylation plays a role in a variety of cellular pathways and in various diseases, so 
understanding these enzymes is incredibly important. The possibilities for further work in 
this system are endless.  
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